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Once diagnosed, cancer is treated by surgical resection, chemotherapy, radiation
therapy, or a combination of these therapies. It is intuitive that physically and completely
removing a solid tumor would be an effective treatment. A complete resection of the tumor
mass, defined by surgical margins that are clear of neoplasia, is prognostic for a decreased
chance of cancer recurrence and an increased survival rate. In practice, complete resec-
tion is difficult. A surgeon primarily has only their senses of touch and sight to provide
“real-time” guidance in the removal of a tumor while in the operating room. Preoperative
imaging can guide a surgeon to a tumor but does not give a continuous update of surgical
progress. Intraoperative pathology is limited to a few slides worth of samples: a prod-
uct of its time-consuming nature and the limited time a patient can remain under general
anesthesia. Technologies to guide a surgeon in effecting complete resection of a tumor
mass during the surgical procedure would greatly increase cancer survival rates by lower-
ing rates of cancer recurrence; such a technology would also reduce the need for follow-up
chemotherapy or radiation therapy. Here, we describe a prototype instrumentation system
that can provide intraoperative guidance with exogenous optical contrast agents. The in-
strumentation combines interactive point excitation, local spectroscopy, and widefield flu-
orescence imaging to enable low-cost surgical guidance using FDA-approved fluorescent
dyes, semiconductor quantum dots (QDs), or surface-enhanced Raman scattering (SERS)
nanoparticles. The utility of this surgical system is demonstrated in rodent tumor models
using an FDA-approved fluorescent dye, indocyanine green (ICG), and is then more exten-
sively demonstrated with a pre-clinical study of spontaneous tumors in companion canines.
The pre-clinical studies show a high sensitivity in detecting a variety of canine tumors with
a low false positive rate, as verified by pathology.
xvii
We also present a fundamental study on the behavior of quantum dots. QDs are a
promising fluorophore for biological applications, including as a surgical contrast agent.
To use QDs for in vivo human imaging, toxicity concerns must be addressed first. Although
it is suspected that QDs may be toxic to an organism based on the heavy-metal elemental
composition of QDs, overt organism toxicity is not seen in long-term animal model studies.
We have found that some reactive oxygen species (ROS) generated by the host inflamma-
tory response can rapidly degrade QDs; in the case of hypochlorous acid, optical changes to
the QDs are suggestive of degradation occurring within seconds. It is well-known that QDs
are sequestered by the immune system when used in vivo—we therefore believe that QD
degradation through an inflammatory response may represent a realizable in vivo mecha-
nism for QD degradation. We demonstrate in an in vitro cell culture model that immune
cells can degrade QDs through ROS exposure. Knowledge of the degradative processes
that QDs would be subject to when used in vivo informs on adaptations that can be made to
the QDs to resist degradation. Such adaptations will be important in developing QD-based
contrast agents for image guided surgery.
xviii
CHAPTER I
OPPORTUNITIES FOR IMPROVING CANCER THERAPY
1.1 Abstract
President Richard M. Nixon began the “War on Cancer” by signing the National Cancer Act
of 1971. From this act sprang a considerable scientific effort to eradicate cancer. Despite
scientific and medical efforts, the mortality rate attributed to cancer is largely unchanged
over the last 50 years. Cancer is a complex and varied disease, and difficult to treat through
drugs or radiation alone. Surgery is an effective treatment, but surgical technique has not
changed since the beginnings of surgical oncology. Recent advancements in nanotech-
nology, the manipulation of materials and structures on the 1–100 nm scale, offer new tools
for cancer research, diagnosis, and treatment.
1.2 Introduction
Every year, the American Cancer Society compiles and publishes a comprehensive statis-
tical analysis describing the current state of cancer within the United States, drawing from
numerous sources.[121] In 2010, 1.5 million patients in the U.S. were newly diagnosed
with cancer. Forty-thousand of these patients lived in Georgia. In addition to these new
cases, there are 11 million estimated people in the U.S. who have or have had cancer. Be-
tween 1975–1977, the 5 year relative survival rate for cancer was 50%. In 2005–2007,
this 5 year relative survival rate increased to 68%. It is important to note that the relative
survival rate compares the death rate of those with cancer to those without (matched for
age, sex, &c.), it does not reflect on the “cure rate” for cancer, and does not inform as to
what happens after the 5 year interval. Lung and bronchus cancer are the leading cause
of cancer-related death in men and women, almost 160,000 individuals. Following lung
1




























Figure 1: The age-adjusted mortality rates for cancer and heart disease, 1950–2005. Rates
shown are for all persons. Lines are a linear regression shown as a visual guide. Data from
statistics provided by the Centers for Disease Control.[176]
cancer is prostate and breast cancer in men and women, respectively. Cancer is still the
number two cause of death in the U.S., behind heart disease. While great strides have been
made in improving patient care for those with heart disease, less progress has been made
for patients with cancer. A comparison of the mortality rates of cancer and heart disease
are illuminating, as shown in Figure 1 on this page. The flat death rate of cancer relative to
other diseases is not due to a lack of effort, but instead, is a reflection of the complexity of
cancer biology and the heterogeneity inherent in cancer. The improvements made in cancer
management (e.g., anti-smoking campaigns for lung cancer) are offset by an increasingly
aging population. In heart disease, the organs systems involved are constant, the disease
pathogenesis is better understood, and there are defined prognostic biomarkers to inform
on the disease state and best course of therapy (e.g., LDL cholesterol levels). Many of these
factors are not true with cancer.
1.3 Carcinogenesis and cancer biology
Cancer is largely a disease of aging. Genetic mutations accumulate throughout life, a result
of ionizing radiation exposure, environmental exposure to mutagens, genetic replication
errors, and viral infections. The varied pathogenesis inherent in cancer genesis means that
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every cancer is to some degree unique. The incidence rate of many cancer types is age-
dependent, suggesting the accumulation of cancer traits is a stochastic process.[205]
For cancer to present, a cell must first acquire a set of traits inherent to most if not all
cancers. Hanahan and Weinberg enumerated these traits:[94]
Evading apoptosis: Cancer cells ignore programmed cell death, reducing the death rate
of cancer cells.
Limitless replicative potential: The normal lifetime limit on cell division (the “Hayflick
limit”) is overridden, allowing cancer cells to replicate endlessly.
Self-sufficiency in growth signals: Cancer cells provide their own growth signals, leading
to a positive feedback loop for cell proliferation.
Insensitivity to anti-growth signals: Cancer cells ignore anti-growth signals to stop pro-
liferation.
Sustained angiogenesis: Cancer cells recruit new blood vessels to supply the nutrients
needed for rapid growth.
Tissue invasion and metastasis: Cancer cells are able to undergo a transformation to a
more mobile cell type, invade into a new area of the body, and grow in the new
location.
These abilities do not need to be acquired in any specific order, as shown in Figure 2 on
the next page. For example, a cell could have a telomerase mutation that allows it to have
limitless replicative potential, but if the anti-growth signal pathways are still functional, the
cell may not proliferate.
1.3.1 Cellular immortality
Apoptosis is orderly, programmed cell death. Cells signaled to undergo apoptosis decrease
in volume, fragment their nucleus, and break down their nuclear contents and skeleton.
3
Figure 2: The hallmarks of cancer. (A) A listing of cancer characteristics that are acquired
through genetic mutations. The characteristics can arise from numerous mechanisms, an
example mechanism is given for each characteristic. (B) The chronological order that these
mutations are acquired is not important to the development of cancer, it is the presence of
all the characteristics that is the hallmark of cancer. Reprinted from Cell, vol. 100, Hanahan
and Weinberg, “The Hallmarks of Cancer”, pp. 57–70, Copyright 2000, with permission
from Elsevier.[94]
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They also express factors that signal phagocytic cells to engulf the apoptotic cell and re-
move it. This process is contrasted to necrosis, which results in the death of the cell and
spillage of its contents into the surroundings (often with deleterious effects to the organ-
ism). Apoptosis is used to maintain homeostasis of tissue and organ size, among other
roles. Apoptosis is suicide, and relies the cell to carry out the program—cancer cells have
mutations in apoptosis regulation pathways that allow cancer cells to ignore pro-apoptotic
signaling.[11] The p53 tumor suppressor gene is the best known example in this area: p53
triggers apoptosis if genetic damage is detected. Mutations in the p53 gene prevent p53
from activating the apoptosis pathway.[109] Genetic defects in the gene encoding p53 result
in a predisposition to early cancer development, called Li-Fraumeni syndrome.[218, 238]
Cancer cells also have the ability for limitless proliferation. Differentiated primary cells
obtained from an organism and grown in cell culture will cease proliferating after time, in
contrast to cancer cells that will endlessly proliferate. The observation that differentiated
primary cells can only undergo a finite number of cell divisions is now called the “Hayflick
limit.”[100, 99] This limit is linked to the length of non-protein coding regions at the end of
chromosomes, the telomeres. Every time a cell replicates its chromosomes, the telomeres
are shortened; if the telomeres become too short, the cell no longer is able to replicate its
genetic material. Telomerase lengthens the telomeres. Cancer cells have upregulated levels
of telomerase, reversing the shortening of telomeres after replication, and allowing them to
replicate without limit.[46]
1.3.2 Alterations in growth signaling
Normal cells are quiescent until they receive a signal to proliferate, transmitted by growth
signals. These growth signals bind to transmembrane receptors on the cell and induce
signaling cascades that initiate cell replication. The need for growth factors is known to
researchers whom use cell culture models: growth hormones must be added to the cell
growth medium to propagate the cell culture. A cell that can self-stimulate proliferation
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produces daughter cells with the same ability, setting up a positive feedback loop. Growth
factor receptors involved in cancer are often receptor tyrosine kinases (RTKs). Mutations
in the receptor could be truncations that result in receptors that are constitutively activated
or increases in the copy number of the receptor (boosting the “gain” of the receptor path-
way). A truncation mutant of epidermal growth factor receptor, EGFRvIII, is found in
glioblastoma multiforme;[101] overexpression of a related member in the EGFR family,
HER2/neu, is found in breast cancers.[275, 210] Mutations in the downstream signaling
effectors of growth factor receptors is also common to many cancers. For example, mu-
tations in the mitogen-activated protein kinase (MAPK) signaling pathway are associated
with many cancers.[71, 188, 241, 258]
Cancerous cells also cease responding to signals to halt proliferation. Cells of the colon
are continuously sloughed off and replaced from a pluripotent cell source at the base of
the colonic crypts. A mutation in the adenomatous polyposis coli (APC) gene prevents the
pluripotent cells from ceasing proliferation. Dysplastic nodules of cells then form, termed
adenomatous polyps.[274, 108] These cells require a second mutation to become neoplas-
tic, such as a mutation that decreases expression of Krüppel-like factor 4 (KLF4).[280]
Patients with a hereditary condition, familial adenomatous polyposis (FAP), have an inher-
ited genetic mutation in the APC gene that causes them to have a predisposition to polyp
growth and eventual cancer development.
1.3.3 Increased nutrient supply and mobility
All cells require oxygen, nutrients, and waste removal to survive; as a consequence of diffu-
sion, all cells must be in proximity to a capillary to survive. Solid-mass cancers without the
ability to promote angiogenesis, the development of new blood vessels, are unable to grow
beyond a small size. Only when solid cancers secrete the soluble factors which promote
angiogenesis can cancers grow large—before acquiring this trait, premalignant lesions can
be detected in otherwise healthy individuals.[80, 82, 20] Anti-angiogenesis chemotherapy
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attempts to circumvent the ability of cancerous lesions to recruit new blood vessel devel-
opment, in effect, starving the cancer.[87] This therapy is able to prevent further growth
of cancer, but must be combined with other therapies to kill the existing disease.[81] A
consequence of blood vessel recruitment is that solid-mass cancers are able to use the neo-
vasculature in transporting itself to another area of the body. The metastasis process may
involve an epithelial to mesenchymal transition (EMT), which produces a cancer cell with
increased mobility.[98, 249] Metastasis is a complex and poorly understood process with
many moving parts: the cancer must be able to “unroot” itself from the extracellular matrix
(ECM), dodge the immune system and travel to a distant location, and then invade into the
tissue of the new location. This requires the alteration of cell-surface receptors, like inte-
grins and cadherins, and the production of proteases to break down the ECM.[5, 32, 145]
Metastasis greatly complicates cancer treatment, since the metastatic disease tends to grow
in not one distant site but many. Metastasis involves the lymphatic system (the body’s
“second circulatory system”) during transport. The involvement of the lymphatics is why
during cancer surgery, lymph nodes are removed during the surgery to stage (determine the
extent of the spread of) the cancer. The lymph nodes are analogous to drains in the body’s
drainage system, and the closest drain to a solid-mass tumor will most likely be the first
stop for metastatic disease. This lymph node is termed the sentinel lymph node (SLN), and
is of great medical importance.
1.3.4 Tumor structure
The tumor structure is heterogenous. The cells found in a tumor have diverse
phenotypes.[58] As discussed supra, the tumor has a vasculature to support it with nu-
trients, however, this vasculature tends to be “leaky.”[117] There is also an interstitial pres-
sure associated with the tumor that can make the tumor difficult to penetrate with small
molecules and macromolecules.[102] The tumor cellular environment is also varied: there
can be necrotic cores of dead cells and detritus distant from neovasculature mixed in with
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the cancerous cells; the necrotic regions are generally apoxic and respond differently to
anti-cancer therapy.[18] These heterogeneities present impediments to therapy. The intra-
tumoral pressure alters the permeation of drugs into the tumor, and biopsies of tumors are
challenging because it is difficult to ensure that the biopsy sample is representative of the
cancer as a while. The heterogeneity also poses challenges in probing the cancer after
surgical excision, since cost constraints prevent routine pathologic examination of the en-
tire tumor mass. Tumor heterogeneity also poses problems in chemotherapy and radiation
therapy because the distribution of cells in a tumor will respond to varying degrees to the
treatment. Using one chemotherapeutic (e.g., cisplatin) may kill most but a small subset of
resistant cells. These cells will then form a new tumor with resistance to chemotherapeu-
tics. The population distribution within cancer is why combination therapies are commonly
used.
1.4 Dissertation Structure
This dissertation describes the development of biomedical instrumentation for intra-
operative guidance during cancer surgery, as well as speculating on the biocompatibility
of some nanoparticle contrast agents. The dissertation is roughly halved into one part de-
scribing instrumentation and the use of the instrumentation for cancer surgery, and one part
exploring nanoparticle degradation. A short description of each chapter appears infra.
Chapter 1: In this, the introductory chapter, we define cancer as the medical area of inter-
est and examine the impact of cancer on society.
Chapter 2: Here, we review the current field of biomedical imaging for cancer, including
nanotechnology-based contrast agents compatible with the instrumentation described
in Chapter 3.
Chapter 3: In this chapter we describe the design and current implementation of bio-
medical instrumentation for image-guided cancer surgery using exogenous contrast
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agents.
Chapter 4: Using the instrumentation developed in Chapter 3, here we use the technology
to guide surgery in animal models of cancer and lay the groundwork for translation
of this instrumentation into the clinic.
Chapter 5: In this chapter, we describe how a class of nanoparticles can be rapidly de-
graded by reactive chemicals, and how the damaged particles can be partially re-
paired.
Chapter 6: Here, we describe how the process described in Chapter 5 is relevant in the
in vivo milieu, and use in vitro assays to speculate on the in vivo fate of some nano-
particles.
Chapter 7: Finally, we predict the future development of the discoveries presented in this
dissertation, including applying the technology to human diseases outside of cancer
and making use of the degradation of nanoparticles for practical purposes.
Appendix A: A detailed listing of materials used throughout the dissertation, including
software, instrumentation, chemicals, and consumables.
Appendix B: A detailed listing of the optical prescriptions of instrumentation developed
in this dissertation.
Appendix C: A pseudocode outline of software developed for use in this dissertation.
1.5 Conclusions
As our understanding of cancer as a disease grows, the difficulty of the challenge of eradi-
cating cancer becomes apparent. Cancer is truly a consequence of life as we know it. The
mutations that allow evolutionary processes to happen in life are also responsible for caus-
ing the suffering that is cancer. Although one word is used to describe it, cancer exhibits
the same individuality as the people it afflicts. The growing knowledge of the genetics
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and biology of carcinogenesis are one development that will improve cancer diagnostics
and prevention. Developments in nanotechnology, which offer fine-grained control over




NANOTECHNOLOGY FOR IN VITRO AND IN VIVO IMAGING
2.1 Abstract
Nanotechnology offers unprecedented control over the physical, chemical, and electronic
properties of materials. Although it is relatively new as a field, nanotechnology has al-
ready found its way into consumer products (such as in cosmetics and sunscreens, stain-
free clothing, and antimicrobial surface treatments). The potential for nanotechnology to
transform human medicine is incredible. In this dissertation, we are concerned with nano-
technology applications in cancer, specifically imaging. The unique electronic and optical
properties of nanoparticles prove to be especially useful for cancer imaging, and biological
imaging in general.
2.2 Introduction
Nanotechnology was conceptually born as a talk, “There’s Plenty of Room at the Bottom”,
given by physicist and Nobel laureate Richard Feynman in 1959.[74] In his talk, Feynman
predicted the emergence of a multidiciplinary field that would focus on the manipulation
of structures and materials at the atomic scale. As an example, he proposed how the entire
Encyclopedia Britannica could be stored on the head of a pin; he (through the suggestion
of an acquaintance and later student, Albert Hibbs) speculated on a “wild idea” that one
could “swallow the doctor”, a micromachine that could be remotely controlled and used for
surgery; and he observed how the unique properties of the atomic scale (where quantum
mechanics dominates) could lead to “a system using quantized energy levels”.
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Figure 3: The scale of things, from macro to nano. The unique properties of nanoparticles
emerge when the particle size decreases below 100 nm. This is below the wavelength of
visible light, part of the reason for some of the interesting properties of nanoparticles. It
is also the scale of biomolecules and proteins. Image courtesy of the U.S. Department of
Energy, Office of Basic Energy Sciences.[254]
atoms or molecules, but a more modern definition is provided by the U.S. National Nano-
technology Initiative:[177]
Nanotechnology is the understanding and control of matter at dimensions be-
tween approximately 1 and 100 nanometers, where unique phenomena enable
novel applications. Encompassing nanoscale science, engineering, and tech-
nology, nanotechnology involves imaging, measuring, modeling, and manipu-
lating matter at this length scale.
It is in the mesoscopic regime where the familiar properties of a bulk material are com-
bined with the weird quantum behavior of atoms and molecules. True nanotechnology goes
beyond being small: it is the control of matter to exploit properties not apparent in individ-
ual atoms or in bulk materials. Nanotechnology produces materials that are smaller than
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the wavelength of visible light and on the same order of size as biomolecules, as illustrated
in Figure 3 on the preceding page. This is in part why nanoparticles have optical properties
not seen in bulk materials; it is also why nanoparticles can have toxicity effects not seen in
bulk materials. This dissertation is in part concerned with the degradation of semiconduc-
tor quantum dots, and so they are discussed thoroughly. Gold colloid, used for enhancing
Raman scattering, is useful as a contrast agent for the instrumentation presented and so
is discussed but in less depth. We begin by discussing the challenges and considerations
inherent to optical imaging in vivo before discussing useful optical nanoparticles.
2.3 Optical imaging in vivo
Fluorescence imaging has several inherent advantages over other imaging modalities:
low instrumentation costs, a high spatial resolution, non-ionizing radiation, stable optical
probes (c.f. radiodecay of radionuclides), facile multiplexing through multispectral imag-
ing, and the opportunity to use switchable or activatable probes to increase sensitivity and
specificity. Imaging with visible or near-infrared (NIR) light has unique difficulties not
inherent to nuclear medicine, sonography, or x-rays. Optical imaging is mainly hampered
by a limited penetration depth through tissues of the body due to Rayleigh scatter and ab-
sorption by endogenous chromophores.[195, 34, 184] As a result, optical imaging has seen
wide use in research studies using rodent models where the light can penetrate deeply rel-
ative to the total size of the animal; In human medicine, optical imaging has been largely
restricted to transparent organs (imaging the retina with optical coherence tomography,
OCT) or surface imaging (i.e., narrow-band imaging in colonoscopy). For some human
medicine applications, the shallow penetration depth of light is not an issue. In surgery, for
example, most areas of interest will be a surface (either intact or freshly cut). For surgical
applications, the imaging will most likely be carried out with an epi-fluorescence scheme,
as depicted in Figure 4 on the next page, because the excitation source and detector can






































Figure 4: Fluorescence imaging in vivo commonly uses one of three imaging arrange-
ments, epi-illumination, transillumination, or tomographic illumination. The excitation
source can be a continuous wave, or can use a time- or frequency-varying signal. Continu-
ous wave epi-illumination is the simplest to implement and is the most common strategy.
tomography to reduce the surface-weighting of fluorescence imaging are not outweighed
by the increased instrumentation cost and complexity. There are several possible imaging
domains that have been used for in vivo imaging, but continuous wave (CW) imaging is by
far the most common. CW imaging offers higher sensitivities because the duty cycle for
CW excitation is unity. The duty cycle for both frequency-domain (FD) and time-domain
(TD) excitation sources is less than unity, reducing the amount of excitation light deliv-
ered and thus emission light that can be collected. The drawback to CW is an inability to
measure fluorescence lifetime, which can be useful to reject unwanted signals. Acquiring
spectrographic information with CW excitation offsets this drawback. FD excitation has
some implementation advantages over TD excitation (namely, an insensitivity to ambient
light); in terms of the data acquired, the two excitation modes are mathematically related
through the Fourier transform.
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2.3.1 The near-infrared window
There exists an optimal region of light for in vivo imaging, the so called “near-infrared
window.”[34, 262, 231] This is the observation that there are ranges of light where absorp-
tion due to endogenous chromophores is relatively low; selecting the most bathochromic
of these ranges will result in the lowest scattering since Rayleigh scatter (scatter due to
structures much smaller than the wavelength of light) is proportional to 1
λ4
. Mie scatter also
occurs in tissues, but is anisotropic (forward-biased) in contrast to the isotropic scatter of
Rayleigh scatter. The sum of absorption and scatter is the total attenuation of light expe-
rienced in the tissues. The major chromophores of the body are water (in the NIR) and
hemaglobin. As shown in Figure 5 on the following page, there is a clear range of imaging
in the 650–1300 nm range; this window is split into two ranges based on the efficiencies
of available imaging sensor materials. Imaging sensors based on silicon (Si) are by far the
most common and economical, and so imaging in the NIR window tends to occur in the
700–850 nm range where the Si sensor efficiency is high and there are a large selection of
fluorophores to use. Semiconductor quantum dots (QDs) are easily tuned to emit within the
entire NIR window: one of many reasons why QDs are attractive for use as biological la-
bels. Raman-scattering tags, such as those based on gold colloids, are another nanoparticle
that can be used within the NIR window.
2.4 Semiconductor quantum dots
A semiconductor quantum dot (QD) is a structure in which an exciton, an excited electron
and hole pair, is spatially confined in three dimensions. Such a structure exhibits many
interesting optical effects as the magnitude of the spatial confinement is altered. If the
structure is confined in two of three dimensions, it becomes a quantum wire; for one in
three dimensions, a quantum well. It is important to note that the term “quantum dot”
refers to the confined particle (in this case, exciton), and is not necessarily synonymous
with a semiconductor QD, much less a colloidal quantum dot. The fine-grained control
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!e "ndings on nanotubes described 
by Bonner and co-workers are, therefore, 
fully consistent with the movement of a 
proportion of any deposited particle through 
the pleura. However, the fact that no carbon 
black was seen in the pleural tissues suggests 
that, in contrast to carbon nanotubes, these 
compact particles are small enough to pass 
rapidly through the pleura, into the pleural 
space #uid and out again through the pores 
in the chest wall. By contrast, the profusion 
of nanotubes visible in and around the 
pleura suggests that the movement of the 
nanotube aggregates is impeded, probably as 
a consequence of their "brous or irregular 
shape. !e relative bulk of the nanotubes may 
slow down their movement and cause them 
to lodge in the sensitive pleural tissue where 
they may then exert pathogenic e$ects over 
time (Fig. 1).
As more research comes to light we can 
look forward to further illumination of the 
behaviour of carbon nanotubes in the pleura, 
including their retention time and the role of 
factors such as "bre length or aggregate size. 
Along with actual measurements of nanotubes 
in the air of the workplace, such studies 
should culminate in rational risk assessment 
and safe management for those handling 
carbon nanotubes. 
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Near-infrared light (700–2,500 nm) can penetrate biological tissues such as skin and blood more e%ciently than 
visible light because these tissues scatter 
and absorb less light at longer wavelengths. 
Simply hold your hand in sunlight and 
your "ngers will glow red owing to the 
preferential transmission of red and near-
infrared light. At wavelengths longer than 
950 nm, however, this e$ect diminishes 
owing to increased absorption by water and 
lipids. Nonetheless, a clear window exists at 
wavelengths between 650 nm and 950 nm 
for optical imaging of live animals1,2 (Fig. 1). 
In practice, however, this window is not 
optimal because tissue auto#uorescence 
produces substantial background noise and 
the tissue penetration depth is limited to 
between 1 and 2 cm (ref. 3).
In 2003, simulations and modelling 
studies4 of optical imaging in turbid media 
such as tissue or blood suggested that it 
would be possible to improve signal-to-noise 
ratios by over 100-fold by using quantum 
dot #uorophores that emit light at 1,320 nm 
(instead of 850 nm). However, the lack of 
biocompatible #uorescent probes in this 
second near-infrared window between 
1,000 and 1,350 nm has prevented the use 
of this highly sensitive spectral range for 
in vivo imaging.
On page 773 of this issue, Hongjie Dai 
and colleagues from Stanford University and 
Soochow University in China report a way to 
generate biocompatible #uorescent single-
walled carbon nanotubes that emit between 
950 and 1,400 nm (ref. 5). !ese bright 
nanotubes allowed deep and highly sensitive 
in vivo imaging of blood vessels immediately 
beneath and through the deep layers of skin.
Single-walled carbon nanotubes are 
grown on solid substrates, so they must 
be detached, debundled and coated with a 
suitable hydrophilic layer before they can 
be used as soluble #uorophores. Dai and 
co-workers observed that the frequently used 
sonochemical method for coating the tubes 
with a layer of biocompatible phospholipids 
shortens the tubes and creates defects that 
quench the #uorescence. However, they 
found that the tubes remained #uorescent 
and intact if they were "rst coated with 
sodium cholate (a biological lipid) before 
replacing the cholate with the phospholipid-
polyethylene glycol coating in a second step. 
!is two-step process generated nanotubes 
that had a biocompatible surface coating 
and emitted stable and strongly enhanced 
#uorescence at near-infrared wavelengths.
When the exchanged nanotubes were 
injected into the bloodstream of normal 
and tumour-bearing mice, a detailed map 
of blood vessels (including the smaller 
ones inside the tumour) #uoresced brightly 
through the skin without any interference 
from background auto#uorescence. 
Furthermore, a 15-times lower dose of 
nanotubes was needed to achieve such 
detailed signals when compared with 
nanotubes prepared using the direct 
sonochemical method. !is work shows the 
advantages of #uorescence imaging in the 
second near-infrared window and has opened 
up new imaging possibilities. However, for 
BIOIMAGING
Second window for in vivo imaging
Enhanced fluorescence from carbon nanotubes and advances in near-infrared cameras have opened up a new 
wavelength window for small animal imaging.






















































Figure 1 | Optical windows in biological tissues. 
Top: These plots of e!ective attenuation coe"cient 
(on a log scale) versus wavelength show that 
absorption and scattering from oxygenated blood, 
deoxygenated blood, skin and fatty tissue is lowest 
in either the first (pink shaded area) or second 
(grey) near-infrared window9,10. Bottom: Sensitivity 
curves for typical cameras based on silicon (Si), 
indium gallium arsenide (InGaAs) or mercury 
cadmium telluride (HgCdTe) sensors. Si and InGaAs 
cameras are sensitive within the first and second 
near-infrared windows, respectively, whereas 
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Figure 5: Biological imaging through the near-infrared window. The near-infrared (NIR)
window is the range where ndogen us chromophores (top) have an abs rption minima.
Using the mo t bathochromic range po sible also reduces the impact of scatter. The wind w
can be split into two ranges, based on the efficiencies of imaging sensors available (bottom).
By far, silicon (Si) is the most common imaging sensor material. Reprinted from Smith
et al. [231]
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over the optical and physical properties of semiconductor QDs is why they are useful to
a wide variety of fields and for applications to a variety of devices, such as light-emitting
diodes (LEDs), photodetectors, solar panels, and biological labels.
The first theoretical framework for a semiconductor quantum dot was published in
1981 by Efros and Efros, and they were first synthesized and described by Ekimov and
Onushchenko in the same year.[64, 65] The first reported QDs were copper chloride par-
ticles precipitated from a supersaturated solution in silica glass; it was found that the size
of the particles could be controlled by varying the recondensation time. Interestingly, the
glasses showed absorption spectra with features that would shift as a function of the aver-
age size of the copper chloride particles—these shifts were correctly attributed to quantum
confinement. Quantum confinement is part of what makes quantum dots interesting; by
merely altering the size of a quantum dot, but maintaining the same material composition,
the emission wavelength can be drastically and predictably shifted as shown in Figure 6 on
the next page. In comparison, a fluorescent dye requires alterations to the structure (e.g.,
addition of electron withdrawing groups) and so tuning the fluorescence emission is much
more difficult to predict and accomplish.
A rough conceptual framework for quantum confinement is given by the “particle in
a box” thought experiment, where the energy available to a free particle of a given mass





where En is the sum of kinetic and potential energies (kinetic only in this case), h is Planck’s
constant, n is the quantum number, m is the mass of the particle, and a is the length of the
dimension that the particle is restricted within.[158] It is readily apparent that by decreasing
the size of the dimension that the particle is restricted within increases the energy available
to the particle. This is a reflection of Heisenberg’s uncertainty principle
∆x∆p ≈ h (2)
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Figure 6: Colloidal quantum dots (QDs) have size-dependent emission color. A series of
semiconductor quantum dots, emitting light between 447–665 nm can be simultaneously
excited with a single UV hand lamp. The composition of the particles are the same, only
the size differs. Reprinted by permission from Macmillan Publishers Ltd: Nature Biotech-
nology ref. [93], copyright 2001.
that as the uncertainty of the position, ∆x, of the exciton becomes smaller (i.e., better known
by decreasing the size of the particle), the uncertainty of the exciton momentum, ∆p, must
increase (and so increase the energy of the now confined exciton).[158]
One year after Ekimov and Onushchenko’s report, Rossetti and Brus described radiative
recombination (i.e., fluorescence emission) in cadmium sulfide (CdS) colloids (i.e., fluo-
rescence emission), and Henglein almost simultaneously reported the fluorescence emis-
sion and quenching of cadmium sulfide colloids.[213, 104] Numerous publications on the
properties of various semiconductor colloids followed, in addition to theoretical frame-
works advanced by Brus and Henglein, among others.[79, 134, 263, 223, 24, 23] In 1993,
Murray, Norris, and Bawendi published a seminal paper on the synthesis of high quality
cadmium chalcogenide (group 16 elements) nanoparticles in high temperature organic sol-
vents, and this work has been the basis for creating high-quality semiconductor quantum
dots since.[173] Cadmium chalcogenide QDs are probably the most commonly used QD in
scientific research: much of this popularity can be attributed to the early publication of the
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high quality synthesis method of Murray et al., published when QDs first began attracting
interest from the wider scientific community.
2.4.1 Structure and synthesis
Colloidal semiconductor quantum dots can be made from a range of semiconductor mat-
erials, most commonly group IV-VI and group III-IV materials. As mentioned supra, an
early method for producing high-quality group IV-VI QDs was published by Murray et al.
in 1993, and this method or adaptations of this method are arguably the method used to
produce most QDs for applications in biology. As such, we summarize the procedure of
Murray et al. in detail. The synthesis is based on injecting precursor solutions into a hot
bath (190–300 C, depending on the chalcogen and precursor stock solution, and coordinat-
ing solvent used) of a coordinating solvent. In the original procedure, trioctylphosphine
oxide (TOPO) was heated to 300 C under oxygen-free conditions. Cold precursor solu-
tions of dimethylcadmium ((Me)2Cd) in trioctylphosphine (TOP) and selenium in TOP
(TOP-Se) are mixed and rapidly injected into the hot TOPO bath. The injection of the cold
precursor creates a supersaturated solution and initiates an immediate nucleation and for-
mation of small crystals. The cold precursor also cools the coordinating solvent bath that
the reaction occurs in; the lower temperature, combined with depletion of precursors due
to nucleation, arrests nucleation of new particles and promotes addition of material onto
the already formed crystals. By controlling the temperature of the coordinating solvent, the
growth rate of the already formed crystals can be controlled. The crude reaction mixture
is monitored by optical spectroscopy to estimate the size and distribution of the particles
produced. Once grown to the desired size, the particles are purified from the crude reaction
mix by precipitation in methanol, centrifugation, and resuspension in 1-butanol (“wash-
ing”). The particles are then further purified by size-selective purification, where the bare
minimum of methanol is added to cause the QD solution to become turbid due to floc-
culation of the largest particles. These large particles are then isolated by centrifugation,
19
leaving the smaller particles dispersed in the supernatant. This size-selective precipitation
method can produce a population with a narrow size distribution (less than 5% RMS in
diameter); other solvent systems (e.g., methanol/chloroform) can be used so long as one
solvent is a non-solvent that causes flocculation, and the other solvent is able to disperse
the QDs. In the methanol/1-butanol example, methanol alters the polarity of the solvent,
promoting flocculation through van der Waals forces. Surfactants other than TOPO might
call for a different solvent system for purification and size-selective precipitation.
The isolated and purified particles are then characterized, usually by a combination
of absorption spectroscopy, fluorescence spectroscopy, dynamic light scattering (DLS),
and electron microscopy (EM). Absorption spectroscopy offers a wealth of information
on the electronic structures of the synthesized particles. For example, differences in the
crystal lattice type (zinc blende vs. wurtzite) can be detected through absorption spectro-
scopy. Fluorescence spectroscopy informs on the purity of the particle population: highly
monodisperse samples will have a narrow band-edge emission peak. The lack of “deep
trap” emission (broad, featureless emission bathochromic to the band-edge fluorescence
peak) is indicative of good surface passivation by solubilizing surfactants. Dynamic light
scattering can be used to estimate the size of the particles and polydispersity of the particle
population. Finally, electron microscopy can confirm size estimates from dynamic light
scattering measurements, and also inform on the lattice structure of the particles (provided
the resolution of the microscope is high enough) and the presence of stacking faults in the
crystals. Some electron microscope modalities can also provide chemical analysis, e.g.,
energy dispersive x-ray (EDX). Electron microscopy of QDs is hindered slightly in that the
particles will tend to orient with the long axis on the microscopy substrate.
Colloidal QDs may also be generated with a core/shell structure, each having a differ-
ent material composition. Hines and Guyot-Sionnest reported a simple procedure to grow
a zinc sulfide (ZnS) shell on CdSe particles (CdSe/ZnS) that has inspired numerous refine-
ments to the procedure.[107] As noted by the authors, growing layers of materials with a
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wider bandgap on top of materials with a narrower bandgap insulates the core from the sur-
rounding solvent, reducing the influence of the shell and surface passivation on the optical
properties of the QD. The result are particles with superior quantum yields and increased
resistance to photooxidation. The synthesis itself begins with a variant of the procedure
used by Murray et al., and then adds dimethylzinc and bis(trimethylsilyl)sulfide precursor
solutions in TOP to the freshly synthesized monodisperse CdSe population.[127] The Zn/S
precursors are added in several steps to promote epitaxial growth of ZnS on the existing
CdSe particles. After synthesis, the particles are purified and characterized in the same
fashion as the CdSe cores.
2.4.2 Water solubilization strategies
The QDs synthesized in high-temperature organic solvents are left with a passivating sur-
factant layer that is in most cases insoluble in water. The Nie group has recently published
methods (applicable to other particles in addition to QDs) that can produce particles that are
both good-quality and directly soluble in water.[233, 125] To make the particles usable for
biological applications, they must be made water soluble. Smith et al. reviewed a number
of water solubilization strategies for QDs, exploring the optical and physical properties, re-
sistance to oxidation, and behavior in live cell cultures.[229] Water solubilization strategies
can be divided into methods which replace the hydrophobic surfactants from QD synthesis
with a water-soluble surfactant (ligand exchange); the other major method is to overcoat
the particles with a layer that interfaces with the existing hydrophobic surfactants and also
presents a water-soluble moiety (encapsulation). A comparison of the physical parameters
of QDs with different surface coatings appears in Figure 7 on the following page.
In general, ligand exchange procedures are easy to carry out and can be done quickly.
Many times, the ligand used is a alkane thiol; mercaptoacetic acid (MAA) and mercap-
topropionic acid (MPA) are common monodentate thiol ligands used in exchange. The
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Figure 7: A comparison of quantum dot (QD) surface coatings. Semiconductor quantum
dots (QDs) synthesized in organic solvents (shown in A) can be made water soluble by a
number of different surface chemistries (shown in B–D). The different surfaces produce
QDs of different hydrodynamic sizes (represented in the cartoon figures of B and the dy-
namic light scattering data shown in D). The bulkiness of the polymer coatings can be seen
as the white ring around the dark QD crystals in the transmission electron microscopy fig-
ures of C. Adapted in part from ref. [229]—Reproduced by permission of the PCCP Owner
Societies.
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downside of ligand exchange as a surface coating is that in many cases, it produces parti-
cles that are unstable beyond a few days following the exchange procedure. This instabil-
ity is attributed to the labile nature of the dative metal–thiol bond. Aldana et al. showed
that CdSe QDs promote photocatalytic oxidation of thiol ligands (into dithiols), and that
these oxidized thiols are less able to keep QDs dispersed in solution.[7] Aldana et al. also
showed that the bidentate thiol, dihydrolipoic acid, had no greater resistance to the pho-
tocatalyzed oxidation process than the monodentate thiol ligands, but this later point is
contested.[194, 153] These thiol ligand exchange QDs, in addition to having poor long-
term stability, also tend to have lower quantum yields than encapsulated QDs. Thiol ligand
exchange QDs are also difficult to functionalize through common carbodiimide chemistry,
reducing their ultimate utility for biological applications.[153] Different from the thiol lig-
and exchange methods, Duan and Nie reported a coating made from polyethyleineimine
(PEI), a hyperbranched amine.[62] This coating was reported to be very stable had have
good optical properties. Later, it was reported that this coating also had unusually high
acid stability.[165] Finally, Smith and Nie have recently introduced a multidentate ligand
with combining multiple thiol and amine ligands, with superior stability and brightness in
comparison to thiol ligands.[232]
Encapsulation procedures, in contrast to ligand exchange procedures, require more
time, more reagents, and more skill. The encapsulated QDs produced are however more
photostable, more colloidally stable, and tend to have better optical properties than ligand-
exchange QDs. Much of the improvement in behavior is because the hydrophobic sur-
factant layer from QD synthesis is maintained, and the hydrophobic layer better protects
the QDs from the deleterious effects of molecular oxygen (O2) in the environment. Alky-
lated polymers are a common encapsulation compound because the QDs that result are
colloidally very stable (years in aqueous solution without special storage considerations),
optically very bright, resistant to photooxidation, overall small, and permit facile biocon-
jugation through carbodiimide chemistry.[269, 9] PEGylated lipids are another common
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encapsulation compound: they produce larger particles, but are otherwise similar to the
alkylated polymer QDs with a slightly simpler and faster encapsulation procedure.[63] Fi-
nally, QDs can be encapsulated in a silica shell as was done in one of the original biological
application papers.[22] These particles are chemically very stable, but the overall quantum
yield tends to be low, and the particle size is very large. Commercially, only alkylated
polymer and lipid micelle QDs are found for general sale.
2.4.3 Mechanism of operation
The innerworkings of QDs have been extensively reviewed in the literature.[159, 235, 160,
68, 239, 15, 183] A bulk semiconductor material has a band gap energy dependent on the
material composition. The band gap is the minimum energy required to promote an electron
from the ground state energy level (valence band) into a higher, unoccupied energy level
(conduction band). If a photon with energy greater than the band gap is absorbed by the
bulk semiconductor material, it will result in an electron leaving the valence band and
entering the conduction band. This leaves behind a positively charged hole in the valence
band. The lowest energy configuration is for the electron to remain bound to the hole
through Coulombic attraction, and this quasiparticle atom pair is known as an exciton.
The exciton can later recombine, releasing the energy as a lower energy photon than the
excitation photon—a radiative recombination event. The exciton can also cease existence
through non-radiative pathways such as the ejection of an Auger electron (leaving behind a
charged and non-emitting “dark” QD) or though lattice vibrations (heat). The lifetime of the
exciton is controlled in part by the spacial overlap of the electron and hole wavefunctions,
and is illustrated in Figure 8 on the next page. In this figure, the band gap is depicted as the
vertical distance between the hole and electron wavefunctions.
In a semiconductor quantum dot, the size of the bulk material is reduced below the size
of the exciton (defined as the Bohr exciton diameter). Below the Bohr exciton diameter, the
confinement of the electron and hole wavefunctions increases the energy associated with
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shell growth occurs in three dimensions, the strain in a
nanocrystal should involve a larger volume fraction than in a
superlattice and have a correspondingly larger effect on the XRD
patterns. Consideration of lattice constants only would lead to
the conclusion that the CdSe near the interface experiences a
net compressive strain, while the CdS experiences a net
expansive strain. Thus, there is expected to be a smooth increase
in the average lattice constant and in the distribution of lattice
constants throughout shell growth, even for submonolayer shell
thicknesses. This is consistent with the observed peak shifts
toward larger d-spacings. Indeed, the distribution of bond
lengths resulting from strain is a possible explanation for why
core/shell XRD peak widths stay about the same as those of
the core despite the overall increase in nanocrystal size (see
Figure 8).
Besides its obvious structural effects, strain could also affect
the electronic properties of core/shell nanocrystals. However,
strain could not cause the red shift of absorption spectra
observed here with shell growth. Here, strain can only serve
to decrease the lattice constant of the core (arising from the
epitaxial growth of a material having a smaller lattice constant).
This effect is known from high pressure experiments to shift
the absorption spectra to the blue.38 The extent to which strain
persists in and how it affects the properties of these core/shell
nanocrystals is still unclear, but the possibility of strain extending
even throughout the entire structure cannot be eliminated.
Modeling of the observed XRD patterns by a method previously
outlined30 is a future topic of research and could shed light on
the degree to which strain affects the structure of these
nanocrystals.
Figure 5 shows a high correlation of the PLE (of band edge
emission) and the absorption spectrum of a highly diluted
solution of core/shell nanocrystals. This is evidence for the
efficient transfer of excitations of all energies to the core. This
result is consistent with the removal of most of the core/shell
interface defects (e.g., dangling bonds) to be expected from
epitaxial growth and also with the growth of a defect free shell.
With luminescence lifetimes known to be very long for
homogeneous II-VI nanocrystals,16,21 this efficient energy
transfer between core and shell would seem to be a requirement
for the high quantum yields observed and for the lack of any
deep trap luminescence.
II. Electronic Structure: Photostability and Electronic
Accessibility. Two important features of the structure and
composition of these core/shell nanocrystals are electronic
accessibility and photochemical stability. Both of these phe-
nomena are a result of the details of charge confinement in these
core/shell structures and are consistent with experimental
observations.
The electronic levels of the core/shell nanocrystals are unique
to this type of nanocrystal. Clearly, the core/shell optical
properties do not reflect a superposition of CdS and CdSe
electronic levels. They more reflect a perturbation of the core
by a shell of large band gap material which serves to slightly
decrease the confinement of and increase the quantum yield as
compared to a core nanocrystal. This perturbation results in
new electronic levels that extend throughout the entire structure.
The conservation of shape but overall red shift of the absorption
spectra of core/shell nanocrystals as compared to the core
suggests this model.
It is possible to discuss the evolution of core/shell electronic
levels from both a molecular and a particle-in-a-box viewpoint.
They both result in a consistent model and correctly explain
the experimentally observed electronic properties.
Molecular Orbital Model. The core/shell HOMO and
LUMO energy levels can be qualitatively derived from a
molecular orbital type framework (see Figure 13a,b). Here, the
core and shell are viewed as molecular fragments. Because of
a large quantum confinement effect, molecule-like discrete
energy states are observed in CdSe-only and CdS-only nanoc-
rystal absorption spectra.8,9 In addition, since in core/shell
nanocrystals the core and shell bond together epitaxially (thus
conserving internal symmetry) and with minimal defects, their
energy levels mix and a new set of core/shell levels emerge.
The individual core and shell LUMOs will mix strongly since
they are relatively close in energy (as determined by bulk
electron affinities39 and confinement theory applied to each part
separately). Consequently, the core/shell LUMO will be largely
delocalized throughout the structure. The energy difference
between the core and shell HOMOs, however, is relatively large.
The core/shell HOMO will be predominantly corelike in
character and localized. Thus, electron/hole overlap in the core/
shell first excited state is confined mostly to the core.
Particle-in-a-Box Model. The particle-in-a-box model can
be used to obtain a first qualitative approximation of the electron
and hole wave functions in the core/shell structure, providing
insight into the extent of charge confinement. The parameters
employed in this model must first be estimated. Figure 13
shows both the potentials (solid lines) and the overall electron
and hole energy levels (dashed lines) along a line through the
center of a core (c) and core/shell (d) nanocrystal. The core
(38) Tolbert, S. H.; Herhold, A. B.; Johnson, C. S.; Alivisatos, A. P.
Phys. ReV. Lett. 1994, 73, 3266.
(39) Nethercot, A. H. Phys. ReV. Lett. 1974, 33, 1088.
(40) Schooss, D.; Mews, A.; Eychmuller, A.; Weller, H. Phys. ReV. B
1994, 49, 17072.
(41) Guzelian, A. A. Synthesis and Characterization of III-V Semicon-
ductor Nanocrystals; Guzelian, A. A., Ed.; University of California:
Berkeley, 1996.
Figure 13. Schematic core and core/shell potentials (solid lines) and
electronic energy levels (dashed lines) as described by a molecular
model (a,b) and a particle-in-a-box model (c,d). (a,c) represent a core,
while (b,d) represent a core/shell nanocrystal. “x” represents the
absorption onset for a CdSe core of 34 Å diameter, “y” for a core/
shell grown from this core with a 9 Å thick shell. The Gaussians shown
are the results of effective mass calculations for electron and hole wave
functions. From core to shell, the conduction band potential step is
0.27 eV, while that of the valence band is 0.51 eV. See text.
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Figure 8: A schematic of th el ctronic configuration of two quantum dot (QD) struc-
tures. The electronic states available to a homogenous quantum dot (left) are compared to a
core/shell quantum dot (right), modele with both a mol cular orbital framework (top) or a
particle-in-a-box framework (bottom). The particle-in-a-box framework depicts the differ-
ences in wav function overlap between the ole and electron i n heterogenous core/shell
structure. Reprinted with permission from ref. [197]. Copyright 1997 American Chemical
Society.
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this state—the band gap of semiconductor becomes quantized, and the optical properties
of the resulting QD become size-dependent. The confinement of the electron and hole
wavefunctions also has implications for the excited state lifetime of the QD (since exciton
lifetime is in part controlled by the spacial overlap of the wavefunctions). In a homogenous
material, the overlap is solely controlled by the size of the QD; in a core/shell or other
heterostructure, the electron and hole can be made to occupy discrete regions of the particle.
A long excited-state lifetime can be useful in biological imaging to discriminate signals
from fluorophores from endogenous fluorophores and the biological background.
Nanoparticles have a large surface area to volume ratio. The optical properties of a
QD are therefore influenced by the state of the QD surface. Preventing the exciton from
interacting with the surroundings is critical in producing particles with high quantum yield
(QY, the rate of photons emitted versus photons absorbed). Growing an insulating shell
on the QD is one way the exciton can be isolated from the surroundings, and this is why
a core/shell structure can have improved brightness relative to the core alone. Fully occu-
pying the orbitals of the atoms on the surface of the QD is also critical: unbonded orbitals
with energy within the band gap can act as traps for the excited electron or hole, result-
ing in non-radiative recombination (i.e., no fluorescence), or alternatively, a “deep trap”
recombination pathway. The effects of the surface chemistry on QD optical emission are
diagrammed in Figure 9 on the following page. Deep trap emission is undesirable because
it is broad (due to the presence of many trap sites on the QD of varying energy levels) and
has an overall low QY. The need to fully occupy the surface orbitals is why the QD sur-
face coating has such a great influence on the QD optical properties. Small-molecule thiol
ligand coatings, which are easily oxidized and lost, tend to result in QDs with lower QY
because they leave behind unoccupied orbitals when they become oxidized. Encapsulated
QDs, which preserve the thick organic surfactants from QD synthesis, provide a steric and
non-polar barrier that better protects the surface of QDs. These encapsulated particles thus
tend to have a higher QY.
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crystal or a glass, or suspended in solution and coated with
organic ligands such as trioctylphosphine oxide (TOPO) or
hexadecylamine (HDA). Thereby, the dangling bonds on the
exposed facets are passivated by bonding with atoms or mol-
ecules (Figure 3D), minimizing intraband gap surface states
and reducing surface atomic reconstruction. For colloidal par-
ticle suspensions, molecules such as TOPO and HDA adsorb
to the nanocrystal surface through dative ligand-metal bonds
FIGURE 3. Surface properties of CdSe nanocrystals. Panels (A) and (B) depict transmission electron micrographs of quasi-spherical quantum
dots with two orientations on the substrate, and panel (C) depicts a quantum rod.11 All scale bars are 5 nm. In the atomic models, the
crystalline orientations and lattice facets are identified by their Wurtzite (WZ) Miller indices, and the polarity of each facet is noted as Cd2+
for cationic, Se2- for anionic, and CdSe for nonpolar. Panel (D) illustrates the terminal dangling orbitals on each type of facet, and panel (E)
shows the effects of surface hole traps on the fluorescence of small 2.1 nm nanocrystals.
Semiconductor Nanocrystals Smith and Nie




































































Figure 9: The surface state of a quantum dot (QD) greatly influences its optical pr perties.
The surface chemistry of a quantum dot greatly influences the optical properties because of
the large surface area to volume ratio of nanoparticles. (E, left) A depiction of the energy
states within two quantum dots, one with a anion-rich surface (i.e., selenium-rich), and one
with a cation-rich surface (i.e., cadmium-rich). The dan ling orbitals of the surface anions
can act as exciton traps, altering the radiative recombination pathway and res l ing in a
broad emission profil bathochromic from the band edge emissi n. (D) T e orbitals can
be passivated in a cation-rich surface by surface liga ds, removing the surface trap states,
enhancing band edge emission efficiency, and eliminating the undesirable trap emission as
depicted in ( , right). Adapted in part with permission from ref. [234]. Copyright 2009
American Chemical Society.
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Figure 10: Semiconductor quantum dots (QDs) offer brighter, multiplexed immunoflu-
orescence over fluorescent dyes. Immunofluorescence was performed with QD-antibody
conjugates on prostate tissue. The symmetrical band edge fluorescence emission of quan-
tum dots is distinct from tissue autofluorescence, and the narrow fluorescence bandwidth
allows many colors of quantum dots to be imaged simultaneously without overlap, as shown
in (A). This allows the raw tissue image, (B), to be easily computer-enhanced to show QDs
without background signal, (C). Reprinted with permission from ref. [144]. Copyright
2010 American Chemical Society.
2.4.4 Applications in biology
QDs were first applied in biology by a pair of research teams, simultaneously publishing
in Science in 1998.[22, 33] The number of groups investigating and applying QDs to prob-
lems in biology grew exponentially. QDs are interesting as optical tags for biology appli-
cations because of their numerous advantageous optical properties when compared to more
conventional fluorescent dyes. Many early applications of QDs have focused on in vitro
diagnostics. QDs can be directly substituted for the organic dye fluorophore in immunoflu-
orescence assays, as is shown in Figure 10 on the current page.[271] Using QD-antibody
conjugates, instead of dyes, has three major advantages, some of which are related to the
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Figure 2. Size and composition tuning of optical emission for binary CdSe and ternary CdSeTe quantum dots. A: CdSe QD with various sizes (given as 
diameter) may be tuned to emit throughout the visible region by changing the nanoparticle size while keeping the composition constant. B: The size of QD 
may also be held constant, and the composition may be used to alter the emission wavelength. In the above example, 5 nm diameter quantum dots of the 
ternary alloy CdSe,Tel-, may be tuned to emit at longer wavelengths than either of the binary compounds CdSe and CdTe because of a nonlinear 
relationship between the alloy bandgap energy and composition (the spectrum maximizing near 790 nm corresponds to CdSeo.34Teo.66) (17). 
properties of QD are fundamentally different from that of organic 
dyes, QD could open new possibilities in a number of research areas. 
As shown in Fig. 3, QD have broad excitation profiles and narrow/ 
symmetric emission peaks (commonly 25-35 nm full width at half 
maximum) (25). Therefore, multicolored QD could be simulta- 
neously excited with a single light source, with minimal spectral 
overlap, providing significant advantages for multiplexed detection 
of molecular targets. Furthermore, QD have been shown to remain 
brightly emissive after long periods of excitation, whereas organic 
dyes are photobleached quickly (2,4,5). For these reasons, QD 
provide the possibility of continuous, real-time imaging of single 
molecules and single cells over an extended period of time. 
QD can be tuned to emit in a range of wavelengths by changing the 
nanoparticle size and composition, whereas new organic dyes must 
be developed to shift their emission wavelengths. This tunability 
allows the synthesis of QD that emit in the NIR spectrum, which is 
optimal for deep fluorescence imaging in living organisms (26,27). 
Most organic dyes with NIR emission suffer from low quantum 
yields, rapid photobleaching, poor stability/aggregation or a com- 
bination of these problems (28,29). It is worth noting, however, that 
QD may not be suitable for applications in which the probe size must 
be minimized, such as intermolecular interaction studies where steric 
hindrance could interfere with biomolecular function. Dyes are 
typically an order of magnitude smaller than QD and will continue to 
be useful in these studies (Fig. 3). Organic fluorophores have other 
properties (e.g. self-quenching) that could be problems in some cases 
but could be valuable for other applications such as activatable 
molecular beacon probes (see Future Directions for further discus- 
sion on QD biosensors and activatable probes). 
SYNTHESIS AND BIOCONJUGATION 
Synthesis and capping 
The prototypical QD is CdSe because colloidal syntheses for mo- 
nodispersed nanocrystals of this semiconductor are well established. 
CdSe is most often synthesized through the combination of cadmium 
and selenium precursors in the presence of a QD-binding ligand that 
stabilizes the growing QD particles and prevents their aggregation 
into bulk semiconductors. Among various synthetic methods 
reported in the literature, high-temperature synthesis in coordinating 
solvents has yielded the best-size monodispersity and fluorescence 
efficiencies. A coordinating solvent serves as a solvent and as a 
ligand and is most commonly a mixture of trioctylphosphine, 
trioctylphosphine oxide (TOPO) and hexadecylamine (1 530). The 
basic functional groups of these ligands (phosphines, phosphine 
Figure 3. Comparison of absorbance (blue) and fluorescence (green) spectra between organic dyes (fluorescein isothiocyanate [FITC]) and CdSe quantum 
dots with the same emission wavelength. Note that the emission peak is more narrow and symmetric for the QD spectrum, and the absorption band extends 
far into the ultraviolet region. The size differences of FITC and QD are also shown. 
Figure 11: A comparison f the absorption and fluorescence spectra of fluorescein is thio-
cyanate (FITC) and a semiconductor quantum dot (QD). The absorption and fluorescence
spectra of a standard fluorescent dye, FITC, are shown on the left. The absorption peak is
near the emission peak, and the emission peak is broad and asymmetric. The absorption
and fluorescence spectra of a quantum dot are shown on the right. In comparison to FITC,
the QD absorption spectra is broad, increasing in the blue and ultraviolet range, and the QD
emission spectra is narrow and near Gaussian. Reprinted with permission from ref. [230].
Copyright 2004 John Wiley and Sons.
absorption and emission spectra as shown in Figure 11 on this page. QDs have a broad
absorption range below the band gap, whereas a fluorescent dye has a narrower absorption
peak. The broad absorption band of QDs allows QDs with different emission colors to be
simultaneously excited by a single band of light (e.g., from a HeCd laser), leading to facile
multiplexing. Multiplexing with fluorescent dyes requires a unique and appropriate band
of light for every dye used. Further complicating multiplexing with dyes is that the Stokes
shift (difference in excitation and emission wavelength) is much less for dyes than QDs,
necessitating sharper optical filters for dyes than for QDs. Another advantage of QDs that
leads to facile multiplexing is that the emission from a QD is narrow and roughly symmet-
ric (Gaussian), whereas for a dye is broader and asymmetric. The symmetric fluorescence
spectra of QDs is computationally simple to isolate from both background light and from
other fluorophores. QDs are also much more photostable than fluorescent dyes, in part be-
cause the polymer-encapsulated QDs used for immunofluorescence are well-isolated from
the surrounding solvent by the thick surfactant and polymer coating. Finally, QDs are
also substantially brighter than many fluorescent dyes, in part because of high absorption
cross-sections in the blue-UV light range. The advantages of QDs over fluorescent dyes for
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immunofluorescence applications has been one of the clear successful applications of QDs.
There are numerous examples of cell culture imaging studies where the superior bright-
ness, resistance to photobleaching, and facile multiplexing inherent to QDs have permit-
ted studies that would not be practical with conventional dyes. For example, in an early
in vivo application, “inert” lipid-encapsulated QDs were injected into individual Xenopus
blastomeres and the tissues derived from the injected cell could then be tracked over the
development of the embryo.[63] This concept of tracking cell lineage was later applied to
stem cell tracking, in which parent stem cells were loaded with inert QDs and the differen-
tiated daughter cells could then be tracked.[142, 211, 215] In these examples, the resistance
to photobleaching was a prerequisite to make the long-term tracking study possible. It is
true that similar studies could be done with green fluorescent protein (GFP) or a similar
expressed fluorochrome, but this would necessitate genetic manipulation and could have
undesired side effects. Fluorescent proteins are also less photostable than QDs, although
they are constantly replenished if constitutively expressed. QDs have also seen success for
receptor trafficking studies. In these studies, the superior photostability and ability to track
a single QD (based on the observation of “blinking”, intermittent photoluminescence in-
herent to isolated QDs) made the studies possible. In an early report, Dahan et al. followed
single glycine receptors in neurons in a cell culture system.[48] Dahan and coworkers, in
a later study, also measured the mobility of kinesis motors inside a cell by functionalizing
QDs with kinesin motor proteins, and then delivering these QD-kinesin probes into the cell
cytoplasm.[47] More recently, the receptor-ligand interaction of neurexin and neuroligin
was studied using QDs functionalized with engineered neuroligin constructs and sophisti-
cated computer modeling. [217]
In another proof-of-concept example illustrating the utility of multiplexing in in vivo
imaging, Kobayashi and colleagues injected mice with several dendrimer solutions la-
belled with different dyes in spatially separated areas around the neck so that the lymph
drainage could then be mapped to the specific node responsible for the area, as shown
30
Figure 12: A mouse was injected at different sites around the neck (shown on left diagram)
with differently colored fluorescent dyes, and the lymph drainage for the injection site could
then be tracked to the draining lymph node. Reprinted with permission from ref. [132].
Copyright 2009 American Chemical Society.
in Figure 12.[133, 132] A limitation that was brought up in this study was that the num-
ber of dyes that could simultaneously be used (for near-infrared imaging) was about five;
using QDs with narrower near-Gaussian emission profiles would allow for greater through-
put multiplexing. Gao and colleagues showed that through hyperspectral imaging, QDs
injected into a mouse could be resolved from the background autofluorescence;[86] hyper-
spectral imaging is used in the same way for multiplexed QD imaging.
2.5 Noble metal colloids
Noble metal colloids have a long history of use, predating the concept of nanotechnology.
Early scientific observations of gold and other metal colloids were made by Michael Fara-
day. Faraday observed in 1857 that when a dilute gold solution is mixed with phosphorous,
“a beautiful ruby or amethystene fluid is immediately produced”.[72] Faraday theorized
that the color was due to small gold particles formed by the transfer of chloride from
chloroaurate to phosphorous. He also observed that the gold colloids would appear dif-
ferent, depending on if light were being transmitted or reflected by the solution: a solution
transmitting daylight might appear amethystine, yet appear brown and hazy when reflecting
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the same daylight. Gustav Mie later, in 1908, provided an analytical solution that would
explain Faraday’s observation.[161] Finally, Faraday noted that minute quantities of salt
would cause a normally ruby colored gold solution to become blue or even transparent, and
attributed this color change to the aggregation of the gold particles. Other early experiences
with gold nanoparticles are ruby glasses, made since Roman times, and as a treatment for
rheumatoid arthritis.[259, 172]
Noble metal colloids, especially gold, have been attractive for biological applications
because of unique properties that emerge on the nanoscale. Much of the utility of nanoscale
noble metals is due to localized surface plasmon resonance (LSPR).[116] The LSPR is the
resonant, coherent oscillation of the electrons of a noble metal nanoparticle, in response
to an oscillating electromagnetic (EM) field (i.e., incident light). For both gold and silver,
the LSPR occurs in the visual to near-infrared range; since silver has known toxicities and
rapidly oxidizes in aqueous environments, gold is the preferred noble metal for biological
applications. Noble metal nanoparticles are efficient light scatterers, and so are useful as a
contrast agent by itself. A simple dark-field microscope (similar to a standard microscope,
but with an obstruction in the light path that allows only scattered light to be observed) is all
that is necessary for imaging, and since the imaging is based on scattering, the probes never
photobleach.[66] Non-radiative relaxation of plasmon oscillations results in absorption of
the incident light, and this absorption leads to heating. This local heating effect has been
used by many groups for photothermal ablation as a medical therapy.[67, 190, 189, 113]
Colloidal gold has also seen interest for use as a drug delivery carrier, sometimes in con-
junction with photothermal therapy for triggered release of drugs or simply as an adjuvant.
The high EM fields surrounding the noble metal particles also can be used for enhancement
of Raman scattering.
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2.5.1 Gold colloid synthesis
Gold colloid synthesis is well-described in the literature and simple to execute using com-
mon laboratory equipment.[49] For larger particles (such as the size useful for Raman scat-
tering enhancement), Frens’ method (itself a modification of Turkevich’s method) of citrate
reduction of auroperchlorate is commonly used.[84, 253] In this process, auroperchorate is
refluxed after the addition of a controlled quantity of citrate; the amount of citrate controls
the size of the particle produced. This produces a good yield of gold particles with ac-
ceptable uniformity and in an aqueous solvent. For very small particles (less than 15 nm),
the Brust-Schiffrin method is more common because of the lower polydispersity and better
control over the reaction than Frens’ method.[25] The downside of the Brust method is that
the particles are synthesized in organic solvent, and so must be somehow phase-transferred
into water. The general framework for water solubilizing hydrophobic gold particles is
much the same as it is for QDs.
2.5.2 Raman scattering and enhancement
Raman scattering is the inelastic scattering of light by molecules. Incident light causes the
molecule to enter a virtual energy state corresponding to a vibrational mode, from which it
later returns to a lower energy state. If the molecule returns to the original state, the scat-
tered light will have the same energy as the incident light (Rayleigh scatter). If the molecule
returns to a higher or lower energy state, then the scattered light will have lower or higher
energy than the incident light (anti-Stokes and Stokes scatter, respectively). Raman scatter
differs from fluorescence in that it involves a virtual energy state (and so does not require
a specific wavelength of excitation light) and is a coherent process. The Raman effect is
named for its discoverer, Chandrasekhara Venkata Raman, who in 1928 measured it in sea
water with the assistance of Kariamanickam Srinivasa Krishnan.[203] Raman scattering is
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Figure 13: The Raman emission spectrum is feature-rich in comparison to the Gaussian-
like emission of quantum dots (QDs). The absorption and emission spectra of Raman-
active gold nanoparticles (A) and QDs (B) are shown. The Raman-active particles have
a feature-rich spectrum compared to the broad emission spectra of QDs (which are them-
selves narrower than comparable fluorescent dyes). The gold nanoparticles also have a
surface plasmon resonance absorption peak closer to the near-infrared window, a spectral
region desirable for in vivo imaging. Reprinted by permission from Macmillan Publishers
Ltd: Nature Biotechnology ref. [202], copyright 2008.
“feeble” (in Raman’s words) and is difficult to detect.1 Powerful monochromatic lasers,
sharp optical filters, and amplified detectors have made Raman spectroscopy possible with
small bench-top instruments. Raman spectroscopy has numerous applications in molecular
fingerprinting because it elucidates molecular structure. The discovery of surface-enhanced
Raman scattering (SERS) made Raman even more practical and introduced new applica-
tions of Raman spectroscopy.
SERS was discovered by Fleischman et al. in 1974 in an electrochemical cell exper-
iment; they discovered that the Raman scatter from pyridine was greatly enhanced on
roughened silver electrodes.[78] Later, in 1977, two competing theories were advanced
to explain the SERS enhancement: Jeanmaire and Van Duyne proposed an electromagnetic
enhancement (arising from plasmon oscillations on the roughened surface);[120] Albrecht
and Creighton proposed an enhancement arising from charge-transfer complexes.[6] Both
theories are still debated today. In 1997, Emory and Nie showed that the enhancement
1The Raman effect is so weak that in Raman’s original experiment, sunlight focused with an 18 cm
diameter telescope required multiple hour exposures on photographic plates to detect the Raman-scattered
light.
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factor for SERS using silver nanoparticles could be as high as 1014–1015![182] Such an
enhancement factor is sufficient to detect the Raman scatter of a single molecule. Porter
and coworkers later used SERS enhancement from gold particles with an adsorbed Raman
reporter in an immunoassay;[143] Qian et al. described a superior strategy featuring a heav-
ily PEGylated gold nanoparticle, functionalized with Raman reporters, that is highly stable
in biological fluids and bright enough to be observed through the skin of an animal.[202]
The greatest advantage of SERS particles for biological applications is that the Raman ef-
fect works on any wavelength of light, so deeply-penetrating NIR light can be used for
excitation and the Stokes-scattered light will also be within the NIR range. SERS parti-
cles are also extremely bright and photostable when using NIR excitation (more so than
QDs, as reported by Qian et al.). Finally, gold nanoparticles are regarded as “non-toxic”,
having a history of medicinal use to relieve symptoms of rheumatoid arthritis. As shown
in Figure 13 on the previous page, SERS particles have a feature-rich emission spectrum
when compared to the near-Gaussian emission of QDs or the broad emission of fluorescent
dyes—the feature-rich spectrum can be advantageous for multiplexing.
2.6 Application of nanotechnology to cancer imaging and therapy
The U.S. National Institutes of Health, recognizing the potential of nanotechnology for can-
cer diagnostics and therapy, launched an “Alliance for Nanotechnology in Cancer” through
the National Cancer Institute in 2004. This effort has catalyzed the development of a wide
variety and number of nanotechnologies targeting cancer (including supporting some of the
work appearing in this dissertation).
For diagnostics, nanotechnology can provide improved imaging agents that have greater
sensitivity and specificity than conventional agents. For example, iron oxide becomes su-
perparamagnetic (magnetic only in the presence of an applied magnetic field) when reduced
in size down to a single magnetic domain. These iron oxide nanoparticles (called SPIONs,
MIONs, CLIO, &c.) are useful as a magnetic resonance (MR) imaging contrast agent.
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They can also be functionalized with fluorescent dyes or chelating functional groups: such
dual-functionality particles can be used for combined MR/fluorescence and MR/positron
emission tomography.[130, 124, 89] QDs and colloidal gold (both for LSPR imaging and
SERS imaging) are useful for sensitive immunohistochemistry of tissue samples. Since
cancer is a heterogenous disease, the ability to probe multiple cancer markers simultane-
ously is important. As discussed supra, both QDs and SERS nanoparticles are useful for
multiplexed imaging. Nanoscale gold is also more reactive than bulk gold—this reactivity
can be combined with silver enhancement for sensitive diagnostic assays.[246]
Nanotechnology is useful for cancer therapy as well. Standard chemotherapeutics like
paclitaxel and doxorubicin have a number of undesirable side effects, some due the excipi-
ents needed to solubilize the chemotherapeutic (e.g., the ethanol and polyethoxylated castor
oil used for taxanes), some due to the compound mode of action itself (e.g., cardiomyopa-
thy for doxorubicin, ototoxicity for cisplatin). Using nanotechnology to create carriers for
chemotherapeutics can overcome these problems. Nanocarriers can be targeted such that
the carriers preferentially accumulate within tumors. The circulation time of the drug and
release of the cargo can also be carefully tailored so that the drug is more likely to release
inside a cancer cell. Already, several nano drugs are FDA-approved (e.g., Doxil, liposo-
mal doxorubicin; Abraxane, albumin-encapsulated taxol) and many more are in clinical
trials (24 reported in 2008).[277] These first-generation drugs rely on a passive accumu-
lation mechanism described infra. Abraxane is also reported to take advantage of active
albumin transport.[97] A large research effort is also in developing “active targeting” drugs
that bind to specific cancer targets, further increasing specificity of the drug and reducing
off-target effects.[250, 251] Finally, nanotechnology can be used to destroy cancer without
using chemotherapeutics, overcoming drug resistence. As noted earlier, colloidal gold can
be used as a photothermal sensitizer, causing localized heating that destroys cancer. Like-
wise, magnetic nanoparticles can be used as a radiofrequency ablation sensitizer, which
also produces localized heating.[155, 105]
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2.6.1 The enhanced permeability and retention effect
The “enhanced permeability and retention” (EPR) effect is the observation that tumors tend
to have a poorly-defined vascular support network and that colloids will tend to extravasate
and accumulate in these areas more so than in normal tissue.[152, 117, 276, 119, 118, 85]
As was discussed in Chapter 1, one of the hallmarks of cancer is the ability to promote the
formation of neovasculature (angiogenesis). This neovascultare is required to supply the
rapidly growing tumor with nutrients—without the neovasculature, the tumor cannot grow
larger than a few hundred microns in diameter. The rapid and disorderly growth of tu-
mors prevents the development of a proper and mature vasculature and lymphatics within
the tumor. As a result, the tumor has a “leaky” vasculature that permits extravasation
of macromolecules combined with poor lymphatic drainage that can clear these macro-
molecules out of the tumor. This is the mechanism behind the EPR effect. Particles in the
20–200 nm size range are well-positioned to exploit the EPR effect to accumulate within
tumors more than within normal tissue. The leakiness of tumor vasculature is not unique in
the body: inflamed tissues also have increased vascular permeability (of course, an inflam-
matory component is also associated with tumors), as do recently injured areas (e.g., an
incisional biopsy site). These areas would also be expected to accumulate macromolecules
by the EPR effect.
2.7 Toxicity associated with nanoparticles
Toxicity associated with nanoparticles is a concern.[185, 75, 260, 240, 156, 282, 61] It is
important to note that while the nanoparticles discussed in this work are man-made, there
are many examples of naturally-occurring nanoparticles. For example, the soot from a
dirty fire has a mixture of carbon fullerenes, and fullerenes have been found in prehistoric
mineral deposits.[35, 26] Since nanoparticles can be found in nature, it is reasonable to
assume that there are some biological responses evolved to handle nanoparticle exposure.
There have been numerous studies of the toxicity associated with particulate inhalation,
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some of which examined particles in the submicron regime.[136, 61] Nanotoxicology ex-
amines many effects that can cause toxicity: colloidal toxicity, the toxicity of the particles
themselves (often linked to the relatively high surface area of nanoparticles); elemental
toxicity, the toxicity associated with the material making up the particle; and also consid-
ering biopersistence, the tendency of the particles to remain in the organism. The exposure
route is also important: nanoparticles have been shown to cross the skin, lung endothelium,
intestinal tract, and even translocate along neural tracts.[106, 167, 214, 31, 186, 69]
Of the nanoparticles addressed in this dissertation, QDs receive the greater scrutiny for
toxicity. Much of the discussion centers on the elemental composition of the QDs. As dis-
cussed supra, the utility of a QD is that the band gap of the particle, and so the fluorescence
emission wavelength, can be tuned by altering the size of the structure. Additionally, the
composition of the structure can also be altered to change the band gap. The problem is
that the materials with a band gap that results in useful biological imaging (visual to NIR
range) are toxic in elemental form. The group IV-VI QDs used for biological imaging are
commonly made from cadmium, selenium, and tellurium; cadmium and tellurium are both
highly toxic, and selenium, while a necessary trace element, is toxic in the moderate quan-
tities. Other materials commonly used for QDs include lead, mercury, arsenic, and indium.
All of these elements cause nephrotoxicity, among other problems.[14, 59] There have been
efforts to make “doped dots”, zinc-based quantum dots that use a dopant of manganese or
copper as a fluorescence recombination site, but these QDs have inferior optical properties
in comparison to the traditional, heavy-metal containing QDs.[270, 200] The toxic com-
position of QDs may not directly translate to organism toxicity: while the components are
known toxins, the toxicity of the elements in the form of a nanocrystal are unknown. Many
studies have attempted to find out if QDs will degrade in biological systems, leading to ex-
posure to heavy metal ions. Hardman reviewed the toxicology literature pertaining to QDs
in 2006 and found that there was no clear consensus on the toxicity of QDs.[95] Partly,
this is because of the lack of the differences in QDs used by the laboratories doing toxicity
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research. Some cell model studies have shown some signs of short-term toxicity, but in
these cases the particles tend to be types known to be colloidally and chemically unstable
during the time course of the experiment (oftentimes CdTe nanoparticles synthesized in
aqueous solution).[226, 279, 147, 278] Cellular studies using more stable core/shell QDs
with thick polymer shells, the type more likely to be used in vivo, do not show short-term
toxicity.[56] More recent long-term studies of QDs in animal models has shown no overt
toxicity effects.[77, 96, 141] Biopersistence is also problematic: heavy metal-containing
QDs that remain in the mononuclear phagocyte system (MPS) (liver, spleen, kidneys) for
years are more of a concern than QDs that are rapidly eliminated from the body. In general,
QDs (and nanoparticles in general) that are systemically injected are found in the MPS and
persist.[199, 4, 39, 221, 137, 138, 76, 13] Designing QDs to be rapidly eliminated from the
body is one way to address issues of toxicity. Choi et al. designed QDs to be efficiently
excreted in the urine, addressing this problem.[40]
Gold colloids do not share the toxicity concerns of QDs, and this is known in part
because of a history of use in human medicine as an anti-inflammatory therapy. Gold leaf
is used as a decoration on foods and in drinks, and can be consumed without deleterious
effects (e.g., gold flakes in Goldschläger). The response of cells to gold nanoparticles is
known to be size and surface-coating dependent.[122] Small gold clusters (i.e., 1.4 nm in
diameter) show severe toxicity effects, presumably due to the reactive nature of gold at that
scale;[191] in contrast, the size and particle coating used for SERS tags (approximately
60 nm gold core diameter, 80 nm total hydrodynamic radius) shows no obvious toxicity
problems.[202, 236, 53] Bulk gold is known for corrosion resistance (famously requiring
aqua regia, “royal water”, for dissolution), and so it is unlikely that the body can degrade
gold colloid. Small gold particles, below the renal excretion threshold, are eliminated in




Nanotechnology is a disruptive and transformative technology because it permits fine-
grained control over materials to expose properties that are unavailable in bulk form. The
application of nanotechnology to cancer diagnostics and therapy is but one promising area
where nanotechnology can make drastic improvements. Semiconductor quantum dots as
a class of nanoparticles received early attention as biological labels primarily because of
the superior optical properties when compared to existing fluorescent labels. There are
many applications where the superior photobrightness and photostability of quantum dots,
in addition to facile multiplexing, have enabled scientific investigations that would not be
possible or practical with conventional fluorophores. Gold nanoparticles have also shown
promise as labels (both through light scattering and as enhancers of Raman scattering)
and photothermal sensitizers. For both of these types of nanoparticles, toxicity has been
a concern (as with all nanotechnology). Early nanotoxicology studies have in some cases




INSTRUMENTATION FOR GUIDING CANCER SURGERY
3.1 Abstract
Surgery is an effective treatment for a wide range of tumors. Generally speaking, complete
removal of a tumor produces a cure. Producing “clean” surgical margins (i.e., no resid-
ual tumor within the surgical cavity) requires removal of small adjacent sites of tumor and
nearby metastatic lymph nodes. Complete tumor removal as confirmed by post-operative
pathology is prognostic of a good surgical outcome. Nevertheless, in a large number of
cases, the surgeon cannot establish during the surgical procedure whether complete tu-
mor removal has been accomplished. Technology to improve the ability of a surgeon to
intraoperatively and in real-time determine the extent of a tumor and the status of tumor re-
moval would be expected to dramatically improve patient care. In this chapter, we describe
an instrumentation platform technology that combines point spectroscopy and widefield
imaging for intraoperative surgical guidance using exogenous contrast agents. This plat-
form has been implemented as a prototype and is presented here for characterization and
validation.
3.2 Introduction
Surgery is an effective tool in treating cancer. It is intuitive that if a tumor could be resected
(physically removed), leaving no tumor behind, that the patient could be cured. It has been
reported that surgery alone can, in fact, be curative in approximately 45% of cases.[52] In
practice, effecting a complete cure through surgery alone is challenging. While in the oper-
ating theater, a practicing surgeon is guided primarily by sight and palpation in locating and
removing a tumor. Preoperative imaging is used for diagnosing a tumor, but preoperative
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imaging is not useful during the surgical procedure. The surgical procedure itself distorts
the body, due to differences in tissue locations (e.g., deflating a lung, moving organs while
searching the mesenteries for a lymph node) between preoperative imaging and surgical
procedures, as well as the distortion of removing tissue! Tumor boundaries are often ill
defined, both in gross appearance and histologically. Simply finding the tumor boundaries
in these cases can pose a challenge, especially if the tumor is small or invasive. Relying on
senses alone also limits the size of the tumor that can be located. If the tumor is not com-
pletely resected, either because the surgical margin (resection boundary) contains tumor or
because there were undetected small satellite tumors not contiguous with the main mass,
then the patient’s prognosis worsens.[242, 1] Following surgery, the area operated on will
develop scar tissue because of the local trauma delivered during the surgical procedure.
This scar tissue is dense and fibrotic, and makes it difficult or impossible to differentiate
from residual tumor on palpation or visual inspection. Because it is difficult to determine
the extent of neoplasia in a scarred area, a scar revision surgery (a follow up surgery to
remove residual disease) removes the entire scarred area. As can be imagined, this is not
always practical because would closure requires a minimum amount of tissue. The diffi-
culty in effecting a complete cure through surgery is why surgery is usually combined with
postoperative chemotherapy or radiation therapy.[283, 42, 123, 237, 110, 228, 266]
The desire to effect a complete cure through surgery (and thus avoid chemotherapy or
radiation therapy) drives interest in intraoperative guidance. Previously, both MR imaging
and sonography have been investigated for providing intraoperative guidance.[204, 179]
Intraoperative MR is cost-prohibitive, bulky, time-consuming, and technically involved to
use in the operating room. In addition to precluding the use of metallic tools, the patient
must be physically moved to the MR scanner while making sure that the patient remains
intubated, intravenous lines remain in place, and sterility is maintained. Once at the MR
scanner, the patient must then undergo a lengthy imaging sequence, at which point the
patient is moved back to the procedure area. Any time added to the surgical procedure
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greatly increases costs and risk to the patient due to anesthesia. Intraoperative sonography
is promising, but it has limited spatial sensitivity and the ultrasound beam can be blocked
by bone. Both scintigraphy and intraoperative computed tomography (CT) are available
for intraoperative guidance, but both expose the patient and operators to radiation. The
radiation dose from CT scans of patients through conventional medical practices is already
a concern;[51] increasing the dose through repeated intraoperative imaging scans is obvi-
ously undesirable and would be avoided if an alternative existed. It can also be argued
at both MR and CT are not real-time technologies since the patient cannot be worked on
during the imaging sequence. Beyond imaging, there is a limited time window in which to
conduct intraoperative pathology, limited again by the time the patient must be under gen-
eral anesthesia and by the availability of attending pathologists. Intraoperative pathology
is done by frozen sectioning, which is labor intensive, or by touch preparation, which is
insensitive and operator dependent. A technique that avoids using ionizing radiation and is
real-time, has good spatial sensitivity, and uses compact equipment, would be welcomed in
the operating room.
In this chapter, we describe intraoperative imaging instrumentation that can be com-
bined into an integrated system. One instrument, the “SpectroPen”, is a hand-held spec-
trometer; the other instrument is a widefield imaging head designed to sit overtop the sur-
gical field. Spectroscopy systems for medical applications have been described previously,
but these systems typically rely on intrinsic biological signals (e.g., intrinsic Raman or cel-
lular organelle scattering).[150, 170, 171, 281] Normal patient-to-patient variability means
that the intrinsic signals between normal and abnormal will vary between patients.[140] Us-
ing an exogenous agent that preferentially accumulates within abnormal tissue to provide
contrast overcomes patient-to-patient variability. Thus, we have optimized this instrument-
ation to work with fluorescent dyes (one of which is FDA-approved for human use) and
SERS nanoparticles. Widefield imaging has been applied to intraoperative surgical gui-
dance, but previous schemes have used wide area illumination.[252, 224, 225, 206, 52, 180]
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Using wide area illumination requires powerful illumination sources to provide suffi-
cient excitation irradiance.[88] These high power light sources raise safety concerns (e.g.,
high power lasers, high voltage sources) and color the operative field, distracting the
surgeon.[252] In contrast, we use the local excitation from the SpectroPen for widefield
imaging, overcoming the limitations of wide area illumination. While each individual in-
strument has been described in the literature previously, combining the two is novel. In this
chapter, we describe the design and validation of the instruments; in Chapter 4, we provide
examples of the system in use for intraoperative guidance.
3.3 Methods
3.3.1 Contrast agents
Indocyanine green (ICG) was diluted into phosphate-buffered saline (PBS) containing 4%
(w/v) of bovine serum albumin (BSA), similar to the concentration of serum albumins in
human blood.
Surface-enhanced Raman scattering (SERS) nanoparticles were encoded with the Ra-
man reporting dye 3,3’-diethylthiatricarbocyanine (DTTC), and the resulting particle was
called DTTC-SERS. The procedure used was from Qian et al.[202] DTTC at 4 µmol/L in
PBS was added to 60 nm gold colloid from a commercial supplier such that there were
approximately 2 × 104 DTTC molecules per gold nanoparticle. Gold nanoparticle concen-
tration was estimated from ultraviolet-visible (UV-vis) spectroscopy of the surface plasmon
resonance peak.[91] Once encoded with DTTC, the gold particles were mixed with an ex-
cess of a 10 µmol/L solution of 5k PEG-SH (5000 MW polyethylene glycol-thiol) solution
and purified by repeated centrifugation and resuspension in a bench top microcentrifuge.
3.3.2 Local excitation and spectroscopy (“SpectroPen”)
3.3.2.1 Design and construction
A commercial off-the-shelf fiber-coupled Raman spectrometer remote head was coupled
to a commercial off-the-shelf bench-top Raman spectrograph. The excitation fiber to the
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remote head was directly coupled to a pig-tailed laser diode in the spectrograph. The col-
lection fiber from the remote head was placed at the entrance to the spectrograph.
3.3.2.2 Validation
Unless otherwise noted, all experiments placed the SpectroPen head 1 cm from the in-
spected area.
The SpectroPen was compared to a commercial bench-top Raman spectrograph by
recording the Raman spectra of polystyrene without background subtraction. The spec-
tra were normalized to the 1001.4 cm-1peak for comparison.
To test the the detection of ICG and DTTC-SERS in porcine fat, the contrast agents
were diluted to 2 nmol/L and 20 pmol/L respectively to record pure spectra in PBS. Porcine
fat was then incubated in ICG at 650 nmol/L and DTTC-SERS at 300 pmol/L, both in
PBS, to saturate with contrast agent for the mixed signal case. The background signal was
recorded from porcine fat not mixed with contrast agent. To generate a reference back-
ground spectra for subtraction, a spectra of 4 points was acquired from normal tissue and
averaged. The background averaged spectra was linearly subtracted from the mixed con-
trast agent and fat signal or background signal to recover the contrast agent or background
signals, respectively.
To measure the limit of detection for the SpectroPen, ICG or DTTC-SERS were diluted
in a black 96-well microtiter plate. ICG was diluted within the range of 0.05–25 nmol/L,
DTTC-SERS nanoparticles were diluted within the range of 0.2–37.6 pmol/L. 4 samples
were measured for each indicated concentration. Lines of fit were a least-squares linear
regression.
The depth of penetration for the SpectroPen in detecting contrast agents was measured
by soaking 8 mm3 tissue in the contrast agent, either 650 nmol/L ICG or 300 pmol/L
DTTC-SERS in PBS. The tissue was placed underneath the SpectroPen and covered with
a layer of polyvinylidine chloride “plastic wrap”. Thin slices of tissue were then overlain
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on top. The distance between the SpectroPen and top-most tissue surface was maintained
at 1 cm.
3.3.3 Widefield imaging head
3.3.3.1 Design and construction
A commercial off-the-shelf C-mount lens designed for broadband imaging between 400–
1000 nm with a 35 mm focal length and f /1.9 maximum aperture was used as a common
objective. Lens layout to extend the focal length and collimate the light from the common
objective was done through a commercial computer software package. The commercial
objective was modeled as a perfect lens as no lens prescription was available. Design goals
were for a 45 cm object distance, 5 cm object height, a 1/2 inch diagonal camera sensor for
the imaging plane, and a collimated light path for filtering. The optimized field lens design
to extend the objective lens used a convex lens with focal length of 60 mm, a positive
meniscus lens with focal length 100mm, and a biconcave lens with focal length of -50 mm;
an achromatic doublet with focal length of 45 mm was used for collimation. The field lens
group and collimating lens were coated with a magnesium fluoride (MgF2) antireflection
layer optimized for 700–1000 nm. The common objective, field lenses, and collimating
lens were mounted in a single lens tube, in that order. The light from the objective lens
group was then folded 90 degrees by a protected silver mirror. Two dichroic mirrors were
mounted sequentially in the collimated light path using kinetic mirror mounts. The first
dichroic encountered is a short-pass dichroic mirror with a center wavelength cut-on of
800 nm and mounted at a 45 degree angle to the collimated light path. The reflected light
is filtered through a rugate notch filter centered at 785 nm to reject Rayleigh scattered laser
light and a bandpass filter with center wavelength of 820 nm and a 25 nm bandwidth. The
light is then focused onto the 1/2 inch camera sensor. This is the NIR channel. The filters,
lens, and camera were mounted onto a common lens tube in that order. The next dichroic
mirror encountered is a short-pass with a center wavelength of 700 nm and mounted at a 45
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degree angle to the collimated light path, and 90 degrees relative to the first dichroic. The
reflected light from this dichroic is filtered through an absorptive neutral density filter with
optical density 2 and coated with an MgF2 antireflection layer optimized for 700–1000 nm.
The attenuated light is then focused onto the 1/2 inch camera sensor. The filter, lens, and
camera were mounted onto a common lens tube in that order. This is the laser tracking
channel. The remaining collimated light transmitted through both dichroics is the color
anatomic view, and is directly used for the color camera. For all 3 channels, the light is
focused onto the camera sensor using an achromatic doublet with a focal length of 45 mm;
the NIR and laser channels have lenses coated with an MgF2 antireflection layer optimized
for 700–1000 nm, the color channel is coated with an MgF2 antireflection layer optimized
for 400–700 nm. A detailed listing of the optical prescription appears in Appendix B.
All lenses, mirrors, and filters are 25.4 mm in diameter. All lens tubes (containing the
lenses and attached cameras) were mounted in slip rings, and these and the other optical
parts were mounted onto a breadboard using standard opto-mechanics parts. The cameras
selected are 1/2 inch uncooled and interlaced silicon CCD sensors with good NIR quantum
efficiency (QE). The cameras are connected by Firewire 400 interface to the computer.
Sensor resolution is 768 × 492, with a pixel size of 8.4 µm × 9.8 µm. The sensors used for
each channel are the same, however the color channel has a Bayer mosaic filter to provide
color imaging, and the NIR and laser channel cameras have no NIR light filter in place.
Overall QE is reported to be 47% at 800 nm for the camera sensor, as reported by the
manufacturer. Illumination of the surgical field was provided by two consumer white-LED
lamps, 40 W each.
The widefield imaging software was written in the C-sharp programming language.
The program uses an application programming interface (API) provided by the camera
vendor. The program is multithreaded: each camera channel acquires frames in a separate
programming thread. The acquisition thread for the NIR frame thresholds the image at
a user-specified level to create a binary mask of NIR probe signal each time a frame is
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acquired. The acquisition thread for the laser tracking channel thresholds the image at
a user-specified level to create a binary mask of the laser position. This centroid of the
positive area in the mask is then calculated, along with the diameter of the area. The
NIR probe mask frame, as well as the laser position information, are acquired by the color
channel thread each frame of the color channel to create the composite view. The composite
frame is the sum of the NIR frame mask (with a cyan false-color applied) and a circle at the
laser centroid and with the laser diameter overlain using the camera vendor API. Additional
video signal processing can be enabled by the system operator and is processed during the
overlay generation. One processing mode, called “virtual phosphorescence” (VP), adds a
delay time to any NIR signal selected for video overlay. When the user elects to use the
VP filter, an accumulation buffer is initialized. As each new frame is acquired by the NIR
camera process, the accumulation buffer is multiplied by a decaying exponential function.
The decay constant is user set, and is defined by the amount of time the user would like the
display to persist. The decay constant is found by solving the equation
I(t) = I(0) · e−D·t (3)
where I is the pixel intensity in the frame, I(t) is the new pixel intensity at the given time
index, e is the base of the natural logarithms, D is the decay constant, and t is the time
index. The equation is solved for D and parameterized for the decay time τ = t, using 255








Applying the decay (“aging” the accumulation buffer) is then done by multiplying every
pixel in the accumulation buffer by
I(s + 1) = I(s) ∗ exp(−D(τ) ∗ ∆s) (5)
where s is discrete time (between frames), I(s+1) and I(s) are respectively the new and old
values of the intensity at the given pixel, exp() is the exponential function, D(τ) is the decay
constant calculated in Eq. (4), and ∆s is the time between frames (i.e., frame interval).
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The software is able to record still images or live video (with MPEG-4 compression) for
documentation (without the effects of overlays or video filters applied), as well as metadata
about the experiment (e.g., mouse tumor model used, contrast agent dose and type) in a
plain text file. A pseudocode description of the software appears in Appendix C.
3.3.3.2 Validation
The minimum resolvable contrast of the imaging head was measured using the USAF-
1951 test pattern, finding the smallest line pairing that could be resolved by line profile
measurement compared to half the value of the square target. Each element, E, of each
group, G, of the USAF-1951 chart has an associated resolution of
Resolution (lp/mm) = 2G+(E−1)/6 (6)
Eq. (6) was used to find the resolution of the smallest element with line pairs that could
still be resolved based on visual inspection.
The modulation transfer function (MTF) of the optical system was calculated from an
image of a slanted knife-edge at a 5 degree angle. The image of the knife-edge was profiled
to create a line spread function. The line spread function was transformed to the frequency
domain through a discrete Fourier transform to generate the MTF.
For limit of detection test, ICG was diluted into a 5% (w/v) tissue homogenate of a
murine tumor model (described further in Chapter 4, Section 4.3.2.1). The ICG fluores-
cence was recorded by placing the SpectroPen at an angle such that the sample, in a glass
vial, was visible by the widefield imaging head. The NIR images recorded of the sample
vial were analyzed by dosimetry: the area of the vial was selected, and the sum of values
in the image was recorded to find the integrated fluorescence over the sample volume. 3
samples were recorded for each data point, ranging from 0.15 nmol/L ICG to 15 nmol/L
ICG. The data were analyzed by linear regression.
49
3.4 Results and discussion
3.4.1 Local excitation and spectroscopy (“SpectroPen”)
3.4.1.1 Design and construction
To make spectroscopic readings possible in an operating room environment, the spectrome-
ter needs to be rugged, compact, ergonomic, and simple to use. The hand-held spectrograph
our group has designed, which we call the “SpectroPen”, is based off of commercially avail-
able parts and meets the above requirements and is pictured in Figure 14 on the following
page. The imaging head is a hand-held probe designed for Raman spectroscopy. Although
compact, is is a sophisticated design. The body is stainless steel, 12.7 mm in diameter,
and 76 mm long. The hand-held unit is fiber-coupled to a spectrometer by a co-linear fiber
design. The excitation fiber light is collimated before passing through a band-pass filter for
cleanup and through a dichroic mirror into a common focusing lens. Emitted light from
the sample is collected by the common focusing lens, reflected by the dichroic mirror and
passes through a long-pass filter to reject reflected laser light. The emitted light is then
focused into a return emission fiber. The co-linear fiber arrangement attenuates Rayleigh
scatter return by 108 because it filters light in both the excitation light before it is directed
to the sample and the emission light before it enters the collection fiber.[29, 30] The current
head unit has a focal length of 0.5 cm with a 100 micron diameter spot size and is designed
for 785 nm excitation light. The head unit is fiber-coupled through a 5 m fiber-optic cable
into a commercial bench top Raman spectrograph. Excitation light is provided by a 100
mW pig-tailed laser diode in the spectrograph, and the emission fiber is coupled to the in-
strument at the entrance to the spectrograph. The spectrograph design uses a fixed grating.
The SpectroPen was compared against a commercial bench-top spectrograph of the same
type used as the basis for the SpectroPen in Figure 15 on page 52. The performance of
the two instruments at equal integration times is similar. Both instruments perform well
in distinguishing between the close polystyrene peaks at 1001.4 and 1031.8 cm-1. The
SpectroPen shows slight attenuation in the higher wavenumber region, but this is balanced
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A
Figure 14: The “SpectroPen” hand-held Raman spectrometer. (A) The SpectroPen being
held next to common surgical tools. (B) The optical layout inside the SpectroPen head
unit: there are two fibers, one for excitation (Ex) and one for collected emission light (Em),
coupled through a series of band-pass filters (BP), long-pass filters (LP), dichroic mirrors
(D), and reflective mirrors (M). The current implementation couples the SpectroPen head
unit through 5 m of cable, terminating in the spectrometer proper as shown in (C). Panels
(B) and (C) are adapted in part with permission from ref. [166]. Copyright 2010 American
Chemical Society.
by slightly greater sensitivity in the lower wavenumber region. For fluorescence, the lower
wavenumber region closer to the excitation light is more important, whereas for Raman,
the higher wavenumber region (the fingerprint region) is more important.
3.4.1.2 Validation
We next measured the ability of the SpectroPen to measure indocyanine green (ICG), a
Food and Drug Administration (FDA) approved contrast agent. The ICG optical properties
change greatly depending on solvent and the presence of solutes, but the properties have
been exhaustively characterized.[198] In pure water, the absorption and emission max-
ima of ICG (780 nm/800 nm) are well matched to the SpectroPen excitation laser and
spectrograph operating range (800–930 nm). When bound to albumin (as would happen
on systemic injection of ICG), both values redshift by approximately 10 nm. Since the
SpectroPen is designed for in vivo applications, we tested the ability of the SpectroPen to
detect ICG fluorescence or Raman scattering from surface-enhanced Raman scattering gold
nanoparticles, encoded with 3,3’-diethylthiatricarbocyanine (DTTC) as a Raman reporter.
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Figure 15: The “SpectroPen” recorded spectra match with those recorded by conventional
spectrometers. Raw Raman spectra from polystyrene were recorded on both the SpectroPen
and a standard, commercial bench-top Raman spectrograph. The spectra were normalized
to the major peak of polystyrene at 1001.4 cm-1. The spectra recorded are similar, with
only slight differences in recorded intensity but identical peak locations.
As shown in Figure 16 on the following page, both ICG and DTTC-SERS are readily de-
tectable by the SpectroPen when in pure solution or when mixed with porcine fat. Inter-
estingly, fat itself has Raman features that are easy to detect. Simple linear subtraction of
an averaged background signal are able in this experiment to restore the original spectra of
ICG and DTTC-SERS. Subtracting the averaged background signal from pure porcine fat
results in what is essentially noise, validating this background subtraction method.
We then tested the linearity of the SpectroPen in measuring both ICG and DTTC-SERS
nanoparticles in pure solution at two integration times (0.1 and 1 second) that are clinically
useful. The SpectroPen is able to detect both ICG and DTTC-SERS, at both integration
times, with a linear response as shown in Figure 17 on page 54. The response encompasses
a 50–60 fold dynamic range. Typically for imaging contrast agents, there is a contrast
ratio of less than 5 between the background and contrast-enhanced regions.[83] Thus, the
instrument is well-positioned to detect both normal tissue background and any contrast
agent likely to be used in the near future under the same instrument settings.
A difficulty in using light for medical imaging is that the penetration depth in tissue
is limited due to absorption and scatter. Using NIR light mitigates these problems. For
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Figure 16: Indocyanine green (ICG) and Raman (SERS) nanoparticles can be distin-
guished from the biological background. Spectra of ICG (A) or SERS nanoparticles (B)
were recorded alone or mixed with porcine fat. Using the pure porcine fat spectra, the
original probe spectra could be recovered. Spectra are scaled by the noted scaling factors.
Reprinted with permission from ref. [166]. Copyright 2010 American Chemical Society.
surgical applications, surface imaging is tolerable because organs and tissues can be me-
chanically moved out of the way to image deeper, and for surgical oncology, it is the mar-
gin status (by definition on the surface) that is of concern. We quantified the ability of the
SpectroPen to detect both ICG and DTTC-SERS contrast agents underneath porcine fat,
liver, and lung. As shown in Figure 18 on page 55, for all cases DTTC-SERS nanoparticles
can be detected deeper in tissue than ICG. One reason the DTTC-SERS nanoparticles can
be detected deeper in tissue might be because DTTC has strong Raman peaks Stokes-
shifted from the laser excitation line, whereas the ICG emission peak is close to the laser
excitation line. The bathochromic infrared light of the DTTC Raman peaks relative to
ICG will scatter less in tissue and so will be slightly deeper penetrating. The feature-rich
emission from SERS tags also increases the ability to pick out the Raman signature from
the background. These data show ICG has a detection depth limit of 1–3 mm in tissue,
whereas DTTC-SERS nanoparticles have a detection depth limit of approximately 5–7 mm
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Figure 17: Limit of detection for the “SpectroPen”for both indocyanine green (ICG) and
surface-enhanced Raman scattering (SERS) particles. For the tested integration times of
0.1 or 1 second, the SpectroPen response is linear. Regression lines are a linear model,
with the 95% confidence interval for the fit shown in flanking red dashed lines. Reprinted
with permission from ref. [166]. Copyright 2010 American Chemical Society.
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Figure 18: Depth of penetration of “SpectroPen” for detecting indocyanine green (ICG)
and Raman (SERS) nanoparticles underneath tissue. (A) The experimental setup for deter-
mining the depth of penetration for the SpectroPen to detect ICG or SERS nanoparticles
deposited in tissue. The detected ICG (B) and SERS (C) signals obscured in tissues atten-
uate as a function of the probe depth in tissue in an exponential-like decay. Reprinted with
permission from ref. [166]. Copyright 2010 American Chemical Society.
in tissue.
3.4.2 Widefield imaging head
3.4.2.1 Design and construction
While the SpectroPen alone is sufficient for medical applications, using the SpectroPen
requires the operator to reconcile the recorded spectra with locations on the patient. We
originally sought to build a widefield imaging system for documentation while using the
SpectroPen, but discovered that it made using the SpectroPen much more intuitive. The
design was refined into a proof-of-concept prototype, and is shown in Figure 19 on page 57.
Design priorities were for economy, NIR light sensitivity, simplicity, and imaging quality,
in that order. The overall design fits on a 20 × 20 cm breadboard and weighs 2.75 kg. The
optical bench is designed to be mounted upside down, such that the common objective lens
is facing downwards over the surgical field. Support lenses mounted in lens tubes are used
to extend the focal length of this lens and collimate the light for filtering, before refocusing
it on one of 3 cameras: one each for imaging the surgical area, imaging the laser excitation
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source from the SpectroPen, and imaging any emitted NIR light from the imaging field.
A system of dichroic mirrors mounted within a collimated light path are used to direct the
appropriate light ranges to each camera, and optical filters increase specificity. The cameras
use uncooled, interlaced charge-coupled device (CCD) sensors with a hole-accumulation
diode design that increases NIR light sensitivity (up to 47% quantum efficiency at 800
nm). The surgical area camera (“anatomic”) uses a color camera, the other two channels
are black and white. All 3 cameras use a Firewire computer interface for both power and
data transfer, and all 3 cameras can be simultaneously imaged at 30 frames per second
(“real-time”). The imaging head is sufficiently compact and light to be mounted onto a
commercial computer display arm and computer cart designed for medical use. A simple
light-tight enclosure was constructed of black polyoxymethylene for prototyping purposes;
a glass UV filter for consumer cameras was used as a window for the common objective.
The optical breadboard is attached to the enclosure by screws with rubber washers sitting
in between the breadboard and enclosure for vibration dampening. The entire enclosure
can then be mounted onto the display arm through drilled and tapped holes.
To handle data acquisition and image processing, we wrote a custom software program
using application programming interfaces (APIs) provided by the camera manufacturer. A
schematic of the processing scheme appears in Figure 20 on page 59. The program itself
images all three channels from the imaging system (future revisions will also simultane-
ously acquire spectra from the SpectroPen). These data are then processed in software to
create a composite display. The composite display shows the location of any NIR light
(presumably from the contrast agent) overlaid onto the anatomic view. The system also
shows the position of the laser excitation source. As currently configured, the contrast
agent is shown in cyan, and the laser position as a red circle. An example of the software
interface is shown in Figure 20 on page 59 as well. The view of the software shown is for










Collimating lens Focusing lens
Camera sensor
Mirrors and filters (not shown)b
Figure 19: Current implementation of the widefield imaging head. (A) A marked image
of the current widefield imaging head, upside-down from the working orientation (with the
objective facing downwards). (B) Optical layout for the field, collimating, and focusing
lenses that are obscured from view by the lens tubes in (A).
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on a physically separate display as to minimize distractions. The software records experi-
ment metadata (e.g., experiment date, system operator, contrast agent used) and can record
still frames or live video. In addition, the software can apply real-time video processing fil-
ters, for example, one filter increases the persistence time that the NIR display is shown on
screen. The filter is inspired by the decaying luminescence over time that defines phospho-
rescence, and so is called “virtual phosphorescence”. Applying the filter (implementation
described in methods) makes any NIR signal appear to “glow” when the SpectroPen is
swept over an area, much like the luminous hands of a wrist watch. Changing the user set
decay time allows the user to select a persistence time that assists in unobtrusively local-
izing NIR emission. This is an example software feature that can increase usability of the
system without experimental changes: other “smart features” that can assist are autofocus-
ing the lens on the laser location or zooming the composite display on the laser location
(by definition, the area of interest), or emitting a click sound with a rate proportional to the
amount of NIR signal detected (similar to a Geiger counter).
3.4.2.2 Characterization
We tested the imaging performance of the proof-of-concept system built using the U.S. Air
Force (USAF) 1951 test chart for the resolution limit, as well as calculating the contrast
transfer function (CTF, closely related to the modulation transfer function, MTF) of the lens
system. The results of the testing are shown in Figure 21 on page 60. The camera resolution
itself is low (768×492 pixels), and is interlaced (acquiring even line pixels in one field, then
odd line pixels in the next field, and combining these two fields to make one frame), and
has a color Bayer filter in place. The interlaced nature of the camera causes the resolution
limit of the system to be different in the vertical and horizontal directions, 2.8 line pairs
per mm in the vertical direction, and 4 line pairs per mm in the horizontal direction. The
imaging quality is reflective of the economy of the system design as well as the nature of




Figure 20: Software processing scheme for the integrated imaging system. (A) is the
general scheme for software processing: information from available channels (anatomic
view, laser tracking, near-infrared (NIR) light, and spectroscopy) are all used to create
a composite image displayed to the system operator. (B) is a screenshot of the system
software that was developed in-house, as would be shown to an assistant to the system
operator.
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Figure 21: Optical resolution testing of the imaging head. (A) The USAF-1951 test target
was imaged by the widefield imaging head, under normal conditions for animal surgery.
Illumination is provided by two consumer white-LED bulbs. Resolution limit of the system
is 4 lp/mm horizontally, 2.8 lp/mm vertically (difference due in part to interlaced camera
sensors). (B) The calculated modulation transfer function (MTF) for the system, measured
by the color camera at the center of the imaging field, in both the vertical and horizontal
directions. The MTF was calculated by using a slanted-edge test target.
is a result of the small diameter (relative to the sensor size) catalog lenses for imaging.
Another issue with the current implementation is chromatic aberration, particularly in the
blue light range. This is unavoidable because of the broadband imaging range required and
cost constraints. The imaging performance in terms of detection sensitivity was tested next.
When used with the SpectroPen, quantification of contrast agents can be done through
the spectra recorded, as was shown in Figure 17 on page 54. This is advantageous because
of the high sensitivity of the SpectroPen, close proximity to the sample, and discrimination
afforded by spectroscopy. The widefield imaging system, because of economy as a design
goal, is one-fifth the cost of the SpectroPen prototype. Combining the widefield imaging
head with a near-infrared “laser pointer” could be useful as a low-cost surgical system.
We tested the limit of detection for the widefield system alone, detecting ICG in tissue
homogenates, by dosimetry on the NIR channel. As shown in Figure 22 on the following
page, the system has a dynamic range of approximately 30 fold, more than sufficient for
surgical imaging where a contrast ratio of 5 is considered outstanding. Assuming a Gaus-































Figure 22: Widefield imaging head limit of detection for indocyanine (ICG) in tissue ho-
mogenate. ICG was diluted into 5% (w/v) tissue homogenate in glass vials and placed un-
der the widefield imaging head, arranged as in (A). As shown in (B), the area sum of ICG
fluorescence as measured on the near-infrared camera channel shows a linear response,
with a Pearson’s coefficient of 0.99. Error bars show the 95% confidence interval (n = 3).
detection limit between 0.15–0.5 nmol/L ICG. Both the dynamic range and detection limit
for the widefield imaging head compare well to the SpectroPen.
3.5 Integrated intraoperative instrumentation as a platform technology
The instrumentation presented describes an integrated platform technology, consisting of
the local point excitation source (with optional spectroscopy), widefield imaging, the soft-
ware powering the system, and the exogenous contrast agent used for tumor imaging. This
system is a flexible design: the local excitation source can be used alone, with fluorescence
spectroscopy, or with Raman spectroscopy (in order of increasing resolution and cost). The
widefield imaging system need not be present (perhaps for ultra-portable needs), could be a
low-cost system as is presented here, or could be a high-performance system using cooled
or intensified imaging sensors for increased sensitivity. The instrumentation enables the
contrast agents to be used, but it is the contrast agents that make the entire system work.
Contrast agents could change the types of tumor lesions detected (perhaps through active
targeting mechanisms), improve sensitivity through an activatible fluorescence scheme (as
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Table 1: Specifications of the currently implemented intraoperative instrumentation
Parameter Specification
Number of imaging channels 3
Imaging wavelengths 400–700, 700–800, 800–900
Camera resolution 768 × 492
Camera maximum frame rate 60 fields/second (interlaced)
Camera sensor size 1/2 in.
Camera cell sensor size 8.4 µm × 9.8 µm
Camera NIR QE 700 nm: 80%, 800 nm: 47%, 900 nm: 23%
System resolution limit 4 lp/mm (horizontal), 2.8 lp/mm (vertical)
Intended working distance 60 cm
Field of view (at working distance) 11 cm × 7 cm
Pixel spacial resolution (at working dis-
tance)
145 µm
System aperture f /4
ICG detection limit 0.15–0.5 nmol/L
Dynamic range 30 fold
Excitation source wavelength 785 nm
Excitation source irradiance (at focus) 1.3 kW/cm2
Excitation source focal length 0.5 cm
Excitation source spot size (at focus) 100 micron
Spectrograph resolution 0.6 nm / 8 cm-1
Spectrograph range 200–2000 cm-1
ICG detection limit 0.05 nmol/L
Dynamic range 40–50 fold
has been demonstrated by Tsien’s group), or be used for combination intraoperative sur-
gery and intraoperative pathology.[180] As shown through the “virtual phosphorescence”
example, the integrated software can greatly enhance the usability of the system. The
specifications of the current prototype implementation, as characterized in this chapter, are
summarized in Table 1 on the current page.
3.6 Conclusions
We have described proof-of-concept instrumentation designed for medical imaging, specif-
ically to offer intraoperative guidance during surgery. The instrumentation is designed to
work with contrast enhancement, instead of native detection of biomolecules. The systems














Figure 23: Operational scheme of widefield imaging with directed point excitation and
spectroscopy. The widefield imaging head (center-right) is positioned over the surgical
area. Directed point excitation is provided in this case by the SpectroPen (S). The area
imaging system uses 3 cameras to image the anatomical view (A), the laser position within
the anatomical view (L), and any near-infrared (NIR) light emitted within the anatomical
view (N). The area is imaged by a common objective lens (O) and the collected light is
folded by mirrors (M) and folded/filtered by dichroic mirrors (D). Complex optics within
the area imaging head (e.g. collimation lenses, bandpass filters, etc.) are not depicted. The
three video channels recorded by the cameras (top-right) and spectral information collected
by the SpectroPen (bottom-center) are processed by a computer system to synthesize a
composite display (bottom-left) to show anatomical landmarks with the laser position and
any detected NIR signal.
63
filter, while widefield imaging offers spatial information that is lost with point spectroscopy.
Integration of the two instruments also makes wide area Raman spectroscopy practical for
medical use. This is a system where the whole is greater than the sum of its parts. In
Chapter 4, we show the application of these two devices to medical imaging in vivo.
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CHAPTER IV
GUIDING CANCER SURGERY THROUGH IMAGING AND
SPECTROSCOPY
4.1 Abstract
The clinical efficacy of cancer surgery is dependent on the skill of the surgeon. Although
preoperative imaging can diagnose and locate tumors, intraoperatively, a surgeon must rely
on their visual and tactile senses, honed through experience, to determine the location of
a tumor and whether a tumor has been completely removed. Improving the ability of a
surgeon to completely resect a tumor would be expected to improve the odds of a patient
having a good surgical outcome. In this chapter, we describe how the instrumentation de-
veloped in Chapter 3 has been applied to animal models of cancer as well as clinical canine
patients with cancer. Initial results show that using clinically-approved fluorescent contrast
agents, along with the instrumentation developed, neoplasia is distinguishable from normal
tissue in both murine tumor models and in spontaneous tumors in companion canines. The
pre-clinical data support the further development of this instrumentation towards clinical
translation.
4.2 Introduction
In Chapter 3, we introduced instrumentation designed for imaging contrast agents in vivo to
be used for guiding cancer surgery. A schematic overview of the integrated imaging system
platform appeared in Figure 23 on page 63. In comparison to other widefield fluorescence
imaging systems that use wide area illumination, the system we presented uses a point
excitation source directed by the operator to probe the patient.[252, 206, 225] Interactive
point excitation has several advantages over wide area illumination. One advantage is
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that by definition, the area of interest to the operator is always known—this is useful for
image processing. Another advantage overcomes fluorescent dye photobleaching: wide
area illumination excites fluorophores in the entire surgical field, photobleaching those of
interest to the operator as well as those not currently inspected by the operator; interactive
point excitation only photobleaches fluorophores undergoing inspection. A third advantage
is that point excitation can have high fluence rates not practically achievable with wide
area illumination, overcoming attenuation due to the absorption and scatter inherent in
biological imaging. Fourth, wide area illumination can color the surgical field, making
operating on the patient more difficult. Finally, a major advantage of the integrated system
is that it makes real-time (30 frames per second video), wide area spectroscopy practical.
Tunable filters or filter wheels, used by some for intraoperative spectroscopy, have a finite
acquisition time and so are not real-time. For imaging Raman scatter (an inherently weak
process) a high numerical aperture is required: this is provided through having the point
excitation probe near the surgical cavity, and cannot happen with a widefield imaging head
sitting over a surgical cavity with clearance necessary for work on the patient. Of course,
a high numerical aperture is beneficial for fluorescence imaging as well. The solution is to
acquire spectroscopy through a local probe and spacial information through a distant probe,
and then combine the information sets into a composite display. Others, notably Michael
Feld, have proposed using spectroscopy in medicine, however spectroscopy alone lacks the
“intuitive” information display inherent in showing spectral information composited on an
image of the surgical area.[170, 171] A major and clear disadvantage of interactive point
excitation and spectroscopy is that it is interactive: it requires a free hand to use. While
the interactive nature might require that a surgeon to switch between imaging and cutting,
there are numerous other personnel in the operating suite who can assist in operating the
instrumentation while the surgeon is cutting, and software features (such as taking and
displaying still photographs) can lessen the burdens of interactive excitation.
We use indocyanine green (ICG) as our lead contrast agent for intraoperative imaging in
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animals. ICG has a long history of use as a blood pool contrast agent, being first approved
by the U.S. Food and Drug Administration (FDA) for human use in the 1950s.[37, 8, 126]
It is considered very safe, with few reported adverse events.[17] The most common ad-
verse event is an allergic reaction, and so ICG is conta-indicated in patients with iodine
allergies. ICG is currently FDA-approved for hepatic blood flow monitoring and retinal
angiography. Interestingly, ICG immediately complexes with serum albumins when in-
jected systemically, due to the overall hydrophobicity of ICG and a hydrophobic binding
pocket within serum albumins. This means that in vivo, ICG tends to behave as a 4–6 nm
macromolecule or nanoparticle. As was explained in Chapter 2, macromolecules and nano-
particles tend to accumulate within tumors through the enhanced permeability and retention
(EPR) effect. ICG would thus be expected to passively accumulate within tumors. As one
of only two FDA-approved fluorophores (the other being fluorescein), ICG is commonly
used as an in vivo human contrast agent for investigational fluorescence imaging systems.
Although it is an off-label use, since ICG is recognized as safe and has FDA-approval
for other applications, it has an easier approval path than novel contrast agents. Recently,
locally-injected ICG has been used by several investigators for fluorescence-guided sen-
tinel lymph node (SLN) mapping.[252, 206, 225, 272] The SLN is the lymph node which
drains a defined area in the body, so if a tumor is to metastasize, it will go to the SLN
first.[19] Colloids (radiocolloids or strongly-absorbing dyes) are commonly used for the
same purpose.[36, 10, 175] In contrast to other groups, we are using systemically-injected
ICG as a tumor contrast agent. ICG has been used as a tumor contrast agent previously,
but required unconventional imaging modalities to detect in vivo because of the overall low
quantum yield of ICG in aqueous environments.[206, 198] Clinically, ICG is used for bo-
lus injections, with total dosages of 0.5–1 mg/kg and a maximum FDA-allowed dose of 2
mg/kg.
In this chapter, we first demonstrate the use of our intraoperative instrumentation in
guiding cancer surgery in murine tumor models. Murine tumor models have contributed
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greatly to human medicine, but they have limitations.[219, 220, 128] Notably, murine
xenograft and ectopic tumor models tend to have a fibrous capsule that clearly delineates the
tumor from normal tissue. These tumors also tend to have poor vascular integrity beyond
that of natural human tumor. Since the EPR effect is dependent on poor vascular integrity,
murine tumor models often have higher accumulations of macromolecules by the EPR ef-
fect than is observed in human tumors. Orthotopic murine tumors are architecturally closer
to a natural human cancer, however, they do not overcome the scaling differences between
mice and men. Operating on a mouse necessitates using smaller tools and instrumentation
with a greater magnification factor than for human surgery. To overcome the challenges
inherent in using murine tumor models, we have also investigated using canines with spon-
taneous cancers. In drug development, there is a growing movement to use companion
canines with cancer as part of the drug development pipeline. [90, 192] Companion ca-
nines are afflicted with the same cancers as humans (but with different incident rates), and
the cancers are biochemically and architecturally similar to the corresponding cancer in
humans. Companion canine cancers are also much more similar in size to those in hu-
mans. The surgical procedures and medical care for canines are in most cases identical
to those in humans: a largest difference being that normal tissue preservation to achieve a
good cosmetic result is less of a concern. Canines also have a similar drug response pro-
file to humans—ICG was originally investigated in canines and so is known to be safe to
use. Using companion canines with spontaneous tumors, we are able to perform correla-
tion analyses between imaging ICG and the pathologic status of the tissue, a critical step in
translating this technology to the clinic.
We envision the workflow of image guided surgery to begin by the patient being di-
agnosed with operable cancer: perhaps through an x-ray computed tomography (CT) or
magnetic resonance (MR) imaging scan with contrast agent, followed by a fine-needle as-
pirate (FNA) or incisional biopsy to confirm neoplasia. A surgery date is scheduled and
a surgical plan is made. The day of surgery, while preparing the patient for surgery, the
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patient is injected with a tumoral contrast agent such as indocyanine green (ICG). This
contrast agent will accumulate through passive (as in the case of ICG) or active means in
the tumor, providing contrast between neoplastic and normal tissue. Surgery begins: the
surgeon, guided by preoperative imaging, exposes the area where the tumor is suspected
to be. The tumor removal procedure is illustrated in Figure 24 on the next page. The sur-
geon uses the imaging system to confirm the tumor position and borders of the tumor. The
surgeon then debulks the tumor, attempting to remove the entire tumor with the smallest
margin between neoplastic and normal tissue possible. The tumor bed is then scanned to
detect residual disease. Any residual disease is then removed until the tumor bed appears
“clean” (i.e., a complete resection). The device could then be used for sentinel lymph nodes
(SLN) dissection by injecting ICG into the tumor bed and following the lymph drainage.
Finally, the resected tissues can be checked intraoperatively to confirm contrast accumula-
tion before submitting to pathology. The pathologist can use the same contrast agents and




4.3.1.1 Murine tumor models
All in vivo murine studies were performed under a protocol approved by the Emory Uni-
versity Institutional Animal Care and Use Committee. Mice used were age-matched nude
athymic females. The tumor cell line 4T1 (a murine mammary carcinoma, stably express-
ing firefly luciferase) was used to create the tumor models. Cell lines were maintained as
per American Tissue Type Collection guidelines. The cells were washed with phosphate-
buffered saline (PBS) before collecting and diluting to a final concentration of 2 × 107









Figure 24: Workflow for resection of tumors by interactive intraoperative guidance. (A)
Initially, the suspect tumor area is scanned to find the borders of the tumor, as determined
by indocyanine green (ICG) accumulation. (B) The tumor is then removed by standard
surgical technique. Following resection, the surgical bed is rescanned to find residual ICG
signal. (C) The resection is revised until no ICG signal is detected in the surgical bed. (D)
Finally, the resected surgical specimen are scanned to confirm ICG accumulation and areas
of pathologic interest for histologic analysis. Areas of ICG accumulation are false-colored
cyan, and the area the point excitation source is being directed is shown by the dashed red
circle.
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cells, per animal. Anesthesia was provided by an intraperitoneal injection of 2.5% tri-
bromoethanol in PBS. For bioluminescence imaging, the animals were injected with 100
µmol/L of luciferin (30 mg/mL) intraperitoneal, then imaged on a bioluminescence imag-
ing system 5 minutes after injection. Animals were sacrificed by CO2 asphyxiation.
4.3.1.2 Clinical canine patients
Clinical canine patients are handled by a veterinary team at the University of Georgia
(UGA) College of Veterinary Medicine (CVM) under a Clinical Research Committee ap-
proved protocol. Canine patients are recruited by a veterinary oncologist, Dr. Corey Saba.
After informed consent is given, canine patients receive standard of care treatment with
the sole addition of an ICG injection (prepared by the pharmacy) before surgery. Canine
patients are monitored for anaphylaxis reactions after ICG infusion. A small financial
incentive (hospital credit for medical costs) is given to owners of canine patients for par-
ticipating in the trial. To participate in the trial, canine patients must have cytologically
or histologically confirmed malignant solid-mass tumors amenable to surgical resection.
There must be no severe underlying disease, and no known allergy to contrast agents.
4.3.2 ICG pharmacokinetics and biodistribution
4.3.2.1 Percent accumulated dose in tumor
ICG at indicated doses was injected by tail vein into mice bearing 4T1 tumors approxi-
mately 5–10 mm in diameter, 3 mice per dose. After 24 hours, the mice were sacrificed
and the tumors were harvested. The tumors from 5 mice not injected with ICG (reference
sample) were also harvested. The tumors within groups were pooled and homogenized.
The homogenized tissue was diluted with PBS such that the percent weight of tumor in
each sample was equal. ICG diluted into 4% BSA (w/v) in PBS was then spiked into
the reference sample homogenate sample with known concentrations of dye. A standard
curve was generated from the integrated ICG fluorescence in the spiked homogenates. The
integrated ICG fluorescence in the dosed mice was then measured and correlated to the
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standard curve to determine the amount of ICG in each tumor group. These values were
then correlated to the administered ICG dose.
4.3.2.2 Pharmacokinetics and biodistribution
ICG at indicated doses was injected by tail vein into mice bearing 4T1 tumors approxi-
mately 5–10 mm in diameter, 1 mouse per dose. At the specified time intervals, the mice
were sacrificed and perfused with saline to flush blood and any ICG in the serum out of the
tissues. The tumor, muscle, and lung were then removed and quantified for ICG fluores-
cence.
4.3.3 In vivo measurements of ICG accumulation in murine tumors
ICG was infused in mice bearing 4T1 tumors at a concentration of 357 µg/kg via the tail
vein for imaging 24 hours later. Mice were anesthetized and injected with luciferin before
bioluminescence imaging. The animals were then scanned with the SpectroPen at regularly
spaced intervals, with the SpectroPen held a constant distance away from the tissue. The
integrated ICG fluorescence signals recorded were then correlated to the measurement lo-
cations on the brightfield and bioluminescence images. Surgery was then performed with
standard technique to remove the tumor mass (without continuous SpectroPen guidance).
After surgery, the resected tumor and tumor bed were imaged a second time with bright-
field and bioluminescence imaging to confirm completion of the resection. Any areas of
bioluminescence activity following surgery were probed with the SpectroPen.
Tissues excised (including tumor, tumor bed, and any other areas of interest) were fixed
in fresh 3.7% formaldehyde in PBS and submitted to a core facility for paraffin-embedding
and processing with H&E or immunohistochemistry.
4.3.4 In vivo measurements of ICG accumulation in companion canine tumors and
histologic correlation
After en bloc removal of the tumor, intraoperative measurements were taken of the tumor
bed by the attending surgeon (Dr. Karen Cornell, Chad Schmiedt, or MaryAnn Radlinsky,
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UGA-CVM) with the SpectroPen placed in a sterile sleeve. Following surgery, tissue spec-
imens resected from the patient, including biopsies of the tumor bed, were probed with
the SpectroPen in the presence of the attending pathologist, Dr. Elizabeth Howerth (UGA-
CVM). Locations of spectral readings were recorded on a photograph of the tissue sample
for later correlation to the histologic preparations, or when available, recorded by the inte-
grated imaging system. The pathologist was blinded to the results of the spectral readings.
After histologic mounting, the points of interest were marked on the prepared slide im-
ages and given to the pathologist to render determination of the presence or absence of
neoplasia in a 0%, 50%, or 100% likelihood scale. In later patient cases, punch biopsies
were taken at sites of interest with a 1.0× 0.5 cm punch biopsy tool—these punch biopsies
were probed for ICG fluorescence using the SpectroPen before being formalin-fixed and
paraffin-embedded by standard practices.
Statistical testing varied based on the circumstances. For complete data sets, including
0%, 50%, and 100% tumor likelihood samples, data were analyzed by Kruskal-Wallis non-
parametric testing. Post-hoc multiple comparison testing was done by Dunn’s method. A
p-value of 0.05 was used as the threshold for statistical significance. For incomplete data
sets (having only 0% and 100% tumor likelihood samples), data were analyzed by a Mann-
Whitney non-parametric test. The receiver-operator characteristic (ROC) was calculated
using the 0% and 100% tumor likelihood values only.
4.4 Results and discussion
Using ICG as a systemically-injected tumor contrast agent is atypical, so we first deter-
mined the accumulation of ICG within murine tumor models as a function of the injected
dose one day before tumor removal. As shown in Figure 25 on the following page, we
find that there is a dose-dependent behavior in the amount of ICG that accumulates in the
tumor. For low doses of ICG (below 500 µg/kg), approximately 0.05% of the injected dose
is delivered to the tumor; for high doses of ICG (1–2 mg/kg, closer to clinical dosing),
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Figure 25: Indocyanine green (ICG) accumulation within tumors is dose-dependent. ICG
at indicated doses was injected via tail vein into mice bearing 4T1 ectopic tumors. The
tumors were harvested after one day, homogenized, and then compared against ICG spiked
into homogenate from mice bearing tumors but not injected with ICG. Each point is the av-
erage of 3 harvested tumors, the line of fit is a one-phase exponential association regression
model shown as a visual guide.
approximately 0.2% of the injected dose is delivered to the tumor. This difference could
reflect a change in the ICG clearance rate from normal tissue: in the sub-clinical dosing
regime, ICG is cleared from normal tissue within one day, whereas in the clinical dosing
regime, ICG is still being cleared from tissues (both normal and abnormal), and so the
apparent dose is higher. This saturation of the clearance mechanism is most likely involv-
ing the lymphatics, since the ICG pharmacokinetics have been well-described and ICG as a
compound is known to clear from the circulation within minutes. Since the subclinical dos-
ing regime offered sufficient signal for imaging, we next quantified the pharmacokinetics
of ICG accumulation within the tumors, compared to lung and muscle tissue (both highly
vascular). As shown in Figure 26 on the next page, doses of 71.4 or 357 µg/kg offered
tumor contrast relative to lung or muscle (selected because they are highly vascularized) at
all time intervals interesting for surgery, between 1–48 hours.
4.4.1 Imaging and spectroscopy of murine tumor models
We then tested the usability of ICG accumulation for delineating tumor boundaries in a
murine tumor model. The tumor cell line used, 4T1, is transgenic with a luciferase reporter
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Figure 26: Pharmacokinetics and biodistribution of indocyanine (ICG) in a murine tu-
mor model. ICG was injected into mice bearing MDA-MB-231 breast cancer cells in
a xenograft flank tumor model in 3 subclinical doses. The tumors and tissue were re-
moved at specified time intervals following injection and quantified for fluorescence with
the SpectroPen. Regression lines are an exponential decay model shown as a visual guide.
gene and so can be detected by bioluminescence. Comparing the bioluminescence readings
and spectra recorded with the SpectroPen shows that there is a an enhancement of 5–10
fold in ICG accumulation in the primary tumor and “satellite tumor” (tumor growing at the
tumor injection site) relative to the tumor-free areas around the tumor. Examination of the
surgical cavity and resected tumor following surgery showed that the high ICG signals were
still associated with the tumor, approximately 10 fold higher in the tumor than the tumor
bed. As shown in Figure 28 on page 77, a small point of tumor cells were detected in the
surgical cavity under bioluminescence imaging that were not obvious on visual inspection.
This area was detectible using the SpectroPen with an approximate 5 fold higher ICG
fluorescence relative to the surgical bed. This illustrates how spectroscopy guidance can
detect residual disease.
We then examined whether the tissue detected as tumor positive by the integrated imag-
ing system was indeed tumor positive, using histology as a gold reference. As shown in
Figure 30 on page 79, we found that the primary tumor mass, visible by eye and under
intraoperative instrumentation by ICG accumulation, was tumor positive by hematoxylin
and eosin (H&E) staining. Curiously, when performing surgery on one mouse, we noticed
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Figure 27: Systemically-injected indocyanine green (ICG) accumulates in mouse tumors
as determined by bioluminescence. (A) A brightfield image of a mouse bearing a subcu-
taneous 4T1 mammary tumor. The mouse was measured at the indicated points by the
SpectroPen. (B) The same mouse, imaged under bioluminescence imaging that can detect
the transgenic tumor cells. (C) ICG fluorescence intensity as measured by the SpectroPen at
the designated points on the image. Reprinted with permission from ref. [166]. Copyright
2010 American Chemical Society.
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Figure 28: Indocyanine green (ICG) accumulation within tumors is specific enough to
detect dirty surgical margins. A mouse bearing a 4T1 ectopic tumor was operated on to
remove the primary mass. (A, B) Images of the mouse and excised tumor, as imaged un-
der brightfield and bioluminescence imaging (which can detect the transgenic tumor cells),
respectively. The SpectroPen was used to measure fluorescence from a prior injection of
ICG at designated points across the animal. Interestingly, a positive tumor margin was
detected by bioluminescence imaging; the positive margin was also distinguishable from
background by using the SpectroPen. Reprinted with permission from ref. [166]. Copy-
right 2010 American Chemical Society.
an area not associated with the tumor that had an abnormally high amount of ICG accu-
mulation. This area was identified as a lymph node by H&E histology, and was shown to
be positive for tumor metastasis by cytokeratin-18 (CK18) immunohistochemistry (IHC).
CK18 is considered a tumor marker for the 4T1 cell line used to create the tumor model.
Areas of low ICG accumulation were shown to be free of tumor by histology. These results
show that ICG accumulates in areas of “surgical interest”. These results also illustrate the
limitations of murine tumor models. In general, the ectopic and xenograft tumor models
are well-encapsulated by a fibrous cap and so are easy to distinguish from normal tissue
by visual inspection. There’s no challenge to removal of the tumor, so the additional gui-
dance provided by instrumentation cannot be tested. The ectopic and xenograft models are
also notorious for having poorer vascular integrity than spontaneous tumors, magnifying
macromolecule and nanoparticle accumulation by the EPR effect; ICG accumulation may
not provide the same high contrast ratios with a spontaneous tumor. Although an ortho-
topic tumor model provides a more “natural” tumor to test, the small size of the mouse and














































Figure 29: An example of the spurious contrast between normal and neoplasia in murine
tumors. A mouse expressing an ectopic 4T1 tumor (expressing luciferase) was injected
with indocyanine green (ICG) 24 hours before imaging with the SpectroPen. Sampled
points were confirmed to be tumor by biolumenscence imaging of the transgenic tumor.
As shown on the left, the contrast between normal and tumor is far higher than would be
expected to be encountered in vivo. On the right is a receiver-operator characteristic (ROC)
analysis of the data, showing perfect discrimination ability with an area under the curve of
unity. The high contrast ratio is due to the limitations of this murine tumor model for this
application and does not reflect the real capabilities of the system.
types through mouse tumor models is logistically difficult, because each tumor model has
an associated cell line that must be cultured as well as verified. The greatest problem posed
by using murine tumor models for histologic correlation is highlighted in Figure 29 on this
page, an analysis of a murine tumor correlated with bioluminescence imaging. In this case,
the difference between normal and neoplasia is so high as to be unrealistic. This high con-
trast is in part due to the artificially high leaky vasculature inherent in large murine tumor
models and the encapsulated nature of the tumor creating an artificially abrupt difference
between normal and neoplasia.
4.4.2 Imaging and spectroscopy of canine patient tumors
Due to the limitations in performing histological correlation in murine tumor models, we
began working in a clinical canine population with spontaneous solid-mass tumors. Tumors
in canines are biochemically and structurally similar to those in humans, and the size scale

































Figure 30: Systemically-injected indocyanine green (ICG) enriches in tumors and metas-
tases but not normal tissue. A nude athymic mouse bearing a subcutaneous 4T1 tumor was
injected by tail vein with ICG one day before dissection and imaging. When the SpectroPen
is directed onto the tumor, the widefield imaging system is able to detect ICG emission
(cyan false-color) and the spectrometer is able to record the ICG emission. Hematoxilyn
and eosin (H&E) histology of the ICG-rich area is characteristic of tumor. Interestingly,
an ICG “hot spot” was found that appeared to be a lymph node; cytokeratin-18 (CK18, a
metastasis marker) immunohistochemistry of the tissue was positive, suggesting the lymph
node was bearing a metastasis from the primary mass. When the SpectroPen is directed
away from the tumor, no ICG emission is detected by the widefield imaging system or
spectrometer. H&E histology of the “off tumor” location is consistent with skeletal mus-
cle.
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Figure 31: Indocyanine green (ICG) spectroscopy correlation with histology in a canine
thyroid specimen. A 12-year old collie with thyroid carcinoma was infused with ICG one
day before surgery to remove the thyroid. The thyroid was sliced in half and was probed
with the SpectroPen. The same specimen was then prepared as a hematoxylin and eosin
(H&E) slide. Areas of low ICG intensity are marked black, moderate ICG intensity cyan,
and high ICG intensity (saturating the detector) are marked in red. Circles denote areas
that are definitively tumor, whereas squares denote areas that are follicular tissue and may
or may not be tumor. Histologic readings were performed by a veterinary pathologist.
the possibility to test efficacy in a number of tumor types and locations. In an early clin-
ical experiment, we examined a 12-year old collie with a thyroid carcinoma. The patient
was infused with pharmaceutical-grade ICG one day before surgery, as was done with the
murine tumor experiments. The thyroid was probed for ICG accumulation and correlated
with histology, as shown in Figure 31 on the current page. In this case, the pathologist read-
ing the slide determined that tissue was either follicular or obviously tumor. In the case of
follicular tissue, it was not possible to determine to what degree the tissue was neoplastic.
A clear difference in ICG accumulation was detected between the follicular and neoplastic
regions of the thyroid, but analysis was complicated by saturation of the SpectroPen de-
tector in the neoplastic tissue regions. The thyroid carcinoma is a well-encapsulated tumor
type, in some ways similar to the ectopic murine models.
We then focused on enrolling canine patients with tumors less encapsulated than thyroid
carcinomas. One such canine patient was a 13-year old mixed-breed with a fibrosarcoma
in the hind leg. The leg was amputated as is standard for this tumor type, size, and location.
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A tissue slice from the amputated leg was placed under the integrated imaging system for
analysis, as shown in Figure 32 on the following page. We found minimal ICG accumula-
tion in normal fat and muscle, and high ICG accumulation within the tumor (which visually
looked like the normal fat). Interestingly, we found an area of ICG accumulation in what
appeared to be muscle, but further dissection showed this area to be occult tumor hidden
by a layer of superficial muscle. Although the penetration depth of SpectroPen is only 1–3
mm for ICG (depending on tissue type, see Figure 18 on page 55), it is sufficient in this
case to find occult tissue that would ordinarily be missed.
Encouraged, we performed histological correlations on several canine patients. The
results of one bearing a histiocytoma (a Langerhans cell histiocytosis in humans), one
bearing a neurofibrosarcoma, one bearing a salivary carcinoma, and one bearing a myx-
osarcoma are summarized in Figure 33 on page 83. Each example case also received a
different ICG dosing: the histiocytoma and neurofibrosarcoma were dosed with 220 µg/kg
at 24 hours before surgery; the salivary carcinoma received 220 µg/kg of ICG at 4 hours
before surgery; the myxosarcoma received 71 µg/kg of ICG 2 hours before surgery. For
human clinical use, same day dosage of ICG greatly reduces costs involved with patient
handling and monitoring across two procedure days for 24 hour dosing versus same-day
dosing, and as such is important for future clinical translation. In these 4 cases, the pathol-
ogist was instructed to classify each measured point as being either “0%” or “100% tumor
likelihood”. If the marked point was close to neoplastic tissue or was likely but not defi-
nitely neoplastic, it was marked as “50% tumor likelihood”. There is some uncertainty in
matching the points recorded with the SpectroPen with points on histologic preparations
due mostly to tissue shape and size changes during processing, so point correlation is at
best approximate (thus necessitating the “50%” category). In each of these cases, there was































Figure 32: Post-operative imaging analysis of a surgical specimen from a canine with
spontaneous fibrosarcoma. A 13-year old mixed-breed canine was infused with indo-
cyanine green (ICG) one day before surgery to amputate the left hind leg that had an 8.5cm
in diameter mass. The leg was dissected post-operatively for analysis of normal and neo-
plastic tissue as determined by visual and tactile inspection. ICG was found to accumulate
and deposit in the tumor (a, cyan false-colored region) but not fatty connective tissue (b) or
normal muscle (c). Interestingly, an ICG “hot spot” was detected in an area that appeared
under gross inspection as muscle (d, small cyan false-colored region); further dissection
into this area showed that the ICG had deposited into occult tumor laying 2 mm underneath
the muscle. Areas rich in ICG deposits (tumor) show a unique spectral signature (e) that is

















































































































Figure 33: Post-operative imaging analysis is able to distinguish neoplasia from normal
in canine patients. Four canine patients bearing a histiocytoma (A), neurofibrosarcoma
(B), salivary carcinoma (C), and a myxosarcoma (D) were administered indocyanine green
(ICG) 24 hours (A, B), 4 hours (C), and 2 hours (D) before surgery. In all four cases, there
was statistically-significant difference between the mean integrated ICG fluorescence in the
tumor tissue versus non-tumor tissue. Tumor likelihood values were given by a veterinary
pathologist examining hematoxylin and eosin (H&E) preparations of the examined tissues.
Error bars show the mean and 95% confidence intervals, statistical analysis was a Kruskal-
Wallis non-parametric test with post-hoc Dunn’s testing in the case of (A, B, and C), and a
Mann-Whitney non-parametric test in the case of (D).
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Knowing the histologic status at each measured point in the three canine patients sum-
marized in Figure 33 on the previous page, we then subjected these data to receiver-operator
characteristic (ROC) analysis using histology as the gold standard reference. ROC analysis
reveals, among other values, how well a sample can be categorized at a given classification
threshold.[261, 187, 70, 146] In each of the three cases, we found that the SpectroPen was
able to sensitively (i.e., high true positive rate) detect neoplasia with a low false positive
rate (plotted as “1 - specificity”), as shown in Figure 34 on the following page. The area
under the curve of an ROC curve is the probability that in selecting a true positive and a
true negative, the true positive will be correctly identified. In the case of these three canine
patients, the AUC are all above 80%, showing good discrimination ability.
4.4.2.1 Observations on imaging lymph nodes in canine patients
Sentinel lymph node (SLN) mapping seeks to dissect the lymph nodes draining a tumor
with the hope of staging the tumor accurately and possibly remove metastatic disease.[19]
Significant research effort by others is allocated towards developing fluorescent probes and
fluorescence instrumentation for SLN mapping.[272, 10, 175, 256, 244, 12] While SLN
mapping was not an objective of the clinical canine studies presented, lymph nodes were
dissected from the patients as part of standard care and these nodes were available for imag-
ing analysis. It must be noted that while others have used fluorescence (including ICG) for
SLN mapping, in those cases it is by local peritumoral injection of the contrast agent, not
systemic injection of contrast agent as in the case of the subjects presented in this disser-
tation. Shown in Figure 35 on page 87, we found that the ICG fluorescence observed in
lymph nodes confirmed by histology to be free of disease to vary based on the time inter-
val between ICG injection and surgery. For long time intervals (24 hours) between ICG
injection and surgery, the pathologically negative lymph nodes were low in ICG signal.
For the shorter time interval (4 hours) between ICG infusion and surgery, a wide distri-
bution of ICG fluorescence in the negative lymph nodes was observed, ranging between
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Figure 34: Receiver-operator characteristic (ROC) analysis shows high sensitivity in de-
tecting tumor by accumulated indocyanine green (ICG). Three separate canine patients
bearing a histiocytoma (A), neurofibrosarcoma (B), salivary carcinoma (C), and a myx-
osarcoma (D) were administered ICG 24 hours (A and B), 4 hours (C), and 2 hours (D)
before surgery. The ROC analysis shows that there is high sensitivity in detecting tumors:
an accepted false-positive rate of 30% gives sensitivities between 90–100%. The area under
the curve (AUC) is a measure of diagnostic quality, and in all three cases is quite high.
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the (low) ICG accumulation in normal tissue to the (high) ICG accumulation in neoplasia.
The pharmacokinetics of ICG are known.[37] It is rapidly cleared from the plasma, within
minutes of injection. It is likely that the ICG detected in the lymph node at the 4 hour
interval is due to clearance of ICG from the tumor, where in murine models, it can persist
for days (c.f. Figure 26 on page 75). These canine data would suggest that for the clinically
important same-day injection of ICG, the dye accumulation may be able to locate lymph
nodes but not inform on metastatic presence. The residual ICG in the lymph nodes would
also preclude the use of local ICG injections for SLN mapping in a patient systemically
injected with ICG for tumor resection. SLN mapping has been performed with isosulfan
blue, an absorptive dye, as well as with technetium radiocolloids for radioscintography
with great success for many years—the inability to do SLN mapping with short time in-
terval systemic injections of ICG has no impact on the future clinical utility of this system
and techniques.[222, 36, 135, 227] A related procedure, axillary lymph node dissection
(ALND), would also be inadvisable to carry out with this instrumentation if same-day sys-
temic injections of ICG are being used. The clinical efficacy of ALND in breast cancer
has been recently shown to be less effective than originally thought;[151] it is therefore
possible that ALND will in the future no longer be part of standard care.
4.4.2.2 Confounding issues in imaging canine cancer patients
Not all canine patients have shown significant contrast between tumor and normal tissue,
but in these cases, there were identifiable confounding issues. In one early case, a schwan-
noma around the mandible, there was heavy bone involvement that attenuated ICG fluores-
cence. In another case, another myxosarcoma, the tumor margin marking dye (a colored In-
dia ink) obscured and attenuated ICG fluorescence. In several cases, the surgery performed
was tissue-conserving (with the intention to follow up with radiation or chemotherapy), so



















































































Figure 35: The indocyanine green (ICG) accumulation within canine lymph nodes is de-
pendent on dosing interval. (A) A canine with neurofibrosarcoma was injected with 220
µg/kg ICG 24 hours before surgery. The lymph node recovered showed low accumulation
of ICG and was pathologically free of metastatic disease. (B) A canine with salivary carci-
noma was injected with 220 µg/kg ICG 4 hours before surgery. The lymph nodes recovered
(all pathologically negative) show a range of ICG accumulation, between the range of nor-
mal and neoplasia in this patient. The boxes show the quartile range, the whiskers show the
minimum and maximum values recorded.
sample; the opposite issue, nearly all normal areas with only a few tumor areas, also oc-
curred in one case. None of these issues would not have arisen in murine tumor models,
underscoring the value of a comparative oncology study.
There is tissue distortion during histology processing that confounds correlation be-
tween gross images and histology images. To overcome this issue, we recently have started
taking punch biopsies of the surgical specimen and using these biopsies for the actual anal-
ysis. Another way to overcome this would be to use a “tissue scanner” to image the tissue
before histology preparations with white light and for ICG fluorescence, mount the tissue
for histology, and rescan the tissue. Computer algorithms can then match the before and
after images of the tissue and generate a mapping of ICG within the tissue, taking tissue
distortion into account.
Another item yet to be resolved is how to make comparisons between patients. Device
calibration is simple and well described: there are industry and government methodologies
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and standard reference materials for Raman and fluorescence calibration. Device calibra-
tion is only one half of the problem. Canines have greater genetic and physical variability
than humans, and humans have greater variability than laboratory mice. Variations in ICG
dosing between patients (e.g., due to pharmacy handling) and in patient response to ICG
(e.g., due to disease burden beyond cancer) could alter the accumulation of ICG within
normal tissues and the tumor. A way to reference measurements, taking ICG dosing be-
tween patients into account, would address the first point; the second point would require
alterations to the research protocol to allow canine patients with underlying diseases to be
enrolled and has additional patient safety burdens associated. We have recently attempted
to find a well-perfused and universally accessible location to take measurements of ICG
deposition in what is expected to be normal tissue in an attempt to establish a reference
system. Finding a suitable location is in itself a challenge: many canines have pigmented
skin that can interfere with the optical measurements. The buccal cavity is vascularized,
universally accessible, and generally has areas of low pigmentation. We therefore tried
using measurements of the gingiva, but the prevalence of gingivitis in canines due to poor
preventative oral hygiene makes this a ill choice—inflamed tissues lose vascular integrity
and become leaky. Another prospective location being investigated is the underside of the
tongue.
4.5 Conclusions
In this chapter, we have demonstrated using proof-of-concept instrumentation that indo-
cyanine green, an FDA-approved contrast agent (albeit in an off-label application) prefer-
entially accumulates within tumors as verified by histology. ICG shows efficacy in murine
tumor models as well as spontaneous canine tumors from a clinical population. Further
developments of this instrumentation would be useful to determine the boundaries of a tu-
mor during a surgical procedure. Being able to completely resect a tumor would reduce the
need for follow up radiotherapy or chemotherapy, in itself improving patient care, as well
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as decreasing the number of scar revision surgeries that would need to be performed. Since
a “clean margin” is in many cases prognostic of surgical efficacy, improving the ability to
effect a clean margin would be expected to greatly increase surgical cure rates.
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CHAPTER V
DEGRADATION OF QUANTUM DOTS BY CHEMICAL
OXIDANTS
5.1 Abstract
Semiconductor quantum dots are interesting for biological applications because of advan-
tageous and unique optical and structural features in comparison to organic fluorophores.
Optically, quantum dots have size- and composition-tunable emission wavelengths, large
absorption cross sections, broad absorption spectra that permit facile multiplexing, and su-
perior photostability to organic dyes. Structurally, quantum dots have a large surface area
relative to volume that can be used for functionalization to one or more affinity ligands, en-
zymes, or other molecules. All of these properties are desirable for an in vivo fluorophore,
however, toxicity concerns have stymied the deployment of quantum dots for human use.
quantum dots are necessarily made of heavy metals known to be toxic (e.g., cadmium, lead),
but it has been unclear if the heavy metals making up a polymer-encapsulated nanocrystal
are bioavailable and so subject to the same toxicity concerns as free heavy metal ions. In
this chapter, we show that quantum dots can be rapidly degraded by hypochlorous acid , a
chemical oxidant found biologically. The degradation process causes photoluminescence
quenching; we also show that another process, photoannealing, can restore fluorescence in
some cases. In Chapter 6, we will demonstrate that live cells can degrade quantum dots
in a manner consistent with the “pure chemistry” experiments of this chapter, and we will
describe the circumstances under which this degradation is expected to occur in vivo.
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5.2 Introduction
Semiconductor quantum dots (QDs) first garnered attraction as biological labels based on
a pair of studies published simultaneously in Science in 1998.[22, 33] These papers intro-
duced two distinct water solubilization strategies that, when combined with high-quality
QDs synthesized in organic solvents, permitted demonstrated applications in in vitro cell
imaging. A few years later, following the development of more stable water-soluble sur-
face coatings, the first in vivo use of QDs was reported.[63] Early on, concerns were raised
about the possibility of toxic effects stemming from either the QD composition or the nano-
particles themselves (i.e., in a composition-independent manner). Despite the concerns
raised about QD toxicity in biological systems, few practical mechanisms for QD toxicity
to be realized have been proposed. QD degradation through hypochlorous acid (HOCl),
a biologically-produced oxidant, represents a realistic and achievable mechanism for QD
degradation to occur in vivo, leading to the release of the heavy metal components of the
QD in a known biologically-accessible form. A more comprehensive review of QD-related
toxicity, as well as experimental findings of QD degradation, appears in Chapter 6—in this
chapter, we are concerned with the chemistry of QD degradation.
Although QDs are a novel structure, the semiconductor materials making up common
QDs have a long history of use in the semiconductor industry as bulk materials in camera
sensors and solar panels. In semiconductor processing, a common step is to “etch” the
substrate to remove material not protected by resist material; it is through repeated cycles
of laying photoresist, etching, adding new material layers, washing and relaying photore-
sist, that semiconductor circuits are built. Wet etching of nanocrystals differs from bulk
materials in that the nanocrystals have a corona layer of passivating organic material and
surfactant (e.g., trioctylphosphine oxide, TOPO), and in that a nanocrystal has numerous
crystal facets exposed to possible etching, whereas the bulk material has a single crystal
facet exposed. The corona layer can act as a steric barrier to etchants, and it can also be re-
active towards the etchants. These differences both would be expected to lead to differences
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in kinetic rates of the etching process.
Hypochlorous acid (HOCl) is familiar as household bleach, a weak acid and strong
oxidant. In addition to using it as a laundering agent and general-purpose antimicrobial
agent (e.g., in maintaining swimming pools), it was investigated as a wet etchant for use
with cadmium and zinc chalcogenides;[54, 55] it is not used presumably because the re-
action proceeds too quickly to be well-controlled. HOCl is a member of the hypohalous
acid family, which also contains hypofluorous acid (HFO), hypobromous acid (HOBr), and
hypoiodous acid (HOI) in the “hypo” +1 halide oxidation state. Of the other halohalous
acids, only HFO can exist in the pure form: the others exist only in aqueous solution, and
in aqueous solution, exist in equilibrium with halo-oxo acids of other oxidation states (e.g.,
hypochlorous acid exists with chlorous acid, chloric acid, and perchloric acid). In gen-
eral, the hypohalite form of the halo-oxo acid (i.e., the halo-oxo acid in basic water) is the
form with greatest stability. Attempts to isolate hypohalous acids other than HFO result
in the hypohalous acid disproportionating into other halo-oxo acids, anhydrous halooxy-
gen compounds, forming salts, or into the diatomic halide proper. Halo-oxo acids have
strong absorbances in the UV range that change depending on if the compound is in the
protonated or neutral form—this strong absorbance also means that halo-oxo acids degrade
rapidly when exposed to UV light or in sunlight.1 Hypochlorous acid is somewhat unique
in that it is a powerful oxidant (the Cl-/HOCl redox potential is 1.495 V vs. SHE), relatively
stable (e.g., a bottle of commercial bleach is still usable after months), and possesses very
fast reaction kinetics, especially against thiols. While H2O2 is a more powerful oxidant and
is more stable, is has very slow reaction kinetics in comparison.[196, 265]
In this chapter, we will show how HOCl exposure quenches the QD fluorescence within
seconds of exposure. In addition to quenching QD fluorescence, we will show that elemen-
tal analysis shows increases in the heavy metal ions that make up the QD in the solvent;
1This is why swimming pools need a constant, fresh supply of chlorine tablets and the pH must be
balanced.
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these increases are consistent with etching of the QDs and release of the components into
the environment. Surprisingly, the reaction proceeds regardless of conventional QD pro-
tection strategy used (insulating shell material, polymer solubilization coatings, and QD
material). Finally, we will show that the QD fluorescence can be restored in some cases
by a process called “photochemical annealing” or “photoannealing”;[149] the band-edge
fluorescence of these quenched and then photoannealed QDs is hypsochromic relative to
the unreacted QDs, consistent with a size decrease.
5.3 Methods
5.3.1 QD synthesis and water solubilization
CdSe QDs were synthesized by procedures described in the literature.[229, 173] The CdSe
particles (“cores”) were then purified from the crude mixture via precipitation in methanol,
capped with a lattice-matching layer of CdS, and several insulating layers of ZnS. The core
diameter was estimated to be 3.4 nm via optical absorbance, and the shell was estimated to
be 1.75 nm thick for a total diameter of 6.9 nm. The final QDs had an emission peak of 618
nm and a full-width-at-half-maximum of 22 nm in chloroform. The QDs were phase trans-
ferred into water using previously-described methods to produce amphiphilic polymer-
coated QDs, lipid-coated QDs, and polyethyleneimine-coated (PEI) QDs.[62, 229, 9] In
the case of polymer-coated QDs, the polymer used (polyacrylic acid graft dodecylamine,
PAA-g-DDA) is similar to the one used by Anderson and Chan with a 12-carbon alkyl
graft.[9] The PAA-g-DDA coated QDs will be referred to as “polymer-encapsulated QDs”
and these QDs are used throughout this dissertation unless otherwise specified. The de-
tailed composition of these QDs is listed in Table 2 on the next page.
5.3.2 Reagent preparation
HOCl for QD quenching experiments was diluted from reagent grade stock in house deion-
ized water (18.2 MΩ) that was treated with Chelex resin to remove transition metal ions.
This stock solution was assayed by iodometric titration with sodium thiosulfate and by
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Table 2: Optical properties and composition of quantum dots (QDs) used. Detailed com-
position and optical properties of the QDs used for fluorescence quenching and degradation
studies. Diameter is approximate and is based on transmission electron microscopy mea-
surements, atoms per QD is an estimate based on complete reaction of the QD precursor
reactants, and the fluorescence peak and full-width-at-half-maximum (FWHM) measures












- CdSe 3.36 468 572.9 23.7
1 CdS 4.06 826 580.6 25.8
2 CdZnS 4.76 1333 586.3 26.5
3 CdZnS 5.46 2013 595.6 23.1
4 CdZnS 6.16 2892 606.0 22.0
5 ZnS 6.86 3995 615.8 20.8
UV-vis absorbance of the stock solution in basic conditions (pH 12). H2O2 for QD quench-
ing experiments was similarly diluted from reagent grade stock into Chelex-treated house
deionized water. Phosphate buffer stock was made from monobasic and dibasic sodium
phosphate diluted in house deionized water, with a pH adjustment to 7.4 made with 1.00M
sodium hydroxide and a final treatment with Chelex resin before use. For UV-vis mea-
surements, the molar extinction coefficient for HOCl was taken to be εHOCl, 292 nm = 350
L mol-1cm-1 , and for H2O2, εH2O2, 240 nm = 43.6 L mol
-1cm-1 . Both diluted HOCl and H2O2
solutions were used fresh.
5.3.3 QD degradation by HOCl
5.3.3.1 Fluorescence change following HOCl and UV light exposure
Polymer-encapsulated QDs were diluted to a final concentration of 50 nmol/L in phosphate-
buffered ultrapure water and reacted with molar ratios of HOCl up to 10,000 times the
QD concentration (a maximum of 500 µmol/L). QDs exposed to HOCl were allowed to
react for 30 minutes light-protected before measuring the photoluminescence intensity (PL)
in a fluorometer and the absorbance in a UV-vis recording spectrometer. Following PL
measurements, QDs were photoannealed by exposing the samples in glass vials under a
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light stand approximately 6 cm from two 15 W UB-B bulbs for 10 minutes. The QDs were
allowed to rest for 30 minutes in the dark before measuring both PL and absorbance again.
5.3.3.2 Elemental analysis of QD degradation products
Polymer-encapsulated QDs diluted in phosphate-buffered water were reacted with increas-
ing concentrations of HOCl and allowed to react for one week light-protected and at am-
bient temperature. The solution was then filtered through a 10,000 MWCO centrifugal
ultrafiltration membrane and the effluent was submitted for inductively-coupled plasma
mass spectrometry (quadrupole) analysis at a core facility for Cd, Zn, and Se. S cannot be
measured on a quadrupole instrument because sulfur is too close in mass to the Xe carrier
gas.
5.3.3.3 Timecourse of QD degradation due to chemical oxidant exposure
Polymer-encapsulated QDs were diluted in phosphate-buffered water in a black plastic mi-
crotiter plate (96 well) and reacted with varying concentrations of either HOCl or H2O2 for
up to 30 minutes at room temperature and light-protected. The microplates were then read
at varying time points on a fluorometric microplate reader with appropriate fluorescence
filters for QD detection.
5.3.3.4 Effect of QD surface coating on degradation due to HOCl exposure
QDs from the same batch of synthesis but with differing surface coatings were diluted into
phosphate-buffered water in a black 96-well microtiter plate. They were then reacted with
varying concentrations of HOCl for 30 minutes at room temperature, light protected. The
microplates were then read on a fluorometric microplate reader with appropriate fluores-
cence filters for QD detection.
Commonly used surface coatings were selected for comparison. PAA-g-DDA is the
“standard” polymer surface coating used for many commercially-available quantum dots,
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described supra. Polyethyleneimine-graft-polyethylene glycol (PEI-g-PEG) is an amine-
containing coating that displaces the alkyl surfactants remaining from QD synthesis, and
was prepared as described by Duan and Nie.[62] Mercaptopropionic acid (MPA) is a
small-molecule thiol that displaces the alkyl surfactants from QD synthesis, used in the
earliest applications of QDs in biology and was prepared as described by Smith et al.
[229] Lipid/PEG coated QDs of varying PEG content intercalate in the alkyl surfactants
from QD synthesis, and were created with the lipids DPPC (1,2-dipalmitoyl-glycero-3-
phosphocholine) and DPPE-PEG (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy(polyethylene-glycol)-2000). The percentage (40% or 100%) is the percentage of
lipid PEG used in the feed for coating. The procedure used was from Smith et al., an
adaptation of a procedure by Dubertret et al. [229, 63]
5.3.3.5 Data analysis of microplate experiments
Microtiter plate (microplate) experiments all included a baseline reference (buffer solution
only) that was used to calibrate the fluorometric plate reader photodetector. The microplate
experiments also included a full-signal reference, typically QDs in buffer solution without
additional treatment. Each data point consisted of at least 4 samples (n = 4), and was
considered acceptable if the coefficient of variation (CV, %CV = 100× x̄
σ
) was below 30%.
The relative fluorescence remaining is the ratio of the mean fluorescence at each data point
to the mean fluorescence of the full-signal reference.
5.4 Results and discussion
5.4.1 Phenomenological observations of QD fluorescence quenching
The finding that HOCl can lead to QD degradation was accidental: during characterization
of QD surface charge (zeta potential) for an unrelated experiment, some samples lost fluo-
rescence. The zeta potential measurement uses a voltage potential across a short electrode
separation (i.e., a high voltage gradient) to induce particle mobility; the applied voltage,
in the presence of chloride ions present in the solution buffer, generates HOCl. This is the
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Figure 36: Hypochlorous acid (HOCl) exposure quenches quantum dot (QD) fluorescence
but photoannealing restores it. HOCl causes fluorescence quenching of QDs in a dose-
dependent manner (A), but the fluorescence can be partially recovered following UV-B
illumination (B). The photographs show a series of vials containing dilute solutions of
polymer-encapsulated QDs with increasing molar ratios of HOCl added to the solution (ra-
tio is indicated above each vial). Increased concentrations of HOCl cause greater levels
of fluorescence loss. The bottom photo shows the same exact vials after being exposed to
UV-B light for 10 minutes. In addition to regaining fluorescence intensity in some sam-
ples, one sample (“1k”, 1,000 HOCl molecules per QD) shows a blue-shift in the band
edge fluorescence peak. The right side of the figure shows fluorescence spectra of the vial
solutions photographed on the left. Reprinted with permission from ref. [148]. Copyright
2008 American Chemical Society.
chloralkali process, which is used to generate Cl2 and HOCl commercially. That HOCl was
being generated in situ was determined later through basic analytical chemistry. In addition
to noting the loss of fluorescence in some samples, it was also noted that a subset of the
samples which lost fluorescence regained it over time. It was later determined that the flu-
orescence recovery was caused by ambient fluorescent lighting inducing photoannealing.
The “big picture” overview of this process is illustrated in Figure 36 on this page.
From a phenomenological standpoint, there are several interesting points about the
HOCl-induced quenching process shown in Figure 36 on the current page. One is that
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the process itself is very fast: QD fluorescence is quenched within seconds of the addition
of HOCl (too fast to record without specialized equipment) and reaches completion within
30 minutes of exposure. Previous work by Derfus et al. showed that H2O2 can also lead
to QD fluorescence quenching, however, this reaction takes days to go to completion and
in even in the presence of a higher molar ratio of oxidant to QD, results in less fluores-
cence quenching as shown in 37.[56] Another surprising aspect of this reaction is that it
occurs so quickly despite the QD crystal being encapsulated both by an aliphatic polymer
and a hydrophobic surfactant. This might be because the pKa of HOCl is 7.53, so at the
physiologic pH at which these experiments are carried out, approximately half will exist
in a neutral form that can cross hydrophobic barriers.[169, 2] Another surprise is that the
fluorescence can be recovered simply by exposing the samples to UV light, and not only
does the fluorescence recover, but is in some cases accompanied by a shift in the band-edge
fluorescence peak—in the case of Figure 36 on the preceding page, the sample treated with
1,000 HOCl per QD and photoannealed displays a hypsochromic band edge fluorescence
shift of 10 nm. The location of the fluorescence peak is determined in part by the size
and composition of the QD, and so the peak shift supports the idea that the QD size has
decreased.
5.4.2 Measurements of bulk QD fluorescence quenching and degradation
Fluorescence quenching by HOCl exposure is rapid, occurring within seconds. We mea-
sured the effects of HOCl exposure on two synthesized batches of QD crystals, both with
similar structures but synthesized years apart and polymer-encapsulated for water solubi-
lization with different batches of polymer coating at different times. As shown in Figure 38
on page 100, the response profiles of both batches of QDs are indistinguishable. The
QD615C crystal batch is the QD sample used in the analysis of QD degradation below
and characterized in Table 2 on page 94; the QD620C crystal batch was used in some
experiments described in Chapter 6. The fluorescence quenching reaction itself was also
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Figure 37: Time course of quantum dot (QD) degradation following exposure to hypo-
chlorous acid (HOCl) or hydrogen peroxide (H2O2). Polymer-encapsulated QDs in
phosphate-buffered water were exposed to specified concentrations of HOCl or H2O2 and
allowed to react over a period of two days. Note that the molar ratio of HOCl added to the
QD solutions, 1,000, is one-tenth that of H2O2 added. Error bars show the 95% confidence
interval (n = 4) and the lines of fit are drawn solely as a visual guide.
carried out one year apart, using different batches of HOCl, phosphate buffer, and water
supply. The core/shell structures of both QD crystals are similar, so the identical reaction
profile towards HOCl is expected. In both cases, a loss in fluorescence is detectible at a
molar ratio of 10 molecules of HOCl per QD, and fluorescence becomes difficult to detect
on the instrument used beyond 1,000 HOCl per QD.
Measurements of the UV-vis absorbance spectra of QDs exposed to HOCl shown in
Figure 39 on page 101 show that as the exposure level of HOCl increases (1,000 HOCl
per QD), the first exciton peak decreases in absorbance and the peak becomes more blue-
shifted: taken together, these are signs of the QD core decreasing in size. Interestingly,
this same exposure level is the same exposure level that shows significant band-edge flu-
orescence peak shift with photoannealing as shown in Figure 36 on page 97. With over-
whelming exposure to HOCl, the absorbance spectra becomes featureless, consistent with
complete destruction of the QDs. Elemental analysis of QD solutions treated with HOCl
and then filtered to remove intact QDs confirms the UV-vis spectroscopy findings that sug-
gest QDs degrade in the presence of HOCl. As shown in Figure 40 on page 101, increasing
exposures of HOCl liberate increasing amounts of the metals (Cd, Zn) and chalcogens (S,
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Figure 38: Fluorescence quenching in quantum dots (QDs) exposed to hypochlorous acid
(HOCl). QDs were diluted into physiologic pH phosphate-buffered water and reacted with
indicated molar ratios of HOCl. The QDs reacted are from two different synthesis batches,
and the reactions were carried out completely independently. Non-linear regression lines
are a one-phase exponential decay model, error bars show the 95% confidence interval (n =
4), and Pearson’s correlation coefficient for both non-linear regressions is 0.98. The best-fit
exponential decay constant between the two regressions are the same, with 64% probability
as calculated by Akaike’s informative criteria, corrected (AICc).
Se) which make up the QDs. Importantly, the stoichiometric ratios of the atoms liber-
ated matches well with the expected chemical composition of the QDs used in this study,
Cd0.65Zn0.35Se0.35S0.65, described layer by layer in Table 2 on page 94. The amounts of each
element are lower than would be expected, however, the polymer used for encapsulating
the QDs can still chelate free metal ions, and during the separation process the polymer
(with chelated ions) could remain in the retentate of the separation. The band-edge fluores-
cence peak shift observed in Figure 36 on page 97 after photoannealing QD reacted with
1,000 HOCl per QD, 609 nm emission (c.f. the unreacted QDs with band-edge emission of
619 nm) is consistent with the loss of the outer ZnS layer of the QD based purely on fluo-
rescence data from Table 2; the characterization table also estimates approximately 1,000
atoms in the outer ZnS shell of the QD, approximately half which would be S and able to
react with HOCl—on the same order as the molar ratio of HOCl added per QD.
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Figure 39: Ultraviolet-visible (UV-vis) absorbance spectroscopy of quantum dots (QDs)
exposed to hypochlorous acid (HOCl). UV-vis absorption spectroscopy of phosphate-
buffered QDs exposed to HOCl shows that at a molar ratio threshold of 1,000 HOCl
molecules per QD, there is a noticeable decrease in intensity and blue-shift in the first
exciton peak of the QDs (noted with arrows), both indicative of a decrease in QD size. An
excess (10,000) of HOCl molecules per QD results in a featureless and broadband absorp-
tion spectrum consistent with scatter, suggesting complete QD destruction. Reprinted with











































Figure 40: Elemental analysis of quantum dot (QD) solutions after exposure to hypo-
chlorous acid (HOCl). (A) Elemental analysis by inductively-coupled plasma mass spec-
trometry (ICP-MS) shows that there is an increase in the free ions making up QDs in solu-
tion that correlates with an increased molar ratio of HOCl molecules added to the solution.
The ratios of the ions are consistent with the QD chemical composition, taking into account
the core/shell structure of the QDs tested. (B) In outer shell layers of the QD there is an
excess of Zn relative to the other elements, so moderate amounts of HOCl (1,000) would
be expected to liberate mostly zinc, whereas more HOCl (10,000) is needed to liberate the
Cd and Se in the core of the QD. Panel (A) reprinted with permission from ref. [148].
Copyright 2008 American Chemical Society.
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5.4.3 Common QD surface coatings do not prevent degradation by HOCl
A surprise in studying degradation of QDs by HOCl exposure is the relative insensitivity
of the reaction to the surface coating of the QDs. High-quality QDs are synthesized in
organic solvents, and are by nature soluble only in non-aqueous solvents. To make these
QDs water soluble, they are either re-coated with a water-soluble ligand (usually called
a “small ligand exchange”), or coated with a polymer or surfactant that intercalates with
the hydrophobic alkyl surfactant layer surrounding the QDs and simultaneously presents
a water-soluble moiety: in the case of PAA-g-DDA, this moiety is the carboxylates of
polyacrylic acid, in the case of phospholipids, this is the charged phosphate group of the
phospholipid head group. We tested the response of QDs coated with common surface
coatings to degradation by HOCl. The surface coatings tested can be divided into two
groups: those that displace the alkyl surfactant layer from QD synthesis, and those that
preserve it. Polyethyleneimine (PEI) is a branched amine-rich polymer that displaces the
QD alkyl surfactant layer and confers water solubility with good quantum yield (QY);
we tested a variant of PEI grafted with 2000 kD PEG side chains that make the overall
QD surface charge more neutral than the positive PEI coating.[62] Mercaptopripioic acid
(MPA) is a small-molecule thiol that displaces the QD alkyl surfactant layer and is only
slightly larger than the mercaptoacetic acid (MAA) water-solubilization strategy used in
the first biological QD application articles.[33] PAA-g-DDA is a polymer coating that has
a alkyl moiety that intercalates in the alkyl surfactant layer of the QD, an acrylic acid
backbone, and carboxylate moieties that provide water solubilization; it is very similar or
identical to the polymer surface coatings used by commercial QD manufacturers. Lipid-
coated QDs are a micellar structure using the alkyl surfactants of the QD and phospholipids
added to confer water solubilization; they are available commercially and are in general
quite “inert” biologically. The form tested had lipids grafted to PEG chains with varying
feed ratios for the QD coating procedure.










































Figure 41: Altered surface chemistry is insufficient to protect quantum dots (QDs) from
hypochlorous acid (HOCl) attack. QDs from the same batch of synthesis were coated
with several different and common surface coatings, then tested for fluorescence quenching
following HOCl exposure at the indicated molar ratios. PAA-g-DDA is polyacrylic acid-
graft-dodecylamine; PEI-g-PEG is polyethyleneimine-graft-polyethylene glycol (2,000 kD
MW); MPA is mercaptopropionic acid; lipid/PEG is a phospholipid coating with varying
graft ratios of 2,000 kD MW PEG. Error bars show the 95% confidence interval (n = 4).
Reprinted with permission from ref. [148]. Copyright 2008 American Chemical Society.
to HOCl rapidly degrade even in moderate levels of HOCl. The PAA-g-DDA surface coat-
ing, in many applications one of the most stable surface coatings, actually performs the
worst. Both PEI-g-PEG and MPA perform well in comparison; both have functional groups
(amine and thiol, respectively) that are targets of oxidation by HOCl. In effect, both sur-
face coatings “buffer” the QD surface from HOCl oxidation. The small molecule thiol
coatings are commonly one of the less-stable surface coatings both by colloidal and optical
measures.[229] In the case of lipid/PEG coatings, there is a considerable steric interference
offered by the QD alkyl surfactant layer (in this case, a mix of hexadecylamine and octade-











































































Figure 42: Photoannealing degraded quantum dots (QDs) results in restoration of fluores-
cence. (A) QDs were exposed to 2,000 molecules of hypochlorous acid (HOCl) per QD
and photoannealed by exposure to UV-B light for the specified time intervals. The QDs
exposed to HOCl showed a dramatic fluorescence increase (relative to the original emis-
sion strength). Error bars show 95% confidence intervals, n = 3, and lines are a one-phase
exponential regression fit provided solely as a visual guide. (B) A single sample of QDs
were exposed to HOCl and photoannealed while the fluorescence emission was continu-
ously tracked. The solid black arrow marks a kink at which the excitation volume becomes
saturated with photoannealed QDs—beyond this point, fluorescence increase due to photo-
annealing previously “dark” QDs is diffusion limited. The open gold arrow shows the point
at which the entire sample has photoannealed, beyond this point, photooxidation occurs.
5.4.4 Observations on single particle and bulk QD photoannealing
The time course in which photoannealing occurs was first tested using UV-B light provided
by a germicidal light stand. As shown in Figure 42 on the current page, significant fluo-
rescence increases are observed in the QD samples treated with HOCl, whereas samples
not treated with HOCl have only minute fluorescence increases. It should be noted that
these fluorescence increases are relative, so while the HOCl-treated QDs may increase in
fluorescence by 10 fold, they are still considerably dimmer than the unreacted QDs (shown
in Figure 43 on the following page, inset). Continuous tracking of a single QD sample, also
shown in Figure 42 on the current page, shows that the fluorescence rise is exponential-like,
before plateauing and then decreasing (presumably due to photooxidation). In addition to a












































Figure 43: Photoannealing degraded quantum dots (QDs) results in fluorescence peak
shifting and broadening. (A) QDs were exposed to specified molar ratios of hypochlorous
acid (HOCl) per QD and photoannealed by exposure to UV-B light for 10 minutes. The
band edge fluorescence peak shifts up to 20 nm, and in the furthest shifted sample, shows
a significant blue tail. In the inset for A is the unnormalized spectra so that the relative
quantum yields may be observed. (B) Correlation between band edge fluorescence peak
(in chloroform) and layer-by-layer structure for the QDs in A.
visible only after photoannealing. The peak shift is dependent on the amount of HOCl re-
acted with the QDs, as shown in Figure 43 on this page, and is roughly correlated with the
known layer-by-layer band edge fluorescence of the QDs from synthesis.
QDs are distinct from organic dyes such as rhodamine in that QDs are a population
of particles with a range of core sizes, shell thicknesses, surface passivation, &c., whereas
organic dyes are all identical. The variation in the properties of a population of QDs would
naturally be assumed to lead to a variation in the behavior of QDs exposed to HOCl. As
such, we examined the single particle and ensemble (a population of singly-identifiable
particles) behavior of QDs exposed to HOCl and reconciled these results with the bulk
behavior. In terms of fluorescence quenching, single particle observations in a fluores-
cence microscope showed that the blinking rate of QDs changes dramatically on addition
of HOCl, decreasing the duty cycle of the QDs and in effect, lowering the quantum yield
of the bulk solution. Attempts were made to investigate the alteration in blinking rates, but
the changes were too subtle to detect on the laboratory equipment available. It must be
noted however that these observations were made under QD excitation, and so the QDs are
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undergoing photoannealing at the same time they are being chemically oxidized.
Deliberate photoannealing of the QDs that were treated with HOCl explains the altered
shape of the bulk solution QD fluorescence peak following photoannealing, depicted in
Figure 44. The bulk QD spectrum following photoannealing, in addition to a 15 nm shift
in the main band-edge fluorescence peak, has a distinct “blue tail” that is not observed
in the untreated QDs. Ensemble observations of QDs under the microscope showed that
the photoannealed QDs had visible fluorescence spanning a range of colors, from green
to red, shown in Figure 45. Smaller (bluer) QDs have lower quantum yields than larger
(redder) QDs, all other things being equal, and in this case, the smaller QDs are produced
by chemical etching and so may have an even lower QY due to defects remaining on the
QD related to the etching process and to loss of the passivating layers of the QD shell.
Therefore, the “blue tail” can be explained as being due to the presence of a range of QD
sizes and structures, with higher QY particles closer to the band edge fluorescence peak,
and lower QY particles farther from the band edge fluorescence peak.
5.4.5 Mechanism of QD degradation by HOCl exposure and restoration of fluores-
cence by photoannealing
The group IV-VI QDs used in this chapter (and throughout this dissertation) contain chalco-
gens (S, Se). HOCl is known to have extremely fast reaction kinetics in oxidizing chalco-
gens, and so it is reasonable to expect that HOCl is oxidizing exposed chalcogens on the
surface. Since HOCl is relatively small and can exist in a neutral acid form at the physio-
logic pH in which these experiments are carried out, it is understandable that HOCl could
penetrate the polymer and alkyl surfactant shell (corona) surrounding the QD. The corona
layer also has potential targets for oxidation, amines of the alkyl surfactants in the case
of the polymer-encapsulated QDs used. Curiously, altering the surface chemistry has lit-
tle effect on the end-result of HOCl exposure, but this probably has much to do with the
reaction kinetics of HOCl being faster for thiols than for amines or unsaturated/aromatic
carbon–carbon bonds.[196] Once HOCl reacts with an exposed chalcogen on the surface
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Figure 44: A comparison of the bulk and ensemble fluorescence spectra of photoannealed
quantum dots (QDs). QDs were reacted in bulk solution with a molar ratio of 2,000 HOCl
molecules per QD, photoannealed with 10 minutes of UV-B exposure from a UV light
stand, and then measured on a fluorometer (“Bulk”) or on a microscope with a 100X ob-
jective (“Ensemble”) and equipped with a spectrograph. Bulk and ensemble spectra show
good agreement. The “Green” sample is a spectrograph reading of a bright green QD ob-
served in the microscope and is shown to illustrate how the range of QD emission profiles,
summed together, can explain the blue tail associated with the photoannealed QD band-
edge fluorescence peak.
A B
Figure 45: Micrograph of quantum dots (QDs) before and after photoannealing. (A) QDs
adsorbed to a glass coverslip were imaged with a 100X objective before addition of HOCl.
Following HOCl addition, QDs were allowed to photoanneal using UV-C excitation light
for 5 minutes, then imaged again. (B) After etching with HOCl and photoannealing, the
ensemble of QDs shows a range of fluorescence colors in comparison to the single color
of the unreacted QDs. Images were digitally adjusted for brightness and contrast with
identical settings used for both images.
107
of the QD, this oxidation site can act as a trap for the exciton, immediately quenching
QD fluorescence.[234] Photoannealing is clearly a correction of this defect, but the exact
mechanism is still elusive. Photoannealing unconnected to the HOCl reaction has been
observed previously, but was explained as a “structural rearrangement.”[149] It is possible
that photoannealing represents the ejection of the oxidized chalcogen, similar to very early
observations of macroscopic CdS electrodes undergoing photocorrosion.[103, 213] This
would make the surface of the QD metal rich, favoring luminescence.
5.5 Conclusions
The degradation of semiconductor quantum dots by exposure to hypochlorous acid is
unique in the fast kinetics and high efficiency of the reaction, and in the relative insensitiv-
ity of the QD crystal material or solubilizing ligands. Beyond the obvious contra-indication
of using QDs in an environment containing HOCl (or in electrophoretic potential measure-
ments), the data presented in this chapter demonstrate that while QDs may be superlatively
photostable, they are not invincible in terms of chemical stability. In addition to indepen-
dently replicating results presented here and in Chapter 6 (published in part in 2008), two
groups have published extensions of this work into new areas.[41, 273] The relevance of
this reaction in the biological context, a prime application of colloidal QDs, will be ex-
plored in Chapter 6. Restoring the fluorescence to QDs through photochemical annealing
could prove to be useful in sensing applications (i.e., determine the amount of QD degra-
dation and so estimate the quantity of HOCl present, as was done in ref. [273]) and in basic
research into the role of surface defects on QD fluorescence emission. Control over the
emissive state of fluorophores is also important for both optoelectronics applications (e.g.,
optical memory) and in super-resolution microscopy and it is possible that the QD/HOCl
interaction could lead to QD adoption for these applications.
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CHAPTER VI
DEGRADATION OF QUANTUM DOTS BY BIOLOGICAL
PROCESSES
6.1 Abstract
The advantageous optical and physical properties of semiconductor quantum dots makes
them desirable for use as optical contrast agents for in vivo human imaging, however, the
toxic composition of quantum dots prevents the use of quantum dots for this application.
These concerns existed despite a well-defined mechanism for the breakdown of quantum
dots in vivo into their substituent materials that are known to be toxic. The toxicity associ-
ated with the presence of the particles themselves is also a factor and must be considered.
We have described in Chapter 5 how quantum dots are rapidly degraded by exposure to
hypochlorous acid. Hypochlorous acid is a biologically-relevant chemical, generated by
phagocyte cells of the immune system as an antimicrobial compound. Quantum dots are
known to be sequestered by immune cells when systemically-injected, and so it is possible
that quantum dots could be degraded in vivo by immune cells via a process involving hypo-
chlorous acid. In this chapter, we explore the sensitivity of quantum dots to degradation by
a range of biologically-relevant reactive chemicals, we demonstrate that quantum dots can
be degraded by cells in in vitro models, and we investigate the limitations of degradation
by these processes. We find that cellular processes can cause quantum dot degradation, but
that the rate of degradation is far slower than is observed in the “test tube” cell-free systems
of Chapter 5. Thus, degradation of quantum dots by immune cells is expected to take long




Semiconductor quantum dots (QDs) are interesting for use as an in vivo imaging probe,
including for human applications, however the toxic semiconductor components making
up the QD and the tendency of QDs to biopersist make regulatory approval unlikely. An
analogy is commonly made between using QDs for imaging and medical technology with
known toxic side effects, e.g., gadolinium chelates used in magnetic resonance imaging.
The difference is that chelates of gadolineum are known to be relatively non-toxic (unlike
free gadolinium which is quite toxic) and the chelates are cleared from the body with well-
defined kinetics. Gadolinium chelates are still used despite the possibility of nephrogenic
systemic fibrosis, a serious complication with a yet to be determined cause.[201] If QDs
were shown to remain intact in vivo until cleared (in an intact state), it could improve the
odds of gaining regulatory approval for QD use in humans. Despite the concerns related to
the toxic components of QDs, it has not been clear how QDs would cause toxicity in vivo.
While it is true that some of the constituent atoms making up the QD are known to be toxic,
it is not clear that the atoms when in crystalline form are equally toxic. Numerous toxicity
studies have been conducted, but a clear consensus of QD toxicity has yet to emerge.[95]
Part of the difficulty is because heavy metal toxicity is in general a chronic disease that
takes years to present. Another major confounding factor is the considerable chemical and
structural variation in QDs used between different research groups.
In Chapter 5, we showed how hypochlorous acid (HOCl) could rapidly degrade QDs
and release the semiconductor materials making up the QD into the environment. HOCl is
one of many reactive oxygen species (ROS) found in the body, generated by the haloperoxi-
dase enzyme family. Notably, two enzymes in this family, myeloperoxidase (MPO) and the
related eosinophil peroxidase (EPO), are found in immune cells.[131, 212] MPO is found
in the azurophilic granules of neutrophils (where it can make up to 5% of the dry weight
of a neutrophil) and in monocytes (the progenitor cell of macrophages); the similar EPO



































































26 APRIL 2002 VOL 296 SCIENCE www.sciencemag.org670
rise in intraphagosomal pH to about pH 8,
despite the release of the acid contents of
granules into the phagosome (7). This rise
in pH is due to the generation of large
amounts of superoxide in the phagosomes,
followed by consumption of protons lead-
ing to the formation of H2O2 (see the fig-
ure). Charge compensation takes place by
proton transfer into the phagosome, both
through the NADPH oxidase itself and
other proton channels (8, 9), but apparent-
ly not in sufficient amounts to totally com-
pensate for the electrogenic process of su-
peroxide formation. 
In the new work, the Segal group shows
that this process is accompanied by an in-
flux of large amounts of potassium ions into
the phagosome (4). This influx enables the
pH to remain elevated and more important-
ly, increases the potassium concentration to
an estimated 200 to 300 mM. The high
tonicity induces solubilization of the cation-
ic proteases that are bound to a strongly an-
ionic sulfated proteoglycan matrix in the
azurophil granules. On the basis of these ob-
servations plus an elegant array of biophysi-
cal and biochemical studies, the authors pro-
pose that the elastase and cathepsin G, once
liberated, attack and kill the ingested mi-
croorganisms. In their view, superoxide gen-
eration is needed only to increase the ionic
strength of the phagosome, which then al-
lows solubilization of the proteases. 
So, is this the prime mechanism by
which neutrophils kill microbes? Do reac-
tive oxygen species themselves have no
place in this process? In our opinion, it is
premature to draw these conclusions.
There is a wide body of evidence support-
ing the notion that oxidants are involved in
killing (6), and many questions remain.
For instance, CGD neutrophils are able to
kill catalase-negative bacteria (which ex-
crete H2O2) and also catalase-positive bac-
teria if they coingest glucose oxidase,
which generates H2O2 (10–12). Both phe-
nomena point to a contribution of H2O2, or
products derived from it, in the killing pro-
cess. Moreover, the killing of bacteria by
H2O2 in a cell-free system is dramatically
enhanced by myeloperoxide (13, 14).
Myeloperoxidase-deficient mice also suc-
cumb to bacterial challenge (15).
In contrast to the conventional view, the
Segal group proposes that myeloperoxi-
dase acts as a detoxicant for H2O2, thus
protecting other microbicidal systems
from inactivation. Their evidence for this
notion is not convincing. The conclusion
that myeloperoxidase does not enhance
killing was obtained with an unrealistically
high concentration of H2O2 (100 mM).
Not only will this rapidly inactivate
myeloperoxidase, but it is several orders of
magnitude higher than best estimates of
what could be achieved in the phagosome,
when consumption by myeloperoxidase
and leakage are taken into account (3).
However, the view that myeloperoxidase is
not strictly an HOCl generator should not
be dismissed. The enzyme does have cata-
lase activity, although this requires con-
centrations of other substrates, such as
chloride, to be low (16). Furthermore,
chlorination of bacteria after ingestion by
neutrophils is surprisingly low (5). 
Other roles for superoxide must also be
considered. S. aureus coated with superox-
ide dismutase is killed less efficiently by
neutrophils, but only when myeloperoxi-
dase is active (17). This points to the in-
volvement of superoxide in a myeloperoxi-
dase-dependent process, rather than an ef-
fect on protease action. Some bacterial
strains even excrete superoxide dismutase,
possibly to evade killing by the myeloper-
oxidase system (18–21). Antibodies
against superoxide dismutase enhance the
killing of these strains both by isolated
neutrophils and in mice (22, 23). The
mechanism of protease release from neu-
trophils into the extracellular environment
(where tonicity is low) (24), and how neu-
trophils kill some bacterial strains under
anaerobic conditions (25) also require ex-
planation. 
In spite of these uncertainties, the new
mechanism of “oxidative” killing proposed
by Segal and colleagues needs to be ex-
plored. It is a thought-provoking concept
that may lead to a radical change in the
way we view this vital area of host defense.
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In the belly of the phagocyte. Within the small space between an ingested bacterium (shaded
area) and the membrane of the phagosome, a number of chemical reactions take place. Molecular
oxygen is reduced to the superoxide radical (O2!) by electrons pumped into the phagosome by the
NADPH oxidase system. This charge transfer is compensated by the influx of protons (H+) or other
cations. The protons are used to reduce superoxide to hydrogen peroxide (H2O2), which can be bro-
ken down to oxygen and water in a catalase-dependent reaction. Alternatively, H2O2 can combine
with chloride to form hypochlorous acid (HOCl) in a reaction catalyzed by myeloperoxidase
(MPO). Under certain conditions, MPO may act as a catalase. If all electrons pumped into the
phagosome are compensated by proton influx, the pH in the phagosome will remain neutral. How-
ever, the pH does in fact rise to about pH 8, despite the release of acid contents from granules in
the cytoplasm that fuse with the phagosome. This indicates that other cations, such as potassium
ions (K+), may enter the phagosome instead of protons (4). If there is an influx of K+, these cations
then mediate solubilization of proteases that are tethered to the proteoglycan matrix of the gran-
ules. As a result, ingested bacteria within the phagosome are killed. Whether this is the main mech-
anism of bacterial killing by neutrophils, or even the only one, or whether HOCl and other reactive
oxygen species are also involved is a matter of debate.






























Figure 46: Phagocytes e gulf foreign bodies and rel ase an array of antimicrobial com-
pounds. A neutrophil engulfs a bacterium, forming a phagosome. Granules fuse with the
phagosome, releasing compounds that can gener te r active oxygen species (ROS). By
forming a phagosome, the cell can cre te high local con en ratio s of ROS, and bet r co -
trol the reaction. From Roos and Winterbourn, ref. [209]. Reprinted with p rmissi n from
AAAS.
acid (HOBr) in addition to HOCl.[154, 255] It is theorized that t e urp se of both enzymes
is to generate hypohalous acids in situ kill fore gn organisms, as show in Figure 46 on
the current page—individuals with a genetic deficiency in MPO (chronic granulomatous
disease) have increased susceptibility to opportunistic diseases associated with individuals
having compromised immune systems (e.g., aspergillosis, candidiasis).[1 3, 178] In this
chapter, we will focus on MPO as a representative haloperoxidase: EPO is found only in
eosinophils (which represent no more tha 5% of circulati g leukocytes) whereas MPO is
found in both neutrophils and monocytes (representing approximately 65% of circulating
lymphocytes). MPO catalyzes the production of HOCl in the presence of chloride ions
(found endogenously at approximately 140mM concentration), and H2O2, generated in situ
by phagocytes during the “degranulation” process of phagocytosis.
Since both HOCl and H2O2 can degrade QDs, and both compounds are considered bio-
logical ROS, we became interested in all biological ROS for their ability to degrade QDs.
Nitric oxide (·NO) is synthesized by nitric oxide synthases (NOS) in the body for signaling
and antimicrobial purposes; in the case of macrophages, the enzyme isoform is inducible
NOS (iNOS). Superoxide (·O2-) is used as an antimicrobial agent by granulocytes and
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Table 3: Sources and biological oxidants assayed for QD degradation
Oxidant Pathophysiologic
concentration
Biological source Chemical source
HOCl 1–1000nmol/L haloperoxidases Pure reagent
·NO 10–1000nmol/L nitric oxide syn-
thases
Angeli’s salt
·O2- 1–100nmol/L NADPH oxidases KO2
ONOO- 10–100nmol/L ·NO + H2O2 Pure reagent
H2O2 10–1000nmol/L ·O2- + superoxide
dismutase
Pure reagent
·OH Unknowm H2O2 + iron(II) H2O2 + iron per-
chlorate
macrophages and is generated by the NADPH (nicotinamide adenine dinucleotide phos-
phate) oxidase (NOX) system. At physiologic pH, ·O2- exists mostly in the anion form. In
the presence of water, ·O2- disproportionates into oxygen and H2O2—this process is cat-
alyzed by the metalloenzyme family superoxide dismutase (SOD). Peroxynitrite (ONOO-)
is not a radical but is a powerful oxidant; it is formed by the adduction of ·NO and ·O2-.
At physiologic pH, ONOO- is in the unstable ionic form which has a half-life of 1.9s.[16]
Finally, hydroxyl radical (·OH) is the most reactive ROS found in the body, presumably
produced through a variant of Fenton’s reaction between H2O2 and iron(II) and through
reaction of HOCl with ·O2-.[92] Hydroxyl radical is so reactive that it is exceedingly short-
lived: its half life in aqueous solutions is on the order of nanoseconds, implying a mean
diffusion distance in pure water of 10 angstroms. The extreme reactivity of ·OH also means
that the in vivo concentration is unknown. All of these ROS, summarized in Table 3 on this
page are generated during the “oxidative burst” (a period of high oxygen consumption)
of phagocytosis, where phagocytes fuse the primary vesicles containing enzymes and pre-
cursors with the phagosome containing engulfed foreign bodies; some of these ROS can
also be generated elsewhere in the body as signaling molecules (e.g., ·NO is also known as
endothelium-derived relaxing factor).
If QDs were to be used as a contrast agent for in vivo imaging, they could be used
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as either a passive or active targeting contrast agent, and would presumably be system-
ically injected. Once injected, QDs encounter endothelial cells lining the blood vessels,
erythrocytes (red blood cells) ferrying oxygen to tissues and carbon dioxide away, leuko-
cytes (white blood cells) that are involved in the immune response, platelets responsible
for wound healing, and any number of serum proteins. Many serum proteins are known
to bind to nanoparticles, and some of these serum proteins are part of the the immune sys-
tem (antibodies, complement proteins).[60] QDs injected in vivo, like most nanoparticles,
are soon sequestered by immune cells in the liver and spleen, and mechanically filtered
and retained in the kidneys.[164, 163] The liver is rich in Kupffer cells, a type of resident
macrophage (and so of monocyte origin);[174] the spleen is a reservoir of monocytes.[243]
While not all monocyte-derived cells have MPO, Kupffer cells do.[21] The immune cells
in these organs (classically referred to as the reticuloendothelial system, RES, now referred
to as the mononuclear phagocyte system, MPS) are designed to recognize and filter foreign
bodies from the blood. It is thus possible that the body may be able to degrade QDs by
the existing foreign body response (nanoparticles are after all foreign matter). Previous
work has shown that QDs in cell culture models of the liver can be degraded following
phagocytosis, however, earlier work only considered H2O2 and the immune response was
ignored.[56] As was discussed in Chapter 5, H2O2 degradation of QDs occurs over a time
span of days, whereas HOCl-mediated degradation occurs over much shorter time periods
as was shown in Figure 37 on page 99.
In this chapter, we will consider the degradation of QDs by HOCl and other biological
oxidants associated with resident macrophages (as has previously been considered), as well
as circulating granulocytes and endothelial cells. Unlike many studies which use easily
manufactured cadmium telluride QDs, which are well-known to be fragile and prone to
degradation simply by being in aqueous solution, we will use polymer-coated core/shell
QDs that are similar to commercially available QDs.[226, 279, 147, 278] These polymer-
coated QDs are ordinarily extremely stable and are more likely to be of a kind useful for
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human in vivo use.
6.3 Methods
6.3.1 Degradation of QDs in vivo by a panel of biological ROS
QDs crystals were the same particles synthesized, described, and used in Chapter 5, and
used the PAA-g-DDA polymer coating. QDs were diluted into phosphate-buffered wa-
ter at pH 7.4 (described as “physiologic buffered”) in a black microplate, to which ROS
were added. ROS were sourced as follows: HOCl was diluted from reagent-grade stock;
·NO was generated by the ·NO donor Angeli’s salt (disodium diazen-1-ium-1,2,2-triolate)
diluted into house deionized water and used immediately; ·O2- was diluted from potas-
sium superoxide diluted in basic water; ONOO- was synthesized by oxidation of nitrous
oxide by hydrogen peroxide in alkaline conditions with a subsequent freeze fractionation
workup;[114] H2O2 was diluted from reagent-grade stock; and ·OH was generated by Fen-
ton’s reaction with the same concentration of H2O2 as in the H2O2 sample. HOCl, ONOO-,
and H2O2 were assayed for concentration by UV-vis absorbance spectroscopy. The mo-
lar extinction coefficients used were εHOCl, 292 nm = 350 L mol-1cm-1 , εONOO-, 302 nm = 1670
L mol-1cm-1 , εH2O2, 240 nm = 43.6 L mol
-1cm-1 .
6.3.2 Degradation of QDs by the MPO enzyme system
QDs were diluted into phosphate-buffered saline (PBS) in black microplates, to which com-
ponents of the MPO enzyme system were then added. MPO was obtained commercially,
isolated from human leukocytes. Activity was confirmed spectrophotometrically by oxi-
dation of guiacol in the presence of H2O2, as per a protocol recommended by the man-
ufacturer and described by Desser et al. [57] MPO, H2O2, and 4-aminobenzoic acid hy-
drazide (ABAH) were diluted into house deionized water (18.2 MΩ) before addition to the
QDs/microplate, and were allowed to react one hour at room temperature, light protected,
before reading in a fluorometric plate reader.
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6.3.3 Cell culture for live cell experiments
HL-60 cells, derived from a human promyelocytic leukemia, were obtained commercially.
[44] The main cell line was maintained in a standard incubator, maintained at 37 de-
grees Celsius and with a 5% CO2 atmosphere. Standard medium for culturing was Iso-
cove’s modification of Dulbecco’s-modified Eagle’s medium (IMDM), supplemented with
20% fetal bovine serum (FBS) and no antibiotics. Cells were maintained, suspended in
culture flasks, between 1 × 105 and 1 × 106 cells per milliliter, counted by automated
cell counter. Cryopreservation was performed using standard technique using the normal
growth medium supplemented with 5% dimethylsulfoxide (DMSO), cell culture grade, as
a cryopreservant. On awakening, the cells were centrifuged to pellet and washed with
balanced salt solution several times to remove excess DMSO that could cause unwanted
differentiation before being transferred to the culture flask. To differentiate HL-60 cells
into a neutrophil-like phenotype, the cell medium was supplemented with 1.3% DMSO,
cell culture grade, with a fresh culture of cells at 1 × 105 cells/milliliter. Differentiation
took approximately 6 days, and was accompanied by acidification of the culture medium
(appearing yellow due to the phenol red indicator solution), cessation of cell proliferation
and stabilization at approximately 5 × 105 cells per milliliter, and a slight decrease in cell
size (from 15 to approximately 12 micron in diameter). Differentiated cells were confirmed
to be differentiated by a smear-prep of the cultured cells on a glass slide, followed by flame
fixation and staining in Wright-Giemsa’s stain: neutrophil-like cells had a clear cytoplasm
and a basic-staining bent or multi-lobular nucleus, similar to a band neutrophil.
Bovine aorta endothelial cells (BAEC) pooled from multiple donors were obtained
commercially and maintained in a standard incubator, maintained at 37 degrees Celsius
and with a 5% CO2 atmosphere. Standard medium for culturing was Dulbecco’s-modified
Eagle’s medium (DMEM), with 4.5g/L glucose, supplemented with 10% FBS and 100
U/mL each of penicillin and streptomycin. Cells were seeded at 2,500 cells/mL, in 10
cm petri dishes maintained between 30–90% confluency as monitored by microscopy, and
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passaged when necessary by using 0.25% (w/v) trypsin in ethylenediamine tetraacetic acid
(EDTA) balanced salt solution. Cells were used between passages 4–9: in order to have
a ready supply of appropriately-aged cells, cells were cryopreserved using standard tech-
nique in the normal growth medium supplemented with 10% DMSO, cell culture grade, as
a cryopreservant. Cryopreserved cells were awakened by standard technique.
6.3.4 QD degradation in the presence of antioxidants
6.3.4.1 Cell-free microplate assays of QD degradation
QDs were diluted in phosphate-buffered saline (PBS) in black 96-well microtiter plates so
that the final concentration would be 1 nmol/L. Samples of biological oxidants were added
so that the final concentration would be equivalent to the human reference values (where
available) or values from the literature, as summarized in Table 4 on page 124. Lyophilized
plasma, lyophilized catalase, and lyophilized serum albumin (Bt Plasma, Bt Catalase, and
BSA) were obtained commercially and were of bovine origin; they were diluted into PBS
before use. L-ascorbic acid, uric acid, L-cyseine and glutathione (GSH) were obtained
commercially as powders and were diluted into PBS before use.
6.3.4.2 Stimulated degradation of quantum dots by live cells
Several days ahead of degradation experiments, BAEC cells were trypsinized and passaged
into clear bottom black 96-well microtiter plates. The BAEC cells were allowed to form a
confluent monolayer (monitored by light microscopy) before proceeding with experiments.
Neutrophil-like HL-60 cells were placed in a separate clear bottom black 96-well microtiter
plate for experiments at a final density of 1 × 105 cells/milliliter. In both cases, cells were
either in physiologic balanced salt solutions (Hank’s buffered saline solution, HBSS, with
calcium and magnesium, Ca++/Mg++) or in respective standard culture medium (IMDM
for HL-60, DMEM for BAEC) containing FBS but not phenol red indicator solution, as
indicated. QDs were added so that the final QD concentration would be 1nmol/L. Cells
were then stimulated with 100nmol/L phorbol 12-myristate 13-acetate (PMA) for HL-60
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or 1 µg/mL lipopolysachharides (LPS) from Escherichia coli (E. coli) for BAEC. Inhibitors
of MPO (1mmol/L sodium azide, NaN3; or 100µmol/L 4-aminobenzoic acid hydrazide,
ABAH) and scavengers of H2O2 (100 U/mL catalase, Cat, from bovine liver) were used to
test inhibition of degradation. Cells were placed in the incubator for the indicated times (1
or 24 hours) before reading the plate on a fluorometric plate reader.
For microscopy, QDs were adsorbed onto glass coverslips, onto which neutrophil-like
HL-60 cells were plated at low density (such that only 3–5 cells were observed in the
field with a 40X objective). Cells were suspended in either HBSS or IMDM and FBS, as
indicated. Cells were then stimulated with PMA and allowed to rest in the incubator 1 hour
before imaging on the microscope. For initial microscopy images, cells were imaged under
excitation light with a bandpass filter centered at 475 nm with 30 nm bandwidth and a 510
nm longpass filter. To photoanneal, the microscope field was exposed to UV excitation
light centered at 358 nm with 55 nm bandwidth for 5 minutes with the sample in focus,
then imaged with the same filter set as before.
6.3.4.3 Data analysis of live-cell microplate experiments
Microtiter plate (microplate) experiments for live cells all included a zero reference of water
that was used to calibrate the fluorometric plate reader photodetector, and a baseline refer-
ence of cell medium only (either balanced salts or cell culture medium). The microplate
experiments also included a full-signal reference of QDs in cell medium but without cells.
In addition to the cell-free references, each microplate also had these references but with
cells added. Each data point consisted of at least 4 samples (n = 4), and was considered
acceptable if the coefficient of variation (%CV = 100 × x̄
σ
) was below 30%. The relative
fluorescence remaining is the ratio of the mean fluorescence at each data point to the mean
fluorescence of the full-signal reference, subtracting the mean fluorescence of the QD-free
cell reference.
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6.4 Results and discussion
6.4.1 QD degradation by biological oxidants is only by HOCl and H2O2
We tested the optical stability of QDs against a panel of ROS that can be found in phago-
cytes, with the assumption that a change in fluorescence emission would indicate that degra-
dation could be occurring. The results are shown in Figure 47 on the next page Of all the
ROS tested in this panel, only HOCl, H2O2, and ·OH showed significant decreases in flu-
orescence intensity. It should be noted that in this case, ·OH was generated by Fenton’s
reaction, which uses H2O2 as a component of the reaction. The fluorescence loss between
the H2O2 and ·OH groups is the same, and so the fluorescence loss due to ·OH exposure is
assigned to the presence of H2O2 in the reaction. ·OH also has an extremely short half life,
on the order of nanoseconds, and so has a mean diffusion distance in pure water of about
1nm. The PAA-g-DDA polymer coating of the QDs has a thickness of 1nm (including
the alkyl surfactants from QD synthesis) as measured by transmission electron microscopy
(TEM), and the layer is thicker when in aqueous solvent and not on the TEM grid. Thus,
it is unlikely that ·OH could diffuse across the thick QD polymer coating to react at the
crystal surface of the QD without reacting with the polymer itself. Beyond diffusion dis-
tance considerations, the QDs used in these studies have a negative charge at physiologic
pH which can repel charged species through Coloumb interactions. Of all the oxidants
tested, only HOCl, H2O2, and ·NO are neutrally-charged at physiologic pH. ·NO binds to
transition metals to form metal nitrosyls, but such an interaction should result in a change
in the optical properties of the QD and no change is observed. ONOO-, in addition to being
charged at physiologic pH, has a short half-life in aqueous solution of 1.9 seconds and so




































Figure 47: Quantum dot (QD) fluorescence loss following exposure to biological reactive
oxygen species (ROS). The fluorescence of QDs in physiologic buffered pH solutions were
exposed to the indicated biologic ROS and the fluorescence was then monitored. The molar
ratio of ROS to QD is based on the initial amount of reagent added and is a approximate
measure in many cases because of the short lifetimes of many ROS. Error bars show the
95% confidence interval, n = 4.
6.4.2 Degradation of QDs by the MPO enzyme system is similar to HOCl alone
Since the MPO enzyme system is known to produce many products, not just HOCl, we
next tested the ability of the MPO enzyme system to cause QD fluorescence quenching.
The canonical MPO-catalyzed reaction is the reduction of Cl- in the presence of H2O2 to
generate HOCl, but MPO actually can exist in three different forms (referred to as com-
pounds I–III) and so the actual reaction may not be so straightforward.[131] As shown in
Figure 48 on the following page, QDs lose significant amounts of fluorescence only when
combined with MPO and the precursors of HOCl production (Cl- and H2O2). The addition
of 4-aminobenzoic acid hydrazide (ABAH), an MPO inhibitor, prevents a large percent-
age of the quenching from occurring.[129] MPO is a cationic protein, and the polymer-
encapsulated QDs used for these experiments is anionic (as are many nanoparticles for
in vivo use). It is possible that MPO is able to electrostatically bind to QDs, creating a “ball


























Figure 48: Quantum dot (QD) fluorescence loss occurs only in the presence of myelo-
peroxidase (MPO) and the precursors for generating hypochlorous acid (HOCl). The flu-
orescence of QDs diluted into phosphate-buffered saline (PBS) was monitored after the
addition of MPO, H2O2, and the combination of the two. The effects of ABAH, an MPO
inhibitor, was also measured. The required precursors for MPO to produce HOCl are Cl-
(supplied in the PBS) and H2O2; only this combination results in significant QD fluores-
cence quenching. Error bars show 95% confidence interval, n = 4.
Wright-Giemsa staining of differentiated 
HL60 cells shows unique staining profiles
Untreated Monocyte Neutrophil
Figure 49: An example micrograph of differentiated HL-60 cells. HL-60 cells can differ-
entiated in culture by exposure to all-trans retinoic acid (ATRA) to induce a monocyte-like
phenotype or dimethylsulfoxide (DMSO) to induce a neutrophil-like phenotype. The un-
differentiated and differentiated cells are shown with Wright-Giemsa staining.
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6.4.3 Degradation of QDs by live cells
To see if live cells could degrade QDs by generating HOCl via MPO, we used the HL-
60 cell line, a human line originally derived from a patient with acute promyelocytic
leukemia.[44] The utility of the HL-60 cell line is that by co-culturing with specific small
molecules, the cells can be terminally differentiated from a promyelocyte-like cell into
other cell types, such as granulocyte-like or monocyte-like cells.[44, 245, 162] In the
case of HL-60 cells co-cultured in 1.3% dimethylsulfoxide (DMSO), the cells adopt a
neutrophil-like phenotype after approximately six days. Like neutrophils, the DMSO cul-
tured HL-60 cells are smaller than the promelocyte progenitor, have a clear cytoplasm
and banded or multilobular nucleus under Wright-Giemsa staining, and are positive for
nitro blue tetrazolium (NBT) staining.[43] Differentiated HL-60 cells stained with Wright-
Giemsa stain are shown in Figure 49 on the previous page. The neutrophil-like HL-60
cells will also phagocytize zymosan particles (yeast) and undergo oxidative burst, releasing
HOCl by MPO catalysis. Alternatively, the cells can be exposed to phorbol 12-myristate
13-acetate (PMA), a PKC activator, to induce a potent oxidative burst without phago-
cytosis.[45] We used PMA to induce an oxidative burst in neutrophil-like HL-60 cells that
were incubated with QDs. As shown in Figure 50 on the following page, QD fluorescence
is lost when QDs are incubated with neutrophil-like HL-60 cells, and the fluorescence loss
occurs in a PMA dose-dependent manner. Addition of sodium azide (NaN3), an MPO
inhibitor, largely prevents the fluorescence loss.
Going beyond population measurements of cells in a microplate as in Figure 50 on the
next page, we adsorbed QDs onto the bottom of coverslips and performed microscopy of
neutrophil-like HL-60 cells. As seen in Figure 51 on page 123, HL-60 cells stimulated
with PMA quench the fluorescence of QDs that are directly underneath the cells (appearing
as “holes” in the layer of adsorbed QDs on the glass coverslip). As in the microplate
experiments, addition of NaN3 prevents the quenching from happening. Imaging one of the
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Figure 50: Quantum dot (QD) fluorescence loss occurs in the presence of cells stimulated
to undergo an oxidative burst. The fluorescence of QDs incubated with HL-60 cells dif-
ferentiated into a neutrophil-like phenotype was monitored after the addition of PMA, a
small molecule that stimulates neutrophils to undergo an oxidative burst and subsequently
produce HOCl. The addition of sodium azide (NaN3) to inhibit HOCl production largely
prevents the fluorescence loss. Error bars show 95% confidence interval, n = 4. Adapted
with permission from ref. [148]. Copyright 2008 American Chemical Society.
and near the stimulated HL-60 cells will photoanneal, and that the photoannealed QDs are
multicolored. That the QDs have blue-shifted in fluorescence emission is indicative of a
size decrease, i.e., etching and degradation.
6.4.4 Degradation of QDs in the presence of endogenous antioxidants
Based on the cell culture results, it would be expected that QDs would rapidly degrade if in-
jected in vivo, however, this is not observed. In fact, Bruchez and coworkers noted that QDs
could still be observed in mice that were injected two years prior, and that these QDs ex-
hibited hypsochromic spectral shifts from the original fluorescence peak—photoannealing
was not considered.[77] The difference between the cell culture experiments presented so
far and the in vivo experiments performed by others can be explained as a difference in
context: in the experiments presented in previous subsections, the solutions were very
“clean”, using pure reagents and cells in balanced salt solutions devoid of serum or other




• QDs were immobilized onto poly-L-lysine treated coverslips. 
When neutrophil-like  HL-60 cells were incubated on the glass 
coverslips and activated with 1-µM PMA, QD quenching is visible 
as ‘holes’ in the immobilized QD layer (C).  Unactivated cells (A), 
or cells treated with 1-mM NaN3 (B, unactivated, D, activated) do 
not show the same pattern of ‘holes’.
Figure 51: Live cells cause quantu dot (QD) fluorescence quenching after a stimulated
oxidative burst. QDs were ad orbed onto the surf ce of glass coverslips, onto which
neutrophil-like HL-60 cells were then placed. (A) Unstimulated cells on the field of
QDs cause no fluorescence quenching. (B) After stimulation to release hypochlorous acid
(HOCl), the cells quenched the fluorescence of QDs underneath and near the cells, result-
ing in a “Swiss cheese” pattern in the adsorbed QD layer. Addition of an inhibitor of the
enzyme which produces HOCl prevented the fluorescence loss both without (C) and under
(D) stimulation to produce HOCl. Images were contrast-enhanced with the same settings
used across images.
Figure 52: Quantum dots near live cells can be photoannealed after fluorescence quench-
ing. QDs were adsorbed onto the surface of glass coverslips underneath neutrophil-like
HL-60 cells. After stimulation with to release HOCl, the cells quenched the fluorescence
of QDs directly underneath the cells. The microscope field was then photoannealed by short
time exposure to UV light. QDs that were previously not visible became visible but with a
shifted emission wavelength consistent with degradation. The cells themselves appear as a
blue haze. Image was digitally-adjusted for color balance.
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Table 4: A partial listing of antioxidants found in the bloodstream
Antioxidant Type Reference value Literature reference










Uric acid Small molecule 3.6–8.3 mg/dL [157]
Catalase Enzyme 94.8–127.8 MU/L [257]
Since ROS are highly reactive, these other entities are possible targets for reaction sim-
ply by being present. These secondary products can themselves be useful as antimicrobial
agents (chloramines), or can be deleterious as in the case of oxidized low-density lipopro-
tein (oxLDL) cholesterol.[247, 248, 50] Additionally, there are many antioxidants present
designed to specifically react with ROS to protect the organism from oxidative damage.
Summarized in Table 4 on the current page is an abbreviated listing of the antioxidants
found in the blood. We will consider the effects of serum albumin, a protein which main-
tains serum osmotic pressure and can act as an antioxidant;[208] glutathione and cysteine
are both small-molecule thiols, both of which are general antioxidants;[168, 264] ascor-
bic acid (vitamin C) is a hydrophilic vitamin ubiquitous in the body and a participant in
many biological redox cycles;[264] uric acid is a major antioxidant in the blood;[207] and
catalase is an enzyme carried by erythrocytes.[3]
Given the high reactivity of HOCl, it would be predicted that the ability of HOCl to
cause QD fluorescence decreases in the presence of any other species in solution would be
greatly reduced; conversely, because H2O2 has a lower kinetic rate of reaction with many
species, it would be expected to be less influenced by the presence of other species in so-
lution. As shown in Figure 53 on page 126, the full story is more nuanced. For HOCl, any
antioxidant specie in solution protects QDs against fluorescence quenching; this is a reflec-
tion on the promiscuous reactivity of HOCl. Ultimately, enough HOCl is able to overcome
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antioxidant protection and begin reacting with the QDs. Uric acid offers no protection,
thiols have minimal protective effects, and BSA and ascorbate have moderate protective
effects against H2O2 attack of the QDs. Both plasma and catalase are sufficient to fully
protect the QDs against H2O2 attack. These data show that while QD degradation in the
presence of biological antioxidants is greatly reduced, it is still relevant. That HOCl showed
degradation even in reconstituted plasma, albeit at super-pathophysiologic concentrations,
suggests that degradation could still occur in in vivo with antioxidants present.
Revisiting cell culture experiments, conducting the experiments in normal cell culture
medium (containing 10% bovine serum by volume) alters the dynamics of fluorescence
loss in QDs after stimulation of primary endothelial cells and neutrophil-like HL-60 cells
to produce ROS, as shown in Figure 54 on page 127. The endothelial cells are expected to
generate H2O2 in majority following stimulation; the HL-60 cells will produce both H2O2
and HOCl following stimulation. Since there is no fluorescence loss in the endothelial
cell experiments for any condition, it is likely that the endothelial cells are not able to
produce enough H2O2 under these experimental conditions to cause a noticeable loss in
QD fluorescence. In the case of the neutrophil-like HL-60 cells, the addition of serum is
sufficient to completely protect the QDs under all condtions.
Revisiting the HL-60 microscopy studies using cell culture medium containing serum
shows that QDs directly underneath cells still are quenched. A difference when compared
to cells in balanced salts is that far from the cells, QD fluorescence is not quenched in the
case of experiments carried out with serum present, whereas QD fluorescence is quenched
in the case of experiments carried out in buffered saline solution. This shows that QD fluo-
rescence quenching can still occur, even in the presence of antioxidants, however the scope
of the fluorescence quenching (and subsequent degradation) is much more limited. Photo-
annealing the quenched QDs underneath the cells shows restoration of QD fluorescence
only on the cell periphery, where the QDs now fluoresce green. That the QDs fluoresce
green is a sign of severe degradation (based on the QD composition, Table 2 on page 94),
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Figure 53: Quantum dot (QD) degradation by reactive oxygen species (ROS) is retarded
in the presence of biological antioxidants. QDs were diluted into physiologic pH buffered
solutions containing biological antioxidants in concentrations matched to in vivo human
concentrations, and then exposed to indicated concentrations of either HOCl or H2O2. In all
cases, the presence of antioxidants retarded the quenching of QD fluorescence. Lines of fit
are a decaying exponential intended as a visual guide, error bars show the 95% confidence
interval, n = 4.
and so it is likely that the QDs directly underneath the cells (which remain dark) have been
oxidized beyond the point of fluorescence restoration. Note that this case of QD degrada-
tion still occurred in presence of serum.
6.5 Conclusions
In this chapter, we have shown that the HOCl degradation process described in Chapter 5
can occur via cell mediated processes. Enzyme-only systems show the same “dramatic”
rapid and severe fluorescence quenching observed in the pure chemical experiments, and
cellular experiments with model phagocytes show that fluorescence quenching and degra-
dation occur. Taking the biological milieu into account, with numerous other species and
antioxidants present, we find that QD fluorescence quenching and degradation still oc-
cur but the scope becomes much more limited—instead of QDs in the local area being
quenched, only QDs directly in contact with cells become quenched. Some of these cellu-
lar results have been replicated in part by Yan et al..[273] The data show that QDs cannot
be assumed to be in a fluorescent state in vivo, and so pharmacokinetics and biodistribu-





































































































































































































































































































Figure 54: Quantum dot (QD) degradation by stimulated cells in a cell culture model is
retarded by the presence of serum. QDs were added to cell cultures of neutrophil-like HL-
60 cells (A, B) or bovine aorta endothelial cells (BAEC, C–F) in a presence of balanced
salts, serum-free (A, C, E) or normal culture medium with serum (B, D, F). Cells were then
treated with phorbol 12-myristate 13-acetate (PMA) or lipopolysaccharides (LPS), ROS
production stimulants for HL-60 and BAEC cells, respectively. Where indicated, catalase
(Cat) or 4-aminobenzoic acid hydrazide (ABAH) were used as inhibitors of HOCl or H2O2
production, respectively. BAECs were measured at 1 and 24 hours because they are known
to produce H2O2, which was shown earlier in cell-free systems to take more time than





















Figure 55: Quantum dot (QD) degradation by stimulated neutrophil-like (HL-60) cells
occurs with serum present, but is limited in scope. QDs were adsorbed to glass cover-
slips, to which cells in either balanced salts (no serum) or culture medium (serum present)
were added. When stimulated, cells in the serum-free sample reduced QD intensity across
the microscope field when compared with the untreated cells; the addition of inhibitors of
HOCl production reduced the scope of degradation to the area nearest the cells. The pres-
ence of serum greatly abated the degradation effect. Photoannealing the cells by short-term
exposure to UV light showed that the QDs on the cell periphery with quenched fluorescence
had a blue-shifted band-edge fluorescence emission (into the green range), consistent with
a size decrease and degradation. White outlines show the borders of activated cells. Images
were acquired with identical camera and filter settings, and are unaltered with the exception
of the drawing of the outline.
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account for possible oxidative degradation. For example, Chou et al. proposed using sil-
ver enhancement staining to find QDs that could be in a non-emitting state in histological
preparations.[41] In sum, the results predict that QD degradation can occur in vivo by re-
action with HOCl, however the degradation will not be the rapid degradation observed in
the pure chemical experiments and will most likely require pathophysiologic conditions to
occur, such as happens in cases of sepsis or organ failure.
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CHAPTER VII
NEXT STEPS IN SURGICAL GUIDANCE AND
NANOTECHNOLOGY
7.1 Abstract
Here, we summarize the work presented in this dissertation and the contributions made
to the fields of cancer surgery and nanoparticle toxicity. We then consider the logical
continuations of this research towards other problems in medicine.
7.2 Summary
This dissertation has been concerned with cancer. Cancer is a complex disease with a
tremendous societal impact in the United States. Beyond the U.S., cancer will become a
global problem as the developing world both grows older and adopts a Western lifestyle.
In Chapter 1, we reviewed the impact of cancer on the U.S. in terms of morbidity, mortal-
ity, and the economic impact. We then briefly reviewed the characteristics of cancer as a
disease, and why diagnosing and treating cancer is a challenge.
Next, we reviewed in Chapter 2 how nanotechnology has use in cancer imaging since
much about cancer imaging is in the design and development of contrast agents. We looked
through the “near-infrared window” and saw why it is a useful region of light for biomedical
imaging. As such, we then reviewed two classes of nanoparticles that are popular as imag-
ing research tools and have the potential for human translation: semiconductor quantum
dots (QDs) and colloidal gold. As this dissertation is in part concerned with the degrada-
tion of semiconductor quantum dots, we concentrated on the synthesis and characterization
of quantum dots and delved into the inner workings of quantum dots. We also explored
how quantum dots are made water soluble, a necessary step for biological applications. We
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then looked at colloidal gold nanoparticles, which beyond their own interesting properties,
can be made into a tool for Raman spectroscopy (SERS).
In Chapter 3, we describe the development of an intraoperative imaging platform tech-
nology. This platform consists of contrast agents, a local excitation and spectroscopy de-
vice, and a widefield imaging system. The system is designed for intraoperative guidance,
using the fluorescent compounds (such as QDs) or Raman-scattering compounds (such as
SERS nanoparticles) described in Chapter 2 for contrast. We characterize an implemen-
tation of this platform technology, before using it in Chapter 4. We began by testing the
instrumentation in murine models of cancer, and show that the system is capable of detect-
ing the difference in contrast accumulation between normal and neoplasia. The technology
is then applied to a cancer more similar to human cancer by imaging cancer in spontaneous
canine tumors. We show that the results of imaging murine tumor models are similar to
imaging of spontaneous canine tumors. We show that a systemically injected and FDA-
approved contrast agent (in an off-label use) accumulates within spontaneous tumors and
can be readily detected by the proof-of-concept instrumentation described in Chapter 3—a
necessary step in translating this technology and related methods into the clinic.
Next, in Chapter 5 we explore the degradation of QDs through exposure to hypo-
chlorous acid (HOCl), a common household chemical that also has importance in biology.
We show that degradation of QDs by HOCl exposure is a rapid process that both quenches
QD fluorescence as well as dissolves the QD crystal itself. We also show that QD fluores-
cence can in some cases be restored through a process known as photochemical annealing,
and that through QD fluorescence changes, we can discover the amount of damage done
to the QD by HOCl. We then explore the biological implications of the QD/HOCl pro-
cess in Chapter 6. We learn that HOCl is a biological oxidant associated with the immune
response, and that nanoparticles themselves tend to induce an immune response. Through
in vitro testing, we show that live cells in a model system can cause degradation of QDs, but
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that the degradation rate under expected biological conditions will be slow. Nanoparticle-
associated toxicity is a great concern, both because of environmental exposures and through
the growing use of nanoparticles in consumer goods and in medicine. These results bring
a better understanding to the ultimate fate of QDs in the biological environment.
7.3 Future directions
This dissertation has been focused on two areas of development, one in biomedical in-
strumentation, and one in contrast agent stability in vivo. The instrumentation developed
has clear translational potential into the clinic, and the spontaneous canine cancer experi-
ments are a first step in this direction. The technology also has applications in other areas
of human medicine. Beyond the implications for toxicology, the degradation of QDs by
HOCl may have use for diagnostic applications.
7.3.1 Refinement of instrumentation
As proof-of-concept devices, naturally, there are numerous improvements and advance-
ments that can be made to the intraoperative instrumentation that we have presented. Many
of these are refinements, such as improvements to the optical layout to compact the system
size, increases to the camera resolution for “HD” imaging, streamlining the physical pack-
aging of the system, and better integration of the devices through software. Some necessary
improvements will only become apparent once usability studies are performed in the oper-
ating room. As part of these usability studies, we would also be developing standardized
protocols for use in the operating room. The increased use of minimally-invasive proce-
dures demands that the system be adapted to laproscopic tools. Primarily, the adaptation
consists of size minimization of the SpectroPen and coupling the widefield imaging sys-
tem to a fiberscope. Beyond instrumentation, there is also potential to improve the contrast
agents used with the system. ICG is useful as a contrast agent because of its favorable reg-
ulatory status and long history of safe use for fluorescence imaging. The optical properties
of ICG are far from ideal, and newer contrast agents with better optical properties would
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enhance the intraoperative instrumentation. Improved fluorescent dyes and semiconduc-
tor quantum dots are one class of candidates (although dyes have a more likely approval
possibility). Activatable contrast agents that turn on only in a tumor would be useful for
increasing the contrast ratio (CR) of the agent (as discussed in this dissertation, a CR of
5 would be considered outstanding). Higher CR probes would make micrometastases eas-
ier to detect in vivo. There is also a new contrast agent, 5-aminolevulinic acid (5-ALA),
seeking U.S. regulatory approval after having already received European approval. This
agent operates within the visual light range and has been applied to intraoperative imaging
in brain cancer. Making the instrumentation compatible with this agent is a matter of ad-
justing the optical setup, mostly in the excitation laser and widefield optical filters. We also
present data using SERS nanoparticles, and show how they have improved depth of pene-
tration in tissue and explain how they can be used for facile multiplexing. Because Raman
scatter operates through a virtual energy state, it can be induced by light of any wave-
length. Developing instrumentation operating at 1064 nm offers the possibility of imaging
with even lower endogenous background, with a tradeoff of greater cost in instrumentation.
The SERS particles we have used are also gold colloid based, and have a favorable regula-
tory approval outlook. Finally, while spectroscopy is powerful it does increase the overall
system cost. Local excitation paired with widefield imaging is in itself useful and would be
loess costly than a system that also includes spectroscopy. Such a lower-cost system could
be important for rural clinics and developing world users.
7.3.2 New applications of instrumentation in cancer surgery, pathology, and cardio-
vascular medicine
We show the application of the intraoperative instrumentation in several cancer types. The
technology itself can be applied to many areas of medicine, so long as there is a suitable
contrast agent. Through ourselves and collaborators, the technology has been applied to
murine models of lung metastases, head and neck cancer, pancreatic cancer, colon can-
cer, and brain cancer. We have not yet explored the utility of this technology for cancer
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screening. Being based on optics avoids the ionizing radiation concerns inherent to x-ray,
x-ray computerized tomography, and nuclear medicine modalities (other than magnetic
resonance, MR). Optical technologies also have a cost advantage over MR imaging.
This technology could also find a home in a pathology laboratory. A 1 cm3 tumor, to
sample completely by histology with 5 micron slices, would require 2,000 slices. Multiply
this by a number of patients and it’s clear that pathologists can only afford to sample a
limited number of areas on a specimen. The correct pathologic determination then relies
on the skill and experience of a pathologist to sample the correct areas of a specimen.
The intraoperative imaging technology, with software customized for pathology, could be
used as an integrated workflow alongside the surgical system. Using one contrast agent, the
surgeon would resect tissues showing contrast accumulation, the pathologist could then use
the same contrast agent accumulation to know what areas of the tissue warranted scrutiny.
Beyond cancer, this technology could also be useful for cardiovascular medicine.
Atherosclerotic plaques, like tumors, have a “leaky vasculature” that could allow contrast
agents like ICG to pool within. To be useful, the imaging instrumentation would need
a catheter adaptation; to truly be useful, contrast agents specific for vulnerable plaques,
perhaps through an activatable contrast agent scheme.
7.3.3 Using QD fluorescence quenching for functional assays
The unusual nature of the fluorescence restoration, through photoannealing, of QDs reacted
with HOCl could be useful in biological assays. Myeloperoxidase (MPO), the enzyme that
generates HOCl in vivo, is recognized as having a role in heart disease; some groups have
also reported that serum MPO has value as a marker of ischemia (although this last point is
actively debated).[267, 181] A simple microtiter plate assay could be developed with QDs
as a functional reporter of MPO activity. Near-infrared (NIR) QDs could be mixed with
whole blood, and the entire sample could be reacted with hydrogen peroxide (H2O2). The
fluorescence quenching (if any) that resulted would be a function of the amount of MPO
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present, its activity, and the amount of antioxidants present in the blood. Using photo-
annealing to restore the QD fluorescence could also be a useful step of the assay. Such a
functional assay may give a more realistic assessment of the impact of MPO on an individ-
ual patient. MPO is also reported as present in atheromas, so QDs combined with photo-
annealing might make a useful in vivo contrast agent.[50] Outside of cardiology, QDs could
be used for assays of total antioxidant capacity, common in food science.[28, 27, 112, 268]
A challenge in these assays is the strong visual absorbance and autofluorescence of food
compounds, which interferes with fluorescent sensors. Using NIR QDs could ameliorate
this problem.
Using QDs for single particle HOCl measurements is an attractive idea, but the wide
population distribution of colloidal QDs makes this quite challenging to implement. It
might be more useful for epitaxially-grown QDs where there is better control of the final
structure, in which case it could be useful both for sensing applications and for fluorescence
emission control. A very specialized application of QD fluorescence quenching in the
presence of HOCl could be in super resolution microscopy.[73] Many of these techniques
require the modulation of the fluorescing state of the fluorophore to work. QDs naturally
have an intermittent fluorescing state, on the order of milliseconds. Some have used this
stochastic blinking property for super resolution microscopy.[111, 139] Quenching of QD
fluorescence through HOCl exposure followed by stochastic recovery of the fluorescence
through photoannealing would work similar to stochastic optical reconstruction microscopy
(STORM).
7.3.4 Designing “safe” QDs for in vivo imaging
Knowing the causes of rapid QD degradation in vivo makes designing degradation-resistant
QDs a possibility. We showed that the common surface coatings of QDs are unable to
prevent degradation by HOCl, and we showed that biological oxidants were able to resist
135
HOCl attack. A QD surface coating incorporating strong antioxidants, such as a water-
soluble vitamin E derivative, could greatly protect the QDs from HOCl attack. Combining
an “armored” QD surface coating with a size-minimized QD (below 5–6 nm hydrodynamic
radius for renal clearance) could result in a probe that would be eliminated from the body
before degradation could occur. Animal model testing, using models of sepsis or multiple
organ failure, could be used to provide worst-case scenarios of reactive oxygen species
(ROS) assault. If ROS-resistant QDs are known to reliably clear from the body and without
degradation, the case for using QDs for human in vivo imaging becomes more analogous to
that of gadolineum chelates. Regardless of applications for human imaging, ROS-resistant
QDs would be desirable for general imaging for animal models.
7.4 Conclusions
In this dissertation, we have presented both a highly translatable platform technology for
intraoperative guidance and fundamental studies of semiconductor quantum dot behavior.
The intraoperative instrumentation has the potential to greatly improve solid-mass tumor
therapy by ensuring effective surgical resection of the entire mass. By doing so, the patient
can be freed from radiotherapy/chemotherapy follow up and from possible scar revision
surgery. In this chapter, we have described how the technology can be brought into other
applications and diseases in medicine, improving medical care beyond oncology. The fun-
damental studies on nanoparticle behavior that we have presented allow predictions to be
made on the in vivo fate of some nanoparticles. We further show how the degradation
process we have described could be useful for diagnostic assays in medicine and beyond.
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APPENDIX A
INSTRUMENTATION, SOFTWARE, AND MATERIALS USED
Table 5: Vendors and sources of instrumentation, software,
and materials used
Supplier or Vendor (Abbrev. name) Location
Aaron Mohs (AMM) Emory University, Atlanta, GA
Acros Organics, Inc. (Acros) Geel, Belgium
Akron, Inc Buffalo Grove, IL
Allied Vision Technology, Inc. (AVT) Newburyport, MA
American Type Culture Collection (ATCC) Manassas, VA
Andrew Smith (AMS) Emory University, Atlanta, GA
BioTek Winooski, VT
Brad Kairdolf (BAK) Emory University, Atlanta, GA
Caliper LifeSciences (Caliper) Hopkinton, MA
Carestream Rochester, NY
CVI Melles-Griot (CVI) Albuquerque, NM
DeltaNu Inc. Laramie, WY
GraphPad, Inc. La Jolla, CA
Hongwei Duan (HD) Emory University, Atlanta, GA
Ika Works, Inc. (Ika) Wilmington, NC
Image Quality Laboratory Polytechnic University of Catalonia,
Spain
InPhotonics, Inc. Norwood, MA
Invitrogen Corp. Carlsbad, CA
Lambda Research Corporation Littleton, MA
Lily Yang, M.D., Ph.D (LY) Emory University, Atlanta, GA
Lonza Walkersville, Inc. (Clonetics) Walkersville, MD
Mallinckrodt Chemicals (Mallinckrodt) Phillipsburg, NJ
Mediatech, Inc (Cellgro) Manassas, VA
Microsoft Corporation Redmond, WA
Midsci, Inc. St. Louis, MO
Nalge-Nunc Int’l (Nunc) Rochester, NY
National Institutes of Mental Health (NIMH) Bethesda, MD
Olympus Life Sciences (Olympus) Center Valley, PA
Pall Life Sciences (Pall) Port Washington, NY
Photon Technology International, Inc. (PTI) Birmingham, NJ
Rapp Polymere (Rapp) Tübingen, Germany
Roper Scientific Acton, MA
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Table 5: (continued)
Supplier or Vendor (Abbrev. name) Location
Schneider-Kreuznach (Schneider) Hauppauge, NY
Shimadzu Scientific Instruments (Shimadzu) Columbia, MD
Sigma-Aldrich Fine Chemicals (SAFC) St. Louis, MO
Ted Pella, Inc Redding, CA
Thorlabs, Inc. Newton, NJ
UGA Animal and Dairy Sciences Department
(UGA-ADSD)
Athens, GA
UVP, LLC Upland, CA
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Table 6: Instruments used






Cell counter Auto T4 Nexcelom Bio-
sciences
6.3.3
Fluorometer QuantaMaster PTI 5.3.3.1, et alibi
Microplate reader Synergy 2 BioTek 5.3.3.1, et alibi
Microscope IX-71 Olympus 4.3.3, 6.3.4.2
Microscope spec-
trometer
SpectraPro 150 Roper Scientific 5.3.3.1
Raman spectrome-
ter
Advantage 785 DeltaNu 3.3.2.2
UV-vis absorbance
spectrometer
UV-2401PC Shimadzu 5.3.3.1, et alibi
Table 7: Software packages used
Software package Vendor Used for Used in section(s)






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































B.1 Lens layout for widefield imaging head
The widefield imaging head has three video channels, as configured. All three channels
share the same main objective lens, field lens group, and collimating lens. The channels
differ in the final focusing lens used to form the image on the camera sensors. The anatomic
or color camera uses one layout; the laser and near-infrared (NIR) probe channels use
a second layout. Both layouts are described infra. More information on the parts used
appears in Appendix A, specifically Table 8 on page 140.
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Object – 609.00 50.00 AIR
Common
objective




2 – 19.00 1.81 AIR
3 30.90 4.70 11.43 BK7 LA1134
(Thorlabs)
4 – 11.43 AIR
5 32.10 3.60 11.43 BK7 LE1234
(Thorlabs)
6 82.20 11.43 AIR
7 – 6.55 2.31 AIR
8 -52.00 3.00 11.43 N-BK7 LC1715
(Thorlabs)
9 52.00 – 11.43 AIR
10 – 31.00 2.28 AIR
11 127.06 1.60 11.43 SFL6 AC254-
045-B
(Thorlabs)
12 25.05 7.00 11.43 LAKN22
13 -29.38 – 11.43 AIR
14 – 127.00 7.78 AIR
15 31.24 7.00 11.43 BAFN10 AC254-
045-A
(Thorlabs)
16 -25.94 2.00 11.43 SFL6
17 -130.62 – 11.43 AIR
18 – 46.79 4.60 AIR













Object – 609.00 50.00 AIR
Common
objective




2 – 19.00 1.81 AIR
3 30.90 4.70 11.43 BK7 LA1134
(Thorlabs)
4 – 11.43 AIR
5 32.10 3.60 11.43 BK7 LE1234
(Thorlabs)
6 82.20 11.43 AIR
7 – 6.55 2.31 AIR
8 -52.00 3.00 11.43 N-BK7 LC1715
(Thorlabs)
9 52.00 – 11.43 AIR
10 – 31.00 2.28 AIR
11 127.06 1.60 11.43 SFL6 AC254-
045-B
(Thorlabs)
12 25.05 7.00 11.43 LAKN22
13 -29.38 – 11.43 AIR
14 – 127.00 7.78 AIR
15 29.38 7.00 11.43 BAFN10 AC254-
045-A
(Thorlabs)
16 -25.05 1.60 11.43 SFL6
17 -127.06 – 11.43 AIR
18 – 46.79 4.60 AIR






PSEUDOCODE FOR SOFTWARE DEVELOPED
C.1 Widefield imaging system software
The widefield imaging system software was implemented in C-sharp using a application
programming interface provided by the camera vendor to handle the camera input/output
and display routines. Each camera captures video on an independent processing thread and
processes the video on the same independent thread. The composite video display, which
is the main video window the user interacts with, is handled in the color video thread. The
main event loop allows the user to alter the software settings as needed.
C.1.1 Main event loop
initialize cameras
initialize user interface
set software options to good default values
begin video capture:
thread nir video capture
thread laser video capture
thread color video capture
thread main event loop:
display composite video

















virtual phosphorescence display mode
virtual phosphorescence decay time
do store single composite video frame
do store composite video frames
C.1.2 Laser video channel thread
thread laser video capture:
get one video frame
do apply laser threshold:
find all points in frame above threshold (area)
calculate centroid of threshold area
calculate circle radius with area equal to threshold area
do calculate circle with centroid, area:
store center, radius
C.1.3 NIR video channel thread
thread nir video capture:
get one nir video frame
do apply nir threshold:
find all points in frame above threshold (nir mask)
store nir mask frame
do if apply nir virtual phosphorescence:
do function virtual phosphorescence:
get vp mask frame
C.1.4 Color and composite video channel thread
thread color video capture:
get one color frame
do apply laser overlay (if set):
(from thread laser video capture):
get center, radius
draw circle with center, radius with false color red
do apply nir overlay (if set):
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(from thread nir video capture):
get nir mask frame
draw nir mask with false color cyan
do apply nir virtual phosphorescence (if set):
(from thread nir video capture):
get vp mask frame
draw vp mask with false color cyan
store composite video frame
C.1.5 Virtual phosphorescence display function
function virtual phosphorescence:
do calculate decay constant:
decay_const = -log(1/max_nir_camera_intensity)/decay_time
do apply decay to accumulation buffer:
new_buffer = old_buffer*exp(-decay_const*framerate)
(from thread nir video capture):
do add nir mask frame to new_buffer
store new_buffer as vp mask frame
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[218] Santibáñez-Koref, M. F., Birch, J. M., Hartley, A. L., Jones, P. H., Craft, A. W.,
Eden, T., Crowther, D., Kelsey, A. M., and Harris, M., “p53 germline mutations in
Li-Fraumeni syndrome,” Lancet, vol. 338, pp. 1490–1491, Dec 1991.
[219] Sausville, E. A. and Feigal, E., “Evolving approaches to cancer drug discovery and
development at the National Cancer Institute, USA,” Ann Oncol, vol. 10, pp. 1287–
1291, Nov 1999.
[220] Sausville, E. A. and Burger, A. M., “Contributions of human tumor xenografts to
anticancer drug development,” Cancer Res, vol. 66, pp. 3351–3354, Apr 2006.
[221] Schipper, M. L., Iyer, G., Koh, A. L., Cheng, Z., Ebenstein, Y., Aharoni, A., Keren,
S., Bentolila, L. A., Li, J., Rao, J., Chen, X., Banin, U., Wu, A. M., Sinclair,
R., Weiss, S., and Gambhir, S. S., “Particle size, surface coating, and PEGylation
influence the biodistribution of quantum dots in living mice,” Small, vol. 5, pp. 126–
134, Jan 2009.
[222] Schirrmeister, H., Kotzerke, J., Vogl, F., Buck, A., Czech, N., Koretz, K., Helm,
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